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Sarcopenia, defined as the loss of muscle mass, strength and function has serious 
personal and societal implications. This is mainly via the loss of independence and 
decreased quality of life, and the prevalence of sarcopenia is known to increase with 
age. Although resistance exercise training is known to combat sarcopenia, 
improvements observed in older adults are blunted in comparison to younger adults. 
Some observational and interventional evidence suggest that vitamin D is associated 
with aspects of sarcopenia, therefore, the aim of this thesis was to determine if 
vitamin D3 supplementation combined with resistance exercise training was more 
effective in improving musculoskeletal health than resistance exercise training alone. 
Chapter 2 presented the first systematic review and meta-analysis of the effect of 
combined resistance exercise training and vitamin D3 supplementation on 
musculoskeletal health in older adults. A total of 7 studies including 792 participants 
were reviewed. A small but significant improvement in muscle strength of the lower 
limb and further improvements in muscle function parameters and bone mineral 
density was evidenced as a result of the combined intervention from a subgroup of 3 
studies (n = 518) adopting a similar methodology. The review highlighted the lack of 
studies implementing an appropriate study design (i.e. the combined intervention 
compared to exercise alone) and sample size to investigate the role of vitamin D in 
improving aspects of sarcopenia. 
Chapter 3 presents a secondary data analysis examining the association between 
seasonal serum 25(OH)D concentration, lean mass and strength and the novel 
outcome of seasonal-dependent sarcopenic status in a subgroup of postmenopausal 
women from the Vitamin D, Food Intake, Nutrition and Exposure to Sunlight in 
Southern England (D-FINES) cohort. No association between lean mass and 
25(OH)D concentration was observed, however, muscle strength and serum 
25(OH)D concentrations were positively associated across all 4 seasons. Sarcopenic 
status was found to be transient in a very small sample of sarcopenic participants (n 
= 10). 
The Exercise and vitamin D study (EXVITD) is presented in Chapters 4 to 6. This 
was a 6-month double-blinded, randomized controlled trial of twice weekly resistance 
exercise training and daily supplemental vitamin D3 (800 IU) or placebo tablet. This 
study recruited 24 community-dwelling older adults (mean age = 70.83 years), with 
19 participants completing the intervention. Between-group differences were not 
detected in any of the outcome measures assessed, most likely due to the small 
sample size of recruited participants. The results presented here suggest that further 
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CHAPTER 1: GENERAL INTRODUCTION 
 
1.1. An ageing population 
The UK has an ageing population. It is projected that, by 2041, older people of 
pensionable age (defined as those aged 67 years and older) will constitute 22.3% of 
the total population, and people within this age category will outnumber the under 
16s by 3.6 million (Office for National Statistics, 2017). The changing demographic 
profile of the UK population has social implications as increasing strain is being 
placed on the pension system, the National Health Service, social care and an 
increased number of people are providing informal care for family members 
(Rutherford, 2012).  
 The consequences of an ageing population are not confined to the UK; an ageing 
population is a global phenomenon, with the number of people aged 60 years and 
older expected to almost triple across the world by 2050 (Rutherford, 2012), and 
countries in Europe, North America, China, Iran, Korea and Russia are expected to 
have over 30% of their populations aged 60 and over (World Health Organization, 
2015).  Although life expectancy at birth is increasing, there is also an increasing 
number of years that men and women can expect to live in poor health; in 2010 this 
was 7.7 years and 8.7 years, respectively (Office for National Statistics, 2014b). 
Babies born in the UK between 2009-2011 are expected to live around 20% of their 
lives in poor health, and for women, disability rates at age 65 years have worsened 
(Office for National Statistics, 2014b). Participation in physical activity and 
maintaining adequate nutrition are essential for healthy older age (World Health 
Organization, 2015), with a large systematic review (n= 83,740) reporting that regular 
2 
 
aerobic physical activity conferred a 30-50% reduction in risk of functional limitation 
and disability (Paterson and Warburton, 2010).  
1.1.1. Physiological characteristics of older age 
Ageing is typified by progressive losses in muscle mass and strength, leading to 
reduced physical functioning and performance (Trombetti et al., 2016). Increased 
amounts of adipose tissue further characterise the ageing process, with 
intramuscular adipose deposits resulting in further detriments to muscle strength and 
function (Visser et al., 2002) . Changes in muscle are accompanied by losses in bone 
mineral density, strength and changes to bone architecture, resulting in fragility and 
an increased risk of fracture (NIH Consensus Development Panel on Osteoporosis 
Prevention and Therapy, 2001). Finally, ageing is also associated with a decreased 
vitamin D status, for which there is evidence of both a direct and indirect influence on 
muscle and bone health (Sanders et al., 2014).                                                                                                                                                                                               
1.1.2. Sarcopenia: Definition and current consensus 
Sarcopenia was first described by Irwin Rosenberg in 1989 as the term used to 
define the age-associated decline in muscle mass (Rosenberg, 1989).  In 2010, the 
European Working Group on Sarcopenia in Older People (EWGSOP) categorised 
sarcopenia as a geriatric syndrome, multifactorial in nature, encompassing losses in 
muscle strength and function alongside losses in muscle mass (Cruz-Jentoft et al., 
2010c). The rationale for the new working definition was thus; losses in muscle 
strength and function are more clinically significant than losses in muscle mass 
alone, as previously described by (Rosenberg, 1989), and losses in muscle mass, 
strength and function are often disproportionate (Marcell, 2003).  
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The EWGSOP met most recently in 2018 (EWGSOP2) to revise the 2010 consensus 
definition and diagnosis. Sarcopenia is now recognised as a muscle disease by the 
EWGSOP2, and designated an  ICD-10-CM Diagnosis Code in the USA in 2019 
(International Classification of Diseases, 2019), the EWGSOP2 describe sarcopenia 
with an operational algorithm, comprising muscle strength to assess suspected cases 
of sarcopenia, muscle quality/quantity to confirm clinical suspicions and functional 
performance assessment to categorise severity (Writing Group for the European 
Working Group on Sarcopenia in Older People 2  et al., 2018). Muscle strength is the 
primary focus of the algorithm, with the EWGSOP2 citing muscle strength as the 
most reliable measure of muscle function (Writing Group for the European Working 














Figure 1.1: EWGSOP2 algorithm for sarcopenia diagnosis and categorisation 
SARC-F: SARC-F questionnaire, DXA: Dual energy X-ray absorptiometry, BIA: Bioelectrical 
impedance, CT: Computerised Tomography, MRI: Magnetic resonance imaging, SPPB: Short physical 
performance battery, TUG: Timed up and go. 
Reproduced with permission from (Writing Group for the European Working Group on Sarcopenia in 
Older People 2  et al., 2018). Published by Oxford University Press on behalf of the British Geriatrics 
Society. Copyright license number 4574820113211 
 
1.1.3. Measurement of sarcopenia 
As shown in Figure 1.1, the EWGSOP2 recommends grip strength, isometric lower 
limb strength and the chair rise test to measure muscle strength (Writing Group for 
the European Working Group on Sarcopenia in Older People 2  et al., 2018). 
Four main techniques are currently used to assess muscle quality and quantity; i) 
bioelectrical impedance (BIA), which is founded on the principle that specific tissue 
types have differences in conductivity. This technique is safe and inexpensive, and a 
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previous validity study (n = 484, mean age = 63.5 years) concluded excellent 
agreement with dual energy x-ray absorptiometry (DXA) for whole lean body mass 
(intraclass correlation coefficient (ICC) female = 0.95, men = 0.96), fat mass (ICC 
female = 0.97, men = 0.93) and percentage fat mass (ICC female = 0.93, men = 
0.88). However, a direct-segmental multi-frequency BIA system using an eight-point 
tactile electrode system measuring the 5 body components at six different 
frequencies (In-body 720) systematically underestimated segmental lean body mass 
(trunk lean body mass ICC female = 0.73, male = 0.69) (Ling et al., 2011). Although 
ii) Magnetic resonance imaging (MRI) and iii) computed tomography (CT) are 
considered to be the gold standards for measuring muscle mass and quality, 
expense, operator expertise and access currently make extensive use unfeasible 
(Beaudart et al., 2016a). Additionally, CT exposes individuals to higher levels of 
radiation compared with DXA (Buckinx et al., 2018a).  
Conversely, iv) DXA is more widely available, produces lower radiation doses and 
measurements of muscle mass and quality are highly correlated with both CT (multi-
slice thigh fat-free mass, r2 = 0.96) (Levine et al., 2000) and MRI (whole body lean 
mass r = 0.94) (Chen et al., 2007). Although DXA does have a number of limitations, 
such as the inability to measure intramuscular fat and reported differences in results 
between devices (Buckinx et al., 2018a), it has been cited as a reliable method of 
indirectly estimating muscle mass in older adults (Chen et al., 2007). 
Muscle quantity is traditionally reported as appendicular skeletal muscle mass (ASM). 
ASM is measured as the sum of lean mass of the arms and legs, and a result of 2 
standard deviations (SD) below that of a young reference population is categorised 
as sarcopenic (Baumgartner et al., 1998).   
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ASM can be used to additionally calculate skeletal muscle mass index (SMI); SMI = 
ASM/body mass x 100. SMI is widely used to define sarcopenia (Rubbieri et al., 
2014), adjusting for the fundamental correlation between body size and muscle 
mass. Sarcopenia is divided into 2 classes; class I if the SMI is 1 to 2 SDs below 
young adult reference values, and class II if the SMI is over 2 SDs below young adult 
values (Janssen et al., 2002). The EWGSOP2 classify sarcopenia as “severe” if 
muscle mass, strength and performance are all determined to be low (Writing Group 
for the European Working Group on Sarcopenia in Older People 2  et al., 2018) 
1.1.4. Prevalence of sarcopenia 
Prevalence rates of sarcopenia vary extensively dependent on the operational 
definition applied and the assessment tools utilised. For example, of 250 men and 
women aged 65 years and older, regarding the measurement of muscle mass, 
sarcopenia prevalence was estimated to be 12.8% using BIA and 21% when 
measured using DXA (Beaudart et al., 2015b). Similarly, when assessing the 
component of muscle strength, use of a pneumatic dynamometer diagnosed almost 
twice the proportion of sarcopenic participants than a hydraulic dynamometer (22% 
vs 11.4% (Beaudart et al., 2015b)). No differences were observed between gait 
speed and the SPPB as methods to assess physical performance (Beaudart et al., 
2015b). 
However, regardless of methodology, prevalence rates of sarcopenia increase with 
increasing age (Baumgartner et al., 1998), with studies reporting prevalence rates 
approaching (Berger and Doherty, 2010) or exceeding 50% in people older than 80 
years (Kenny et al., 2002). A systematic review of 18 publications (n = 15,824) in 
adults aged ≥50 years reported sarcopenia prevalence rates using the EWGSOP 
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definition to be 1 – 29% for community dwelling older adults, 14 – 33% for older 
adults living in care homes (as high as 68% in men) and 10% for older adults 
receiving acute hospital care (Cruz-Jentoft et al., 2014a). A more recent study using 
the EWGSOP definition of sarcopenia within a UK cohort published prevalence rates 
of 21% in men and women of mean age 86.5 years (Dodds et al., 2017). 
1.1.5. Aetiology of sarcopenia 
As a geriatric syndrome, sarcopenia is multifaceted and complex in nature. The key 
factors believed to be involved are cited in a review study as age, malnutrition, 
lifestyle, hormonal changes, neuromuscular impairments, changes in muscle protein 
synthesis and a decline in motor unit number (Narici and Maffulli, 2010). These 
factors are represented in Figure 1.2 and are discussed in the following sections. 
 





Significant changes in body composition are known to occur with age, due in part to 
an increasingly sedentary lifestyle (Kyle et al., 2001). Accelerated declines in ASM 
and fat free mass (FFM) have been reported in older (>75 years) compared to 
younger (18-35 years) adults; ASM -16.4% and -12.3% (men and women 
respectively), and FFM –11.8% and -9.7% (men and women respectively) (Kyle et 
al., 2001). However, losses in muscle mass may not manifest as weight loss, and 
body mass index (BMI) may remain stable or non-significantly altered due to 
increases in fat mass, potentially concealing sarcopenia (Gallagher et al., 2000). 
Furthermore, one study of men and women aged 70 – 79 years (n = 2,307) reported 
that greater fat mass predicted accelerated losses of lean mass in men and women; 
this was not explained by insulin resistance, although may be mediated via increased 
local inflammation as a result of greater adipose tissue and/or physical inactivity. 
Greater fat mass was also significantly related to lower muscle quality at baseline 
(Koster et al., 2011).   
An overall decrease in subcutaneous fat is a feature of advancing age, with 
increases in fat mass mainly visceral and intramuscular (Stenholm et al., 2008). 
Infiltration of fat into the muscle tissue is known to negatively impact muscle strength 
and performance, independent of total body fat and muscle area, particularly within 
the lower limbs (Visser et al., 2002); in a 13 year longitudinal study of 3075 older men 
and women (mean age = 74.2 years), every 1 SD increase in thigh intramuscular 
adipose tissue area correlated with a 37% and 8% increased risk for mobility 
limitation (2 consecutive reports of difficulty walking 0.25 miles or ascending 10 
steps) in men and women, respectively (Murphy et al., 2014). 
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This relationship appears to true of muscles with secondary roles supporting and 
stabilising force production and movement. The Framingham Heart study assessed 
paraspinous muscles via 8-slice multidetector CT in 1152 older men and women 
(mean age = 66.2 years) and found every 1 SD decrement in muscle attenuation (i.e. 
more intramuscular fat) was associated with an increased odds of walking speed ≤1 
m/s of 1.29 (95% confidence interval (CI) 1.11,1.50, p = 0.00009); the relationship 
was still significant after adjustment for BMI, visceral adipose tissue (VAT) and 
subcutaneous adipose tissue (SAT) volume (Therkelsen et al., 2016). Furthermore, 
every 1 SD decrement in muscle attenuation was associated with a - 1.29kg 
decrement in strength (handgrip strength; 95% CI -2.01, -0.57, p = 0.0005), although 
this relationship was observed in men only (Therkelsen et al., 2016). 
 Additionally, those with both sarcopenia and obesity, known as sarcopenic obesity, 
have higher levels of onset of activities of daily living disability than those with either 
sarcopenia or obesity alone (Baumgartner et al., 2004). The two diseases working 
synergistically are known to be associated with poor health outcomes, such as frailty 
and metabolic disorders (Zamboni et al., 2008). Additionally, in a meta-analysis of 12 
cohort studies including 35,287 men and women aged 45 and over, sarcopenic 
obesity was associated with an increased risk of all-cause mortality (Hazard ratio 
(HR) 1.24, 95% CI 1.12–1.37, P < 0.001); heterogeneity was no longer significant 
following a subgroup analysis by sarcopenia definition, however the increased risk of 
all-cause mortality remained (Tian and Xu, 2016) 
 Physical activity levels are negatively associated with age (Milanović et al., 2013). 
Reductions in physical activity are responsible for approaching 50% of the decrease 
in energy expenditure (EE) observed in older people (Elia et al., 2000), and a 
sedentary lifestyle (assessed by the International Physical Activity Questionnaire) is 
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associated with obesity (Silva et al., 2013) and losses in muscle mass and physical 
functioning (Gianoudis et al., 2015); in a cross-sectional study of 162 older men and 
women (mean age = 67.5 years), every 1 hour increase in daily sitting time was 
associated with a 33% increased risk of being sarcopenic (relative appendicular 
skeletal muscle mass (RASM) estimated by DXA) (Odds ratio (OR) 1.33, 95% CI 
1.05, 1.68, p <0.01) (Gianoudis et al., 2015). 
In a multi-continent study including 18,363 adults aged 65 years and over, low levels 
of self-reported physical activity were significantly associated with an increased risk 
for both sarcopenia (OR  1.36, 95% CI 1.11, 1.67, p <0.01) and sarcopenic obesity 
(OR 1.80, 95% CI 1.23, 2.64, p <0.01), but not skeletal muscle mass (SMM) 
(Tyrovolas et al., 2016). Percentage body fat (indirectly estimated using specific 
population formulas) was significantly associated with lower SMM (OR -0.005, 95% 
CI -0.006, -0.005, p <0.001) and an increased risk for sarcopenia (OR 1.03, 95% CI 
1.02, 1.04, p <0.001) (Tyrovolas et al., 2016). 
1.1.7. Hormonal changes 
Also contributing towards a change in body composition are the hormonal changes 
observed with ageing.  The observed age-related declines in anabolic hormones, 
including testosterone, growth hormone (GH) and insulin-like growth factor 1 (IGF-1) 
(Kamel et al., 2002) are proposed as a potential factor influencing the pathogenesis 
of sarcopenia.  
Serum testosterone concentrations are known to decline during healthy ageing; 
decreased testosterone production results in a decline of approximately 25% in 
serum free testosterone between the ages of 25 – 75 years (Kaufman et al., 2018). 
The reduction in both free and total testosterone concentrations in older men is 
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known to be associated with negative body composition outcomes (decreased 
muscle mass and increased fat mass), along with diminished muscle strength and 
physical function (Bhasin et al., 2010); longitudinally, higher concentrations of 
testosterone are associated with smaller losses in both lean mass and lower limb 
function in older men losing weight (LeBlanc et al., 2011). 
A recent review of systematic reviews investigating possible pharmacological 
interventions to improve sarcopenia domains in older people concluded, from high 
quality evidence, that testosterone supplementation may be one possible intervention 
to improve muscle mass and strength in older men with androgen deficiency (De 
Spiegeleer et al., 2018). Individual studies included in the review report gains of up to 
4kg in lean body mass, with duration and type of testosterone regimen noted as 
influencing intervention response (O’Connell et al., 2011). There was a less 
prominent effect of testosterone supplementation on muscle strength, with 
supplementation producing a moderate increase in overall muscle strength of 
approximately 19.3% (Ottenbacher et al., 2006); a smaller effect still was observable 
on physical functioning (De Spiegeleer et al., 2018). 
The Testosterone Trial (Snyder et al., 2016) and the TEAAM trial (Storer et al., 2016) 
were recent randomized controlled trials (RCTs) supplementing with testosterone. 
The Testosterone Trials were a series of 7 studies recruiting men aged 65 years and 
older with low serum testosterone (<9.5nmol/L) who were randomized to receive 
testosterone or placebo gels for 1 year. Serum testosterone concentration was 
assessed periodically, and testosterone gel dose adjusted to maintain concentrations 
within the normal range for young men. The Physical Function Trial arm included a 
subgroup of 387 older men, and it was concluded that there was no significant 
difference in the percentage of men whose 6-minute walking distance improved by at 
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least 50 meters between the testosterone and placebo groups, although self-reported 
walking ability score was higher in the testosterone group (Snyder et al., 2016). 
The TEAAM trial recruited 256 older men (mean age = 66.6 years) with low or low 
normal serum testosterone concentrations (3.5 – 13.9 nmol/L) whom were 
randomized to receive 7.5g of 1% testosterone gel or placebo gel daily for 3 years; 
dosage was adjusted as required to maintain normal serum testosterone 
concentrations. Chest-press strength (number of presses +16.3), chest-press (+22.5 
W) and leg-press peak power (+83.8 W), stair-climb power (loaded = +22.4 W, 
unloaded = +10.7 W) and lean body mass estimated by DXA (arms = +0.9kg) were 
significantly improved within the testosterone group compared to the placebo group. 
However, no significant differences were observed in leg-press strength, chest-press 
or leg-press fatiguability between groups (Storer et al., 2016).  
Although testosterone supplementation has been shown to improve sarcopenia in 
men with low serum testosterone concentrations, and (via a much smaller body of 
evidence) in women (Morley and Perry, 2003), concern of adverse effects, such as 
the risk and exacerbation of some cancers (Dimopoulou et al., 2016), and a 
substantially increased risk of erythrocytosis (Ponce et al., 2018), means that its use 
remains controversial. Alongside testosterone, vitamin D is the only other 
pharmacological intervention that would be “clinically justifiable” in the improvement 
of sarcopenia (De Spiegeleer et al., 2018), with one study stating that “no other drugs 
have been shown to be clinically more therapeutically effective” than vitamin D 
(Morley, 2016). 
A further factor proposed to influence age-related loss of skeletal muscle mass is 
insulin resistance. Hyperinsulinaemia is known to stimulate the accretion of muscle 
13 
 
mass via the activation of p38 mitogen-activated 154 protein kinase (MAPK) and the 
mammalian target of rapamycin (mTOR) pathway (Guillet and Boirie, 2005), 
however, the anabolic action of insulin in blunted in older compared to younger 
adults, resulting in a reduction in muscle mass, strength and function (Rasmussen et 
al., 2006). 
In a study of 399 men and women aged 60 years and over, the homeostasis model 
assessment of insulin resistance (HOMA-IR; calculated as fasting plasma glucose x 
fasting insulin) was found to be inversely associate with ASM (BIA; β=0.47, p = 
0.001) following adjustment for body weight (Lee et al., 2015). Furthermore, it has 
been suggested that sarcopenia may contribute towards insulin resistance, in turn 
exacerbating skeletal muscle loss (Lee et al., 2015). 
1.1.8. “Inflammaging” and its associations with sarcopenia 
The term “inflammaging” was conceived to describe the persistent, chronic low-grade 
inflammation characteristically observed with ageing, which is believed to result from 
an increase in pro-inflammatory markers resulting in a vulnerability to antigenic 
stressors (e.g. malnutritional, physical and psychological trauma) (Franceschi et al., 
2000), which can be positively or negatively affected by lifestyle factors (e.g. physical 
activity) (Abramson and Vaccarino, 2002). 
The Senescent-Associated Sensory Phenotype (SASP) acquired by accumulating 
senescent cells triggers the production of pro-inflammatory cytokines such as 
interleukine-6 (IL-6) and tumour necrosis factor-alpha (TNF- α), which have both 
positive (e.g. promoting tissue repair) and negative (e.g. inflammation and ageing) 
effects (see Figure 1.3) (Lopes-Paciencia et al., 2019). The subsequent chronic 
inflammation has been proposed as one factor contributing to the dysregulation 
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between muscle protein synthesis (MPS) and muscle protein breakdown (MPB) 
observed with chronological ageing, resulting in direct catabolic effects and a loss in 
skeletal muscle mass (Dalle et al., 2017). Alternatively, it has been suggested that 
inflammation may indirectly contribute towards sarcopenia via its negative 
association with anabolic hormones such as GH and IGF-1; for example, the 
Women’s Health and Aging Study, a study of 718 community-dwelling women aged 
over 65 years concluded that women in the both the lowest quartile for IGF-1 and the 
highest quartile for IL-6 had significantly greater limitations in walking, disability in 
mobility tasks and instrumental activities of daily living (ADL) and a 2-fold higher risk 
of mortality during the 5 year follow-up compared with those in the high IGF-1/low IL-
6 group (Cappola et al., 2003). However, whether the role of inflammation in muscle 





IL-6, TNF-α and C-reactive protein (CRP) are the markers most frequently associated 
with chronic diseases and physical disability (Singh and Newman, 2011), with cross-
Figure 1.3: Cellular senescence, frailty and sarcopenia 
Increasing cellular senescence, the SASP and a possible predisposition towards frailty and 
sarcopenia. Increasing numbers of senescent cells across the lifespan, further increased by age-
related disease and the spread of senescence to healthy cells in close proximity. Reproduced with 
permission from (Tchkonia et al., 2013). Published by the American Society for Clinical Investigation 




sectional studies consistently reporting these markers to be negatively associated 
with muscle mass, strength, physical function and frailty (Beyer et al., 2012). A 2016 
meta-analysis of 17 studies including 11,249 sarcopenic (mean age = 66.3) and non-
sarcopenic (mean age = 66.2) control participants concluded that sarcopenic 
participants experienced significantly higher CRP concentrations than controls 
(Standardised Mean Difference (SMD) = 0.51, 95% CI 0.26, 0.77, p <0.0001). No 
differences in IL-6 nor TNF-α concentrations were observed between sarcopenic and 
control participants, although studies assessing these markers were 
underrepresented within the sample (Bano et al., 2017). 
Inflammatory markers were associated with muscle strength in the Longitudinal 
Aging Study Amsterdam; every 1 SD increment in IL-6 resulted in a 3.21kg decrease 
in muscle strength assessed by grip strength, and high CRP concentrations 
(>6µg/ml) and high IL-6 concentrations (>5pg/ml) were associated with a 2 and 3-fold 
greater risk of strength loss, respectively, in the 986 older men and women (mean 
age = 74.6) included (Schaap et al., 2006). Inflammatory markers have also been 
negatively associated with knee extension strength (Zembron-Lacny et al., 2019), 
appendicular skeletal muscle mass (Alemán et al., 2011) and activities of daily living 
(ADL) (Sujarwoto and Tampubolon, 2015) in older adults. 
In addition, obesity is an important risk factor for chronic inflammation; obesity-related 
inflammation acts synergistically with senescent cells to produce a pro-inflammatory 
environment (Kalinkovich and Livshits, 2017). Increases in fat mass result in the 
enlargement of adipocytes and an accumulation of macrophages, which secrete a 
number of pro-inflammatory markers such as IL-6 and TNF-α (Tilg and Moschen, 
2006). In a cross-sectional study of 130 postmenopausal women ( mean age = 66.7 
years), individuals with sarcopenic obesity demonstrated higher serum 
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concentrations of CRF and TNF-α and significantly higher concentrations of IL-6 in 
comparison to non-sarcopenic obese controls; additionally IL-6 and CRP were also 
significantly associated with waist circumference, percentage body fat and fat mass 
in all participants (Dutra et al., 2017). In a further study, sarcopenic older adults over 
60 years demonstrated significantly higher serum concentrations of IL-6 and TNF-α 
than non-sarcopenic controls, with BMI and visceral fat area found to be predictive 
factors of this difference (Bian et al., 2017). 
Exercise has been found to have a positive influence on inflammatory status; in a 
study including 16 type II diabetic men (aged 55 – 70 years) randomized to 3 
sessions of combined aerobic and resistance exercise training (RET) for 16 weeks or 
a usual care control, the exercise group not only significantly improved their aerobic 
(VO2max), muscular (strength and endurance) fitness and body composition 
parameters, but also significantly reduced their TNF-α (-19.8%) and IL-6 (-25.3%) 
and significantly increased their IGF-1 (+16.4%) concentrations; CRP was also 
reduced by a greater amount than the control group (-12.5%), although this was non-
significant (Annibalini et al., 2017). 
Furthermore, there may be an association between vitamin D deficiency and 
inflammatory markers; in a cohort of 23 older men and women (mean age = 68.8 
years), vitamin D deficiency (defined as <50nmol/L) was significantly correlated with 
TNF-α concentrations (Elizondo-Montemayor et al., 2017). In addition to TNF-α 
concentrations, IL-6 and CRP concentrations were significantly higher with vitamin D 
deficiency (defined as <25nmol/L) and vitamin D deficient participants were 3-times 
more likely to have a IL-6:interleukin-10 (IL-10) ratio of 2:1 in a sample of 957 older 
adults (mean age =70.5 years) (Laird et al., 2014). These studies raise the possibility 
that vitamin D deficiency predisposes older adults to a pro-inflammatory environment. 
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1.1.9. Changes in motor unit number 
With chronological ageing, losses in muscle mass associated with sarcopenia are 
due to a combination of muscle fibre atrophy and muscle fibre loss (Narici and 
Maffulli, 2010); and although fibre atrophy may be partially overcome with particular 
interventions (evidence presented in section 1.3), hypoplasia remains unaffected 
(Piasecki et al., 2018). A motor unit consists of an alpha motor neuron and all of the 
muscle fibres that it innervates; ageing is associated with a net loss in motor units 
(Hepple and Rice, 2016). Post mortem anatomical studies have demonstrated 
progressive losses in motor neuron cells after the age of 60 years, with the average 
75 year old displaying approximately 30% fewer motor neuron cells in the lower limbs 
than younger subjects, although this loss reached 50% in several older subjects 
(Tomlinson and Irving, 1977). 
In a study comparing younger (n = 22, mean age = 25.3 years) and older (n = 20, 
mean age = 71.4 years) habitually active men exceeding Department of Health 
physical activity guidelines, older men had 50-60% fewer motor units than younger 
men (Piasecki et al., 2016). Additionally, the remaining motor units observed in the 
older men were larger with significantly slower discharge rates than the younger 
men; these changes were observed before the onset of any muscle weakness, 
according to grip-strength cut-offs, or functional impairments, as none of the men 
were classified as sarcopenic, and 95% of the cohort scored maximum marks in the 
SPPB test (Piasecki et al., 2016).  
Cycles of denervation and reinnervation result in fewer but larger surviving motor 
units (Jones et al., 2009), fibre type grouping and selective hypoplasia of fast type 
fibres (Vandervoort, 2002); denervated cells are left vulnerable to atrophy and loss 
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(Wilkinson et al., 2018). Furthermore, Piasecki et al concluded that in sarcopenic 
older men, there was a failure to reinnervate fibres compared with non-sarcopenic 
older men, with fibre loss occurring when reinnervation could no longer keep pace 
with denervation (Piasecki et al., 2018). 
1.1.10. Malnutrition 
Food intake may be reduced by as much as 25% in older adults (Robinson et al., 
2012a). The prevalence of malnutrition and those at risk of malnutrition aged over 65 
years and living within the community have been reported to be 4.3% and 25.4%, 
respectively, with much higher prevalence rates observed in residential care 
(Nieuwenhuizen et al., 2010).  The reasons behind the so called “anorexia of ageing” 
are complex and multifactorial, but include physical impairments such as losses in 
sight, smell and taste perception (Methven et al., 2012), dentition status, impaired 
masticatory ability and dysphagia, all of which may negatively influence food choices 
(Mann et al., 2013). Appetite is known to be decreased in older age, due to a 
reduction in the secretions that regulate appetite (Tsutsumimoto et al., 2018), and 
changes to the gastrointestinal tract and gut such as delayed gastric emptying, affect 
postprandial anorexia (Morley, 2017). Chronic disease, medications, altered 
absorption of essential nutrients and social determinants are additional factors 
effecting nutritional status in older adults (Brownie, 2006).   
Protein and vitamin D are among the nutrients most consistently associated with 
sarcopenia (Robinson et al., 2012a), although the influence of dietary vitamin D 
intake on sarcopenia is not clear (Cruz-Jentoft et al., 2017) (Section 1.6 discusses 
vitamin D in more detail). Approximately 20-35% of amino acids required to maintain 
the balance between MPS and MPB are supplied through the diet (Mader, 1988), 
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and in the Maastricht Sarcopenia Study of older people (n= 227, age range = 65 – 95 
years), the lowest quartiles for essential amino acids, total branched-chain amino 
acids and leucine blood concentrations were associated with significantly lower SMI 
(assessed by bioelectric impedance), muscle strength (grip strength) and function 
(chair stand time) (Ter Borg et al., 2019). 
There is currently much debate as to whether current guidelines for protein intakes 
are sufficient for older people; a Recommended Daily Allowance (RDA) of 0.8 g.kg-
1.day-1 (Food and Nutrition Board, 2005) has remained unchanged since the 1985 
joint World Health Organization/FAO/UNU Expert Committee and is the minimum 
recommendations to avoid progressive lean mass loss based on nitrogen balance. 
Some studies advocate that current RDAs need to be almost doubled to protect 
against losses in muscle mass and function (Wolfe et al., 2008, Phillips et al., 2016). 
There is evidence suggesting that the postprandial protein anabolic response is 
blunted in older adults compared to younger, which may increase the threshold of 
protein intake necessary to produce the desired stimulation of MPS; 43 older men 
(mean age =71.1 years) required significantly greater amounts of absolute protein to 
maximally stimulate MPS (up to an additional 140%) compared to 22 younger men 
(mean age = 22 years) (Moore et al., 2014). In addition to quantity, the quality, timing 
and distribution of protein intake have also been identified as other important factors 
influencing optimal MPS (Lonnie et al., 2018). For example, the consumption of 
protein and carbohydrate together may blunt the expected synthetic response 
(Robinson et al., 2017).  
Vitamin D has been stated by the European Society for Clinical and Economic 
Aspects of Osteoporosis and Osteoarthritis (ESCEO) as important for “optimizing the 
effect of dietary protein on skeletal muscle anabolism” (Rizzoli et al., 2014). This was 
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demonstrated via post-hoc analysis of an earlier RCT study (Baier et al., 2009); older 
men and women (mean age = 76 years) were assigned to an active (N=40, 
supplemented with β-hydroxy-βmethylbutyrate, arginine and lysine) or control group 
(N=37). After one year, active supplementation resulted in a significant increase in 
FFM, however, it was only those within the active group with serum 25(OH)D3 
concentrations ≥75nmol/L, that demonstrated significant increases in muscle strength 
measured as isokinetic knee extension strength (Fuller et al., 2011) Additionally, the 
PROVIDE study determined that in older adults with sarcopenia (N = 380, >65 
years), sufficient baseline concentrations of 25(OH)D and protein intake may be 
required to respond to supplemental vitamin D and protein and increase muscle 
mass; the 13 week double-blind RCT of supplementary protein and vitamin D or iso-
caloric control found that male and female participants with higher baseline vitamin D 
(≥50 nmol/L) and higher baseline protein intakes (>1.0 g/kg/d) had a significantly 
larger gain in ASM (+0.59kg, 95% CI: 0.29, 0.90, p < 0.001), SMI and relative 
skeletal muscle mass than those in the intervention group with low baseline vitamin D 
and protein intake (Verlaan et al., 2018). 
One mechanism for this action may be that the active form of vitamin D, 1,25(OH) 2D3 
sensitizes the Akt/mTOR-dependent pathway to the anabolic effects of proteins; 
10nM of 1,25(OH) 2D3 in addition to leucine and insulin enhanced protein fractional 
synthetic rate by 14 – 16% in murine C2C12 myotubes and also increased vitamin D 






1.1.11. Consequences of sarcopenia 
The personal and societal costs of sarcopenia are serious. One of the major 
consequences of sarcopenia is the significant association with functional impairment 
and disability (Janssen et al., 2002).  Sarcopenia is associated with a loss of 
independence, poorer quality of life, depression, admissions to care homes, an 
increased risk for hospitalization and even death (Leveille et al., 2000, Vaughan et 
al., 2015). Additionally, sarcopenia is associated with number of comorbidities such 
as diabetes, obesity and osteoporosis (Kim et al., 2014). Losses of muscle mass 
have further detrimental effects, since the tissue contributes towards many other 
roles, such as blood glucose and body temperature homeostasis (Vandervoort, 
2002).  
Sarcopenia represents a substantial burden to the healthcare system; a previous 
study reported that elderly hospitalized sarcopenic patients had a longer length of 
stay by 4 days, and the risk of non-elective readmission was significantly higher in 
these patients (Gariballa and Alessa, 2013). Furthermore, both short and prolonged 
periods of disuse have been shown to exacerbate muscle atrophy in older persons 
with sarcopenia (Wall et al., 2013); moreover, Welch et al coined the term “acute 
sarcopenia” to denote disuse atrophy and associated losses in function due to 
hospitalization (Welch et al., 2018). The cost of treating a sarcopenic patient older 
than 65 years is estimated to be increased by 34% compared with non-sarcopenic 
patients (Sousa et al., 2016), and sarcopenic patients have increased rates of 





1.2. Osteopenia and osteoporosis: Definition 
Alongside a decline in muscle mass and strength, ageing is defined by a reduction in 
bone mass and strength parameters. Osteopenia and osteoporosis describe 
decreased bone density, resulting in adverse changes to the skeleton (Karaguzel and 
Holick, 2010). Compromising alterations in bone structure (geometry, 
microarchitecture, porosity) and bone material (mineralisation, collagen composition 
and damage accumulation) reduce the strength and integrity of bone, resulting in 
fragility and a predisposition towards an increased risk of fracture (NIH Consensus 
Development Panel on Osteoporosis Prevention and Therapy, 2001), see Figure 1.4. 
Clinically, osteopenia and osteoporosis are assessed by comparing the results of a 
T-or Z-score via reference to a population of the same age and sex or a young adult 
population. Osteopenia is present in an individual with a T-score of between -1.0 and 
-2.5 and osteoporosis is confirmed in an individual with a T-score of 2.5 or more SDs 
below that of a young adult reference population (World Health Organization, 1994). 
The measurement of bone mineral density (BMD) (a proxy of bone strength) at the 
hip using DXA is considered to be the gold standard method of osteoporosis 





Figure 1.4: Changes in the structural composition of bone from infancy to older age.  
Published by Springer London and reproduced with permission from (Weaver et al., 2016). 
 
1.2.1. Prevalence and consequences of osteoporosis 
As with sarcopenia, the incidence rate of osteoporosis continues to rise 
concomitantly with an ageing population; globally, it is estimated that 200 million 
people have osteoporosis (Reginster and Burlet, 2006). The most profound outcome 
of osteoporosis is the prevalence rate of fractures and their consequences; 1 in 3 
women and 1 in 5 men over the age of 50 years will experience an osteoporotic 
fracture in their lifetime, and globally, an estimated 9 million osteoporotic fractures 
are reported per annum, equating to one fracture every 3 seconds (International 
Osteoporosis Foundation, 2017). 1 in 5 people suffering an osteoporotic hip fracture 
will die within the following year (Klibanski et al., 2001), and two thirds of those who 
survive never fully regain their pre-fracture function (Lane, 2006). In addition to 
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clinical consequences, osteoporosis is also the source of significant disability, pain, 
depression, anxiety and fear (Gold, 1996).  
On a societal level, the financial cost of osteoporosis is considerable. In 2010 the 
medical cost attributed to treating osteoporosis in the European Union was an 
estimated €37 billion; nearly €25 billion of this amount was ascribed to fractures 
(Hernlund et al., 2013). Osteoporosis also significantly increases the risk of 
hospitalization, and a hip fracture increases average length of stay by 8.7 days 
(Becker et al., 2010). 
1.2.2. Aetiology and risk factors for osteoporosis 
As with sarcopenia, osteoporosis is a result of disequilibrium; in this instance, bone 
resorption rate outpaces formation rate. There are several factors which influence the 
decline in bone mass, such as the impaired functionality of osteoblast cells observed 
in older adults (Kveiborg et al., 2000). Peak bone mass is an important determinant 
of bone mass and fracture risk, with a failure to accrue a strong skeleton in younger 
life indicative of fragility in later life (Raisz, 2005). 
Sexual dimorphism influences peak bone mass; in a 2-year longitudinal study of 620 
men and women (age range = 20 – 89 years), peak BMD (estimated via DXA) in men 
was approximately 12-25% higher than in women (Warming et al., 2002). Similarly, a 
study of 51 male (mean age = 22.2 years) and female (mean age = 22.4 years) 
students found that BMD (estimated via DXA) was higher, and bone mineral content 
(BMC) significantly higher (p <0.01) in the total femur, lumbar spine and distal radius 
and bone area significantly higher (p <0.0001) at the lumbar spine and distal radius in 
males than in females (Avdagić et al., 2009).  
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A 4 year longitudinal study demonstrated much higher absolute mean percentage 
losses in BMD at all sites in older women than in older men of mean age 74 years 
(Hannan et al., 2000).  Sex hormones such as oestrogen play a substantial role on 
BMD, primarily in women, but also in men; the withdrawal of oestrogen signals a 
period of accelerated bone loss in women, with cumulative BMD losses at the 
femoral neck and lumbar spine approximating 9.1% and 10.6%, respectively in the 
decade following the menopause (Cauley, 2015). Additionally, undetectable total 
serum oestradiol concentrations (<18pmol/L) were associated with a 2.5-fold greater 
risk for subsequent hip and vertebral fractures compared to concentrations 
>18pmol/L; 33% of the cohort of 247 older women (mean age = 72 years) were found 
to have undetectable oestradiol concentrations (Cummings et al., 1998). Oestrogen 
deficiency is known to influence bone mass by i) increasing rates of bone turnover, ii) 
increasing bone resorption by lengthening the lifespan of osteoclasts and increasing 
osteoclastogenesis (Seeman, 2002) and iii) decreasing bone formation by shortening 
the lifespan of osteoblasts (Lane, 2006). A low BMI (De Laet et al., 2005) and weight 
loss are significant indicators of bone loss; older women who lost weight also lost 
significantly more bone mass than those whose weight remained stable in a study of 
1134 women over 60 years with an average follow-up of 2.7 years (Nguyen et al., 
1998).  
Low BMD has been associated with a number of inflammatory conditions, including 
systemic lupus erythematosus (Alele and Kamen, 2010) and rheumatoid arthritis 
(Heinlen and Humphrey, 2017). Additionally, chronic inflammation may contribute to 
the aetiopathology of osteoporosis by inducing adverse effects on bone metabolism 
(Lorenzo et al., 2008). Numerous inflammatory cytokines have been found to be 
associated with bone resorption, including IL-1, TNF and IL-6 (Lorenzo, 2000); bone 
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turnover is amplified via mechanisms including increased bone resorption by 
increasing the formation of osteoclasts, inhibiting osteoblast activity and therefore 
bone formation and by the stimulation of prostaglandin synthesis which may 
stimulate or inhibit bone resorption dependent on local conditions (Blackwell et al., 
2010). In a 2.9 year longitudinal study of 168 older adults (mean age 63 years), the 
highest quartile of circulating Il-6  (>4pg/ml) and CRP (>4.2mg/L) concentrations at 
baseline were significantly associated with greater loss of total body BMD compared 
to the lower quartiles (Ding et al., 2008). Additionally, serum concentrations of 
interleukin-1-beta (IL-1β) and IL-6 were found to be significantly higher in 
postmenopausal women with osteoporosis (N=100, mean age = 56.2 years) than 
controls (N=100, mean age = 55.2 years) (Al-Daghri et al., 2017). In a case-cohort 
study of men aged 65 years and older who were followed-up for an average period of 
6.13 years, men in the highest quartile for serum TNF-α concentrations had a 2.0 – 
4.2 folder greater risk of experiencing a hip or vertebral fracture than men in the 
lowest quartile (Cauley et al., 2016). Furthermore, men with 3 or more inflammatory 
markers in the top quartile (IL-6, CRP, interleukin-soluble receptor 6, TNF-α, TNF-α 
soluble receptors 1 and 2 were more likely to be older, less physically active and 
have lower appendicular lean mass (ALM), along with an increased risk for hip (2.03; 
95% CI: 1.11, 3.71) and vertebral fractures (3.06; 95% CI: 1.66, 5.63) in comparison 
to men in the lowest quartile, although being in the highest quartile for IL-10 was 
protective against vertebral fracture (Cauley et al., 2016). 
Physical activity is known to be beneficial for bone health, both during the 
development of peak bone mass and in maintenance in the period following. Strong 
evidence shows physical activity to be the most important lifestyle factor, along with 
adequate calcium intake, for bone mass and density in people ≤21 years of age 
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(Weaver et al., 2016), and in reducing the loss of bone mass in later years; physically 
active older women lost significantly less BMD at follow-up than habitually inactive 
older women (assessed by nurses during interview) ((-0.5% vs -1.4% per year, 
respectively (Nguyen et al., 1998)).  
1.3. The influence of resistance exercise training (RET) on muscle and bone 
health 
1.3.1. Influence of RET on muscle size and function 
Physical activity, specifically resistance exercise training (RET), has long been 
established as the gold standard for maintaining and improving musculoskeletal 
health in older adults (Marcell, 2003), and is the only existing intervention proven to 
treat sarcopenia (Offord and Witham, 2017). In a recent systematic review and meta-
analysis of cross-sectional studies including 40,007 sarcopenic and non-sarcopenic 
people (age range = 40 – 106 years), physical activity significantly reduced the risk of 
developing sarcopenia in later life (OR = 0.45; 95% CI 0.47 – 0.55) (Steffl et al., 
2017). 
Additionally, RET increases anabolic hormone production; concentrations of free 
testosterone in men, and GH in both men and women are acutely elevated following 
exercise (Nascimento et al., 2018). RET also confers benefits on the cardiovascular 
system, endurance and falls prevention (Hurley and Roth, 2000). 
It is well documented that physical activity declines with increasing age; two thirds of 
people aged 65 years and older reportedly do not take part in any form of leisure time 
physical activity (Nascimento et al., 2018).  RET has been shown to increase muscle 
strength, mass and function even in very old adults; nonagenarians increased their 
quadriceps one-rep max (1-RM) strength by 175%, their thigh muscle area by 9% 
and their gait speed by 48% after 8 weeks of high-intensity RET (Fiatarone et al., 
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1990). A systematic review including 6700 participants from 121 trials of RET in 
people aged 60 and older concluded that RET significantly improved functional ability 
and muscle strength. Importantly, no serious adverse events were reported directly 
related to the exercise programme, as have been reported with pharmacological 
interventions, and adverse events were related to mild musculoskeletal discomfort 
(Liu and Latham, 2009).  
 These results are concurred by various groups; Taaffe and colleagues demonstrated 
that once-weekly RET sessions significantly improved muscle strength and function 
in adults aged over 65 years (Taaffe et al., 1999b); Lindenberger et al. reported 
significant gains in strength and cross-sectional area (CSA) of type I and II fibres 
after 30 weeks of RET (Lindenberger et al., 1994) and Frontera et al found significant 
muscle strength increases and hypertrophy following 12 weeks of RET (Frontera et 
al., 1988). A dose-response relationship appears to occur between muscle strength 
and RET intensity; meta-analysis of studies suggests high intensity training confers 
more benefit than moderate or low intensity training (Steib et al., 2010). For example, 
64 older men and women (mean age 70.8 years) were randomized to 16 weeks of 
low, moderate or high intensity resistance training or a control group, the high 
intensity training group demonstrated the greatest increases in strength at low 
velocities in comparison to the other groups (Beneka et al., 2005).  
Conversely, there is evidence to suggest that the response to high intensity RET may 
not be universally beneficial in males and females. For example, following 12 weeks 
of progressive RET, female participants experienced the greatest benefits on tendon 
stiffness at lower forces (<40% maximum voluntary isometric force), whilst male 
participants exhibited most benefit at higher forces (>40% maximum voluntary 
isometric force) (Onambele-Pearson and Pearson, 2012), with tendon stiffness 
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impacting the speed at which muscle can generate force (Brumitt and Cuddeford, 
2015).   
Mode, rather than frequency of exercise appears to be most important when 
designing a training programme to improve strength in older adults (Taaffe et al., 
1999a, Henwood and Taaffe, 2006, DiFrancisco-Donoghue et al., 2007), with 
resistance training concluded to be superior to strength training at improving 
functional ability in 67 older men and women aged 65 – 84 years (Henwood and 
Taaffe, 2006), although little information is available in this area.   
1.3.2. Influence of chronic exercise on muscle health 
The chronic effects of exercise are demonstrated in studies involving Master athletes, 
who maintain high levels of function across the lifespan. Lifelong participation in 
physical activity appears to conserve muscle mass and prevent fat infiltration into the 
muscle when compared with untrained older adults (Sipilä and Suominen, 1993). 
Although increases in FM were still observed in the Master athletes, no decline in 
absolute muscle mass with age was reported (Wroblewski et al., 2011). Concerning 
muscle strength, Master athletes displayed significantly higher isometric knee flexion 
and extensor strength (66% and 38%, respectively) than healthy age-matched 
controls (McCrory et al., 2009). In a recent systematic review and meta-analysis, 
maximal voluntary contraction was significantly higher in Master strength/power 
athletes and young healthy controls in comparison to Master endurance athletes, 
older controls and young endurance trained individuals (Mckendry et al., 2018) . 
Additionally, Master athletes maintained body fat percentage comparable to 
untrained young controls, whereas older controls exhibited higher body fat 
percentages (Mckendry et al., 2018). 
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Figure 1.5: The role of exercise in maintaining bone health throughout the life 
span. Adapted with permission from (Beck and Snow, 2003). Copyright license number 
4634180942587 
 
Importantly, in Master athletes aged 40 to 81 years, no differences in quadriceps 
muscle strength were observed until participants entered the 60 years and older age 
category where upon there was a decline in strength. However this decline was not 
further increased with additional ageing (Wroblewski et al., 2011).  
1.3.3. Influence of RET on bone health 
Peak bone mass of the total skeleton occurs at around 30 years of age, as shown in 
Figure 1.5, with much of this mass attributed to periods of rapid growth and 
remodelling, e.g. puberty (Baxter-Jones et al., 2011). Since it is understood that 
individuals who accrue higher levels of peak bone mass in earlier life generally 
exhibit higher levels of bone mass in later life (Heaney et al., 2000), many 
interventions are aimed at  younger generations and optimising peak bone mass. It 
has been suggested that osteoporosis susceptibility may be detectable in childhood 
(Bonjour et al., 1998). The aims of exercise interventions change across the lifespan; 
the goal during childhood is achieving optimum peak bone mass via growth and 
acquisition, maintenance of mass during adulthood and lowering the rate of bone 





Physical activity, such as RET, plays a central role in bone health, with the Royal 
Osteoporosis Society recommending a combination of weight-bearing and muscle 
strengthening exercises for the maintenance of bone strength and management of 
osteoporosis (The Royal Osteoporosis Society, 2019a). Moreover, exercise such as 
RET has the additional benefit of impacting all domains of fracture risk such as falls 
risk parameters (e.g. balance) and bone strength, which pharmacological 
interventions alone do not (Kemmler et al., 2016). 
RET has been shown to exert modest benefits on BMD and bone architecture, 
although these results are not unanimous. For example, large strength gains and 
gains in muscle CSA and functional capacity but not BMD were reported after 42 
weeks of RET in older adults (McCartney et al., 1995). Regional changes in BMD 
have been reported in other studies; improvements in femoral neck BMD (+1.96%) in 
older men and women were observed after 6 months of high intensity resistance 
exercise (Vincent and Braith, 2002). Similarly, BMD at the total and inter-trochanter 
hip significantly increased after 2 years of strength training in 126 postmenopausal 
women (mean age = 60), although no effect was seen at the forearm, lumbar spine 
or whole body regions (Kerr et al., 2001). 
Trochanteric BMD was significantly increased and femoral neck BMD decreased in 
both older men and women after 6 months of high intensity RET, however significant 
BMD gains at the spine were only documented in men (Maddalozzo and Snow, 
2000). Conversely, no sex or age differences were observed in the BMD gains 
reported at the femoral neck, Ward’s triangle or the greater trochanter between 
young (mean age = 25) and older (mean age = 69) men and women following a 6 
month RET regime (Ryan et al., 2004).  
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When considering BMD in athletes, high intensity resistance training and impact 
sports are the optimum modes of physical activity to stimulate an osteogenic effect 
(Kohrt et al., 2004). In addition to exhibiting higher bone mass, weightlifting athletes 
in all age groups have superior bone structure compared with untrained individuals, 
with higher cortical thickness and CSA of long bones observed in the athletes 
(Suominen, 2006).  Maintaining long-term participation in physical activity appears to 
confer benefits into older age; chronic, regular participation in sport and leisure 
activities, including impact and loading, is positively associated with bone size, 
quality and strength, and reduces the risk of low bone mass in the mid-femur of older 
adults (Daly and Bass, 2006). 
 Conversely, participation in non-impact activity negatively affects bone health. Male 
Master cyclists demonstrated significantly higher losses of BMD after a 7-year follow 
up compared with non-athletic active controls. Master cyclists were also significantly 
more likely to meet the criteria for clinical osteopenia and osteoporosis compared 
with controls; however, participation in weight training or impact sports had a 
protective effect on the loss of BMD at the spine and femoral neck (Nichols and 
Rauh, 2011). 
1.3.4.  Influence of RET on falls and fractures 
Falls and fall-related injuries are a principal cause of hospitalization and death in 
older adults (Gerards et al., 2017), and a fear of falling represents a source of 
significant physical and psychosocial ill health (Scheffer et al., 2008). Figures 
suggest at least 33% of community-dwelling adults over 65 years fall each year 
(Sherrington et al., 2019); fall rates are much higher in care facilities, where 62% of 
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older adults were found to fall in one year (Kennedy et al., 2015), and in hospitals, up 
to 8.9 falls per occupied bed days have been reported (Oliver et al., 2010). 
Intervention studies comprising of strength and balance training unanimously report 
reductions in the number of falls and fall-related injuries in older people; a meta-
analysis pooling data from 1116 men and women over 65 years taking part in a 
home-based strength and balance program reported a 35% lower rate of falling in the 
exercise group and fewer injurious falls than observed in the controls (Robertson et 
al., 2002). Supervised, individually tailored exercise programmes and also untargeted 
group-based exercise programmes have both been shown to reduce falls 
(Sherrington et al., 2004, Kannus et al., 2005); 163 people aged 65 years 
randomized to 1 year of group exercise comprising strength and balance work 
demonstrated a 40% lower rate of falls and improved balance in comparison with the 
control group (Barnett et al., 2003). 
A number of Cochrane systematic reviews report on the relationship between 
exercise and falls prevention; a large systematic review (n = 23,407 from 25 
countries) concluded exercise reduced rate of falls, and specifically a programme 
containing RET, balance and functional exercises was more effective at reducing the 
rate of falls in community-dwelling older adults (mean age = 77 years) than exercises 
such as Tai Chi and balance and functional exercises alone (reduction of 34%, 19% 
and 24%, respectively) (Sherrington et al., 2019). A further review including 138,164 
participants reported on the effect of interventions for preventing falls in older men 
and women in care home facilities (mean age = 84 years) and hospitals (mean age = 
78 years); conclusions as to the effect of exercise on falls in these settings were not 
possible due to the very low quality of available evidence, however, moderate quality 
evidence supported the role of vitamin D supplementation in reducing the rate, but 
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not risk, of falls in individuals with low vitamin D concentrations (Cameron et al., 
2018). Exercise was associated with a small to moderate reduction in fear of falling 
following the intervention, and a small reduction in fear of falling both up to and 
beyond the 6 months post-intervention in a review of 2878 community-dwelling older 
adults (mean age range 68 – 85 years); however, the latter was concluded from very 
low quality evidence (Kendrick et al., 2014). 
1.4. Age and the musculoskeletal response to stimuli 
     1.4.1. Blunted anabolic synthetic response to anabolic stimuli in older adults 
When muscle protein synthesis (MPS) and degradation (MPD) are not balanced, 
muscle loss occurs; the consequence of an accumulating disequilibrium over time is 
sarcopenia (Bowen et al., 2015). Longitudinally, rates of muscle mass loss have 
been reported to be as high as 0.7% and 0.98% per year in women and men aged 75 
years and over, respectively (Mitchell et al., 2012). Losses in muscle strength have 
been shown to be three times higher than losses in mass (Schwartz et al., 2006), 
with low muscle strength a strong predictor of decreased functional ability and 
disability in older people (Hairi et al., 2010). The disparity observed between losses 
in muscle strength and mass in older adults may be explained by the accumulation of 
non-contractile materials within the muscle which are not as efficiently removed with 
age (Marcell, 2003), contributing to overall CSA but not force production. Additionally, 
intramuscular fat and strength are known to be negatively correlated (Akazawa et al., 
2017), further reducing the quality of aged muscle.  
RET interventions have demonstrated significant gains in muscle strength and/or 
mass in older adults, with evidence suggesting modality of loading may be a 
differentiation factor in degree of hypertrophic and strength response to training. 
Intuitively, it is assumed that training involving eccentric contractions produce a 
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greater hypertrophic and strength response than concentric contractions, since 
lengthening skeletal muscle results in a higher generation of force at a lower 
metabolic cost than shortening or concentric contractions, as kinetic energy is 
converted to elastic energy of tendons and regained during limb support (Vogt and 
Hoppeler, 2014). This theory is supported by some reviews and intervention studies; 
a systematic review and meta-analysis of 20 RCT studies of adults aged 18-65 years 
concluded that high velocity eccentric training resulted in superior total muscle 
strength (WMD = 7.84 Nm; 95% CI 3.14, 12.54, p = 0.001) and mass (measured as 
girth: WMD = 1.47 cm2, p = 0.001) gains than concentric training (Roig et al., 2009). 
Similarly, an RCT of 62 older adults (mean age = 80.6 years) completing 12 weeks of 
eccentric ergometer or traditional concentric RET found that maximal isometric leg 
extension strength was significantly improved only within the eccentric training group 
(+8.4% Vs +2.3%, p < 0.01; adjusted for body mass). Leg lean mass significantly 
increased within both groups, although this increase was highest within the eccentric 
training group (+2.5% Vs +2.0%, p < 0.01) (Mueller et al., 2009). Conversely, a 
literature review found that eccentric and concentric training resulted in similar 
hypertrophic gains when matched for maximum load (Franchi et al., 2017). 
 Improvements in skeletal muscle parameters as a result of RET are blunted in 
comparison with those observed in younger adults. For example, following 12 weeks 
of RET, muscle volume (+6.2% and +2.5%) and strength (+27% and +16% ) 
increased in both young (median age, 26y) and older (median age, 80y) women 
respectively, but improvements were significantly higher in the younger women 
(Greig et al., 2011a). Similarly, after 12 weeks of high intensity RET, muscle strength 
increased significantly in both young (n = 9, mean age = 21y) and elderly women (n= 
6, mean age = 85y), although improvements were greater in young women (+36% vs 
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+26%). Additionally, although thigh muscle CSA was significantly increased by +5% 
in young women, no change in muscle size was observed in the elderly women 
(Raue et al., 2009). 
 In general, studies have shown a blunting of the anabolic response following RET in 
older adults; myofibrillar fractional protein synthesis rate was shown to be 27% 
slower in older versus younger adults following 3 months of RET and the percentage 
of total protein synthesised after a single session of resistance exercise was 
concluded to be 30% lower in older versus younger men (Welle et al., 1995. Since 
general consensus is that basal (i.e., postabsorptive) rates of MPS are equal in both 
young and older adults (Cuthbertson et al., 2005, Kumar et al., 2009), the deficit in 
the response could be due to alterations in anabolic signalling with age, such as the 
blunted phosphorylation (Welle et al., 1995), of ribosomal protein S6 kinase beta-1 
(p70s6K) and 4E binding protein-1 (4EBP1), downstream effectors of the mammalian 
target of rapamycin (mTOR) (Kumar et al., 2009). 
In addition to attenuating the MPS response to RET, ageing has been shown to 
diminish the anabolic response to feeding. A cross-sectional retrospective study of 
young (mean age, 22y) and older (mean age, 75y) men concluded that post-prandial 
MPS rates were significantly reduced, less responsive and the increase in MPS from 
the post-absorptive to post-prandial state was greatly diminished in older men in 
comparison to their younger counterparts following ingestion of an anabolic stimulus 
(Wall et al., 2015). Following ingestion of differing amounts of essential amino acids 
(EAA), older men demonstrated a reduction in the degree of anabolic sensitivity and 
responsiveness to stimuli, again perhaps the result of reduced phosphorylation of 
mTOR and downstream translational regulators (Cuthbertson et al., 2005). 
Additionally, the anabolic effects of insulin were diminished and leg protein 
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breakdown suppression was attenuated to a smaller degree in older vs younger men 
during moderate insulin availability (Kumar et al., 2009). 
1.4.2. An age-related blunting in the osteogenic response to loading? 
The blunting of the anabolic muscle synthetic response to stimuli in older adults has 
been previously described, but is this effect also observed in bone; i.e. is there an 
age-related blunting in the osteogenic response to mechanical stress? 
Few data exist in this area, but animal studies appear to suggest a relationship 
between age and response. For example, bone CSA in young turkeys increased by 
30.2% but remained relatively unchanged in older animals after an eight week 
loading regimen (Rubin et al., 1992). After 2 weeks of tibial loading, both young and 
old mice increased their trabecular thickness and number of trabecular connections, 
however, the latter was diminished in the old mice (Meakin et al., 2014). Older 
animals were shown to be less responsive to mechanical stimuli by Turner et al; older 
rats required a higher amount of mechanical loading to exhibit bone formation than 
younger rats, and even after higher mechanical loading, bone formation in old rats 
was 16-fold lower than in younger rats (Turner et al., 1995). Additionally, as reported 
in muscle, VDR expression in the bone cells of older mice was significantly reduced 
in comparison to younger mice (Duque et al., 2002). 
In humans, 12 months of jumping exercises significantly increased proximal femur 
BMD in premenopausal women after 6 months, although in postmenopausal women 
there was no change in BMD after 12 months of jumping (Bassey et al., 1998). The 
ability to improve total and/or regional BMD is retained in older men (Kukuljan et al., 
2011, Allison et al., 2015, Kemmler et al., 2018) and women (Wallace and Cumming, 
2000, Kerr et al., 2001, Suominen, 2006, Huovinen et al., 2016, Zhao et al., 2017), 
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thus the capacity to respond to mechanic stimuli must be attenuated. It has been 
suggested that the blunting of the osteogenic response in older adults may be due to 
reductions in muscle mass and strength with age resulting in lower force production 
than required to overcome the remodelling threshold (Sinaki, 1998). Indeed, in a 
study of 112 healthy, independently-living older adults (mean age = 72.5 years), 
physical activity, determined objectively by 7-day accelerometry, had a negligible 
effect on regional and total-body BMD, with the authors suggesting that participants 
did not take part in activities breaching the threshold of impact required to stimulate 
bone formation (Onambele-Pearson et al., 2019). It was also suggested that high 
levels of physical activity were not enough for BMD maintenance; a reduction in 
sedentary behaviours may also be needed (Onambele-Pearson et al., 2019).  
Furthermore, declining concentrations of hormones which act directly on bone and 
influence turnover, for example oestrogen, may alter the mechanical signalling 
sensitivity to loading (Kohrt, 2001).  
1.5. Muscle-bone relationship: Osteosarcopenia 
Muscle and bone work together towards a shared functional purpose; force 
production, movement and structure (Bruyère et al., 2017), and are linked not only by 
proximity but also by endocrine and developmental factors, as shown in Figure 1.6 
(Edwards et al., 2015). The most obvious way in which muscle and bone are related 
is via the mechanostat theory (Frost, 2003); the mechanical loading of bone by 
muscle contraction stimulates osteogenesis, and was described as the most 
important factor effecting bone strength (Frost, 2003). However, several other factors 









The aetiology of sarcopenia and osteoporosis have factors which intersect, and both 
have a similar patient demographic, with prevalence increasing with age. In a cross-
sectional study of 17,891 African-American, Caucasian and Chinese adults (age 
range 18 – 97 years), participants with sarcopenia defined by relative appendicular 
skeletal muscle mass (RASM), and by the EWGSOP definition were 2 times and 1.8 
times, more likely to be osteopenic or osteoporotic than non-sarcopenic participants 
(He et al., 2016). Additionally, BMD was significantly associated with lean mass, grip 
strength was significantly associated with BMD at all sites, and each SD increase in 
RASM resulted in a 37% decreased risk for osteopenia or osteoporosis (He et al., 
2016). 
Figure 1.6: Relationship between muscle and bone 
GH: Growth hormone, IGF-1: Insulin-like growth factor 1, IL-6: Interleukin 6, IL-7: Interleukin 7. 




The presence of both osteoporosis and sarcopenia may present a cumulative risk, 
resulting in worse health outcomes than either condition alone (Drey et al., 2016); 
this “hazardous duet” (Crepaldi and Maggi, 2005) has been termed osteosarcopenia 
in the literature. However, a lack of clear definition guidelines for the condition has 
resulted in high levels of heterogeneity and therefore difficulty in comparisons 
between studies (Bruyère et al., 2017). 
Nevertheless, individual studies provide evidence for a link between sarcopenia and 
osteoporosis; a study examining physical performance and bone health in 68 
community-dwelling older adults (aged 65 – 94 years) found that osteosarcopenia 
had an additive effect on fracture risk, with osteosarcopenic men at a 3.5-fold higher 
risk for fracture than men without osteoporosis or sarcopenia (Yu et al., 2014). An 
additional cross-sectional study of 313 women who had suffered a hip fragility 
fracture (mean age = 79.7 years) found a significant association between sarcopenia 
and osteoporosis, and a significant increase in risk for osteoporosis was found in 
sarcopenic women (odds ratio = 1.8) (Di Monaco et al., 2011). 
1.6. Vitamin D: Background, status and influence on musculoskeletal health 
and function 
1.6.1. What is vitamin D? 
Rickets, the epidemic disease of the 19th century, provided the catalyst for the 
discovery of vitamin D. As a consequence of the industrial revolution, high levels of 
air pollution and low levels of sunlight contributed to as many as one third of children 
under the age of 2 years suffering from rickets in England (Hess, 1930). In 1922, a 
new vitamin was announced to have cured rickets and was named “vitamin D” 
(McCollum et al., 1922).  It is now recognised that the “vitamin” in vitamin D was a 
misnomer; vitamin D is more appropriately labelled a biologically active hormone with 
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numerous roles, including calcium and phosphorus homeostasis and with a range of 
target tissues including skeletal muscle and bone (Girgis, 2015).  
1.6.2. Synthesis of vitamin D 
The two main forms of vitamin D are vitamin D2 and vitamin D3. Vitamin D2 
(ergocalciferol) is synthesised by plants and fungi after UV exposure or created by 
irradiating food sources, for example mushrooms (Lips, 2006). Vitamin D3 
(cholecalciferol) is synthesised cutaneously upon exposure to UV radiation and 
ingested from dietary sources. Under ideal conditions the skin is able to produce 
enough vitamin D3 to fulfil 80-100% of vitamin D requirements (Glerup et al., 2000c).  
Synthesis of vitamin D begins with exposure to sunlight; UVB radiation converts 
provitamin D3 (7-dehydrocholesterol) in the skin to previtamin D3. Since previtamin 
D3 is highly unstable, conversion to fat-soluble vitamin D3 is rapid. Circulating 
vitamin D3 is then bound to the vitamin D binding protein (DBP), and together with 
dietary sources of vitamin D2 and D3 bound to chylomicrons, transported to the liver 
and hydroxylated to 25-hydroxyvitamin D. 25-hydroxyvitamin D, or 25(OH)D, is the 
major circulating form of vitamin D used to assess vitamin D status and is biologically 
inactive. 25(OH)D is converted to the biologically active metabolite 
1,25hydroxyvitamin D, or 1,25(OH)2D3, in the proximal tubule of the kidneys. From 
here, 1,25(OH)2D3 is transported to tissue such as bone, where it binds to the vitamin 






1.6.3. Vitamin D2 or D3? 
When compared with vitamin D2, D3 possesses an additional methyl group and 
double bond, and, as depicted in Figure 1.7, both D2 and D3 are hydroxylated in the 
Figure 1.7: Synthesis of vitamin D and the regulation of calcium and bone 
metabolism 





liver and kidney. There is some evidence that D3 is the ‘preferred’ metabolite in the 
liver, since hydroxylation of D3 has been found to be over 4 times as fast as that of 
D2 (Holmberg et al., 1986). 
Previously vitamin D2 and D3 were assumed to be of equal potency in humans; this 
is now a subject of some contention. Although no difference in serum 25(OH)D 
concentration was reported after 1000 IU of D2 and D3 was administered daily for 11 
weeks (Ameri et al., 2008), the majority of available literature supports the theory that 
D3 is more effective than D2, with no studies suggesting D2 is more efficient than D3 
(Wilson et al., 2017). 
Vitamin D3 supplementation has been shown by a number of studies to be more 
efficient at increasing serum 25(OH)D; serum concentrations in vitamin D3 
supplemented participants increased by 1.7 times (Trang et al., 1998) to over 3 times 
(Armas et al., 2004) as much in those provided with equal amounts of D2. 
Additionally, serum 25(OH)D concentrations continued to rise 14 days after 
administration of 50,000 IU D3, and remained elevated after 28 day; in participants 
supplemented with identical amounts of D2, serum 25(OH)D was no different from 
baseline after 14 days (Armas et al., 2004).  
Supplementation with D3 (1000 IU) appeared to be protective of serum 25(OH)D 
concentrations over the winter months; D2 supplementation (1000 IU) resulted in a 
significant decrease in total serum 25(OH)D, however, this was unaltered in the D3 
group (Logan et al., 2013). Furthermore, total calciferol storage in subcutaneous fat 
was found to be 3 fold higher in participants supplemented with 50,000 IU D3 per 
week for 12 weeks in comparison with equivalent doses of D2 (Armas et al., 2011). 
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The differing plasma half-lives of 25(OH)D2 and 25(OH)D3 may provide one possible 
explanation for the reason equivalent doses of D3 and D2 do not raise serum 
25(OH)D to equivalent concentrations; the half-life of 25(OH)D2 was found to be 
significantly shorter than that of 25(OH)D3 (Harnpanich et al., 2014). This is 
suggestive of a higher affinity of 25(OH)D2 for the vitamin D binding protein (DBP) or 
perhaps a greater rate of catabolism of 25(OH)D2 within the liver (Logan et al., 
2013). 
1.6.4. Vitamin D status: measurement  
Vitamin D status is measured as serum 25(OH)D concentration, due to the stable 
nature of the metabolite (Thacher and Clarke, 2011). The absence of clear 
international guidelines for optimal serum 25(OH)D concentration is due to 
widespread variation between different assays and laboratories, yielding 
subsequently non-comparable results. This measurement bias has been reported to 
be up to 25% between methods (Salti et al., 2012), and importantly may 
underestimate the proportion of the population requiring treatment for vitamin D 
deficiency (Power et al., 2007).  
However, the general consensus is that a serum 25(OH)D concentration of 
<50nmol/L can be considered as insufficient (Lips, 2004) (Ross et al., 2011a), with 
25(OH)D below 25nmol/L associated with bone disease (Thacher and Clarke, 2011). 
The current gold standard methodology for assessing 25(OH)D is liquid 
chromatography‐tandem mass spectrometry, and is the technique favoured by the 
National Health and Nutritional Examination Survey (NHANES) and the UK Food 




1.6.5. Vitamin D deficiency: prevalence  
Despite a lack of standardisation between assays making population studies of 
serum 25(OH)D status difficult, over 50% of the worldwide population are considered 
to have inadequate vitamin D3 in winter (<50nmol/L) (van Schoor and Lips, 2018), 
with clinical deficiency widely accepted as serum 25(OH)D concentration <25nmol/L 
(van Schoor and Lips, 2018). Older people are one of the population groups 
regarded to be most at risk for deficiency due to changes in the skin, diet and 
behaviour; Figure 1.8 depicts the prevalence of worldwide low serum 25(OH)D status 














Figure 1.8: Prevalence of worldwide low serum 25(OH)D status in adults aged 50 – 105 years 







Comparison of 6 young (20-30) and 6 older (62-80) participants receiving whole body 
phototherapy revealed serum vitamin D concentrations in the younger participants 
increased over three times as much as older participants within 24 hours (Holick et 
al., 1989). The same research group concluded earlier that ageing significantly 
reduced cutaneous production of previtamin D3 (MacLaughlin and Holick, 1985). 
Additionally, older people may require higher concentrations of 25(OH)D to overcome 
hyperparathyroidism and the differing relationship between parathyroid hormone 
(PTH) and 25(OH)D in comparison to younger adults (Ladak et al., 2003).  
 Observational data report high levels of deficiency within older adults; a study of the 
2005 Health Survey for England (HSE) reported that 8% of men and 14% of 
community-dwelling women aged 65 years and over were considered vitamin D 
deficient (<25nmol/L) and 49% of men and 58% of women over 65 were vitamin D 
insufficient (<50nmol/L); vitamin D concentration also decreased with increasing age 
(Hirani et al., 2009). Additionally, serum vitamin D concentrations were significantly 
lower in UK adults over 65 years living in care homes compared with those observed 
in community-dwelling older adults (Hirani and Primatesta, 2005). Similarly, of 
patients living in an elderly care rehabilitation facility (n=1578, median age = 82), 
89% were reported to have hypovitaminosis D (<50nmol/L) and 67% were reported 
to be severely deficient (<25nmol/L) (Schilling, 2012). 
In the UK, the Scientific Advisory Committee on Nutrition Vitamin D working group 
(SACN) published their recommendations in 2016 regarding reference nutrient 
intakes (RNI) of vitamin D advised for protecting musculoskeletal health. A daily 
supplement of 400 international units (IU) per day of vitamin D was recommended 
throughout the year for everyone aged 4 years and above; this was calculated to be 
a sufficient amount for 97.5% of the population to maintain a 25(OH)D serum 
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concentration ≥ 25 nmol/L (Scientific Advisory Committee on Nutrition, 2016). This 
supplement is to be in addition to dietary intakes, which were found to be low; 
community dwelling men and women aged over 65 years had a total intake (dietary 
sources and supplementation) of 51% of the RNI, and institutionalised adults over 65 
years had a total intake of 33% of the RNI (Scientific Advisory Committee on 
Nutrition, 2016). 
1.6.6. Factors influencing vitamin D status 
Together with age, a number of factors effect vitamin D status, including sunlight 
exposure, skin pigmentation, physical activity and disease. Sunlight is known to be 
the most important source of vitamin D, with exposure to ultraviolet (UV) radiation in 
the summer months responsible for 80% of annual vitamin D intakes (Macdonald et 
al., 2011b). The photolysis of provitamin D3 can only occur from UVB light of a 
wavelength between 290 – 316nm; the relationship between serum 25(OH)D 
concentration and season tracks a sinusoidal pattern, with highest concentrations 
detected during summer, then declining until the end of winter (Grey et al., 2007). A 
recent study using both observational and intervention data from UK populations 
concluded that 9 minutes of midday sun exposure every day between March and 
September is required to maintain serum 25(OH)D concentration above deficiency 
throughout the winter months (Webb et al., 2018). However, UVB exposure is not 
only limited by season, but also by latitude, cloud cover, time of day (Kimlin, 2008). 
Additionally, cultural factors such as clothing influence vitamin D status; traditional 
Islamic dress covering the whole body was shown to significantly decrease 25(OH)D 
concentrations in comparison with women clothed in a western style; vitamin D 




Skin pigmentation is a further factor influencing 25(OH)D status; lightly pigmented 
skin can produce 6-fold the amount of vitamin D than heavily pigmented skin types 
(Mostafa and Hegazy, 2015), and darker skin types have been shown to exhibit 
significantly lower 25(OH)D concentrations than whites (Gutierrez et al., 2011, Powe 
et al., 2013). Additionally, physical inactivity, obesity and a number of chronic 
diseases are associated with lower serum 25(OH)D concentrations (Scragg et al., 
1992, Scragg and Camargo, 2008, Brock et al., 2010, Tsiaras and Weinstock, 2011).  
1.7. Relationship between vitamin D status and bone density  
The relationship between vitamin D and bone health has long been recognised. 
Vitamin D during human formative years is vital for the healthy development and 
mineralization of the skeleton, and deficiency restricts peak bone mass and height 
and causes the deforming bone disease rickets (Holick, 2004). Traditionally, vitamin 
D is considered in association with calcium and phosphate; promoting absorption at 
the intestines, reabsorption at the kidneys and mobilization from the skeleton to 
maintain homeostasis. 1,25(OH)2D, the biologically active vitamin D metabolite 
stimulates calcium absorption from the small intestine, and during periods of vitamin 
D insufficiency the efficiency of the intestines to absorb calcium drops by up to 35% 
(Holick, 1996), leading to bone loss, osteopenia and osteoporosis (Lips and Van 
Schoor, 2011). Additionally, vitamin D receptors (VDRs) have been identified on a 
number of bone cells, including osteoblasts, denotating that vitamin D plays a direct 
role in bone turnover and remodelling (St-Arnaud, 2008).  
The European Society for Clinical and Economic Aspects of Osteoporosis and 
Osteoarthritis (ESCEO) concluded that serum 25(OH)D concentrations <50nmol/L 
are detrimental to bone health and are associated with increased bone turnover, 
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bone loss, increased non-vertebral and hip fractures (Rizzoli et al., 2013). In a group 
of 549 postmenopausal women (mean age = 74.95 years) both with and without 
acute hip fractures, serum 25(OH)D concentrations were found to be significantly 
lower in the fracture group than the controls (30.78 Vs 59.70 nmol/L, p < 0.001), 
additionally, the hip fracture group consisted of a significantly higher percentage of 
deficient participants (defined as <50 nmol/L) than the controls  (86.3% Vs 
40.8%, p < 0.001) (Fan et al., 2018). Serum 25(OH)D was identified as an 
independent risk factor for hip fracture in postmenopausal women (OR = 0.878; 95% 
CI 0.855, 0.902, p < 0.001) (Fan et al., 2018). 
With regards to BMD and vitamin D status, 25(OH)D concentrations were analysed in 
a sample of 5002 women (mean age = 68 years) from the Swedish Mammography 
Cohort (SMC). In the summer months (June-August), women with serum 25(OH)D 
concentrations <30 nmol/L (n = 245) had 11% lower BMD at the total hip (95% CI 3, 
19, assessed via DXA), in women with concentrations of 30 – 40 nmol/L (n = 520) 
BMD at the total hip was 6% lower (95% CI 1, 11) in comparison to women with 
serum 25(OH)D concentrations >80 nmol/L (n = 559) (Michaëlsson et al., 2017). 
Additionally, vitamin D deficiency (<30 nmol/L) was associated with a 5-fold 
increased risk of osteoporosis (95% CI 2.9, 8.4) compared with concentrations >80 
nmol/L (Michaëlsson et al., 2017). 
Intervention studies have reported the positive effects of vitamin D supplementation 
on BMD, both alone (Chevalley et al., 1994, Ooms et al., 1995) and combined with 
calcium (Dawson-Hughes et al., 1997, Baeksgaard et al., 1998, Jackson et al., 
2006). A meta-analysis of 29 studies (n=63,897) found that treatment with calcium, 
alone, or in combination with vitamin D reduced the risk of all fracture types by 12%, 
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and significantly reduced the rate of BMD loss at the hip (0.54%) and spine (1.19%) 
in men and women aged 50 years and over (Tang et al., 2007).  
However, the effect of vitamin D supplementation on falls and fractures is a subject of 
some controversy, with many studies published within this area in disagreement. 
Some studies report a beneficial effect (Bischoff-Ferrari et al., 2004, Bischoff-Ferrari 
et al., 2005, Kalyani et al., 2010, Bischoff-Ferrari et al., 2012). For example, a 2011 
meta-analysis of 26 trials (n = 45, 782, mean age = 76 years) reported a significant 
reduction in risk of falls associated with vitamin D and calcium supplementation in 
comparison to a control group (OR = 0.86, 95% CI, 0.77 – 0.96), with a greater effect 
observed in participants with hypovitaminosis D at baseline (Murad et al., 2011). This 
reduction in risk of falls was comparable to a smaller (n = 1237), earlier review study 
reporting an Odds Ratio of 0.87 (95% CI, 0.80 – 0.96), equivalent to a 22% reduced 
risk of falling with vitamin D supplementation (Bischoff-Ferrari et al., 2004). 
However, some studies report no effect of vitamin D supplementation on falls and 
fractures (Jackson et al., 2006, Raphael et al., 2007, Uusi-Rasi et al., 2015), although 
this was thought to be due to an insufficient dose of vitamin D supplement (Bischoff-
Ferrari et al., 2012). One study of 36,282 women of mean age 62 years reported that 
although vitamin D supplementation increased hip bone density, there were no 
significant reductions in vertebral, lower arm, wrist or total fractures, and the 12% 
reduction in hip fractures was not statistically significant after a 7-year follow up 
period. However, adherence to supplementation was poor, and a sensitivity analysis 
of adherent participants revealed a significant reduction in hip fracture risk of 29% 
(Jackson et al., 2006). 
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A 2-year RCT of vitamin D3 and/or exercise found no reduction in falls in 409 women 
(mean age = 74.1 years); unlike many other trials, the authors noted that recruited 
participants unintentionally had sufficient serum 25(OH)D concentration at baseline 
(mean = 67 nmol/L) (Uusi-Rasi et al., 2015). 
A recent systematic review and meta-analysis of 81 RCTs (n = 53,537) investigating 
the effect of vitamin D supplementation on fractures and falls, concluded no effect on 
total or hip fractures or falls. Additionally, no consistent clinically relevant effects were 
observed on BMD at any site, although this review included only 4 studies (n = 831) 
of populations with serum 25(OH)D concentration <25 nmol/L (Bolland et al., 2018b).  
This finding is consistent with Cochrane reviews on interventions to prevent falls in 
older people (Gillespie et al., 2012) and vitamin D and its analogues to prevent 
fractures in postmenopausal women and older men (Avenell et al., 2014), which both 
concluded from high quality evidence that vitamin D alone was unlikely to prevent hip 
fractures (Avenell et al., 2014) and had no overall effect on reducing falls or risk of 
falls (Gillespie et al., 2012), although a greater reduction in rate and risk of falls was 
observed in participants with lower serum 25(OH)D concentration at baseline 
(Gillespie et al., 2012) and a small reduction in hip fracture risk and risk of any 
fracture type was observed with vitamin D and calcium supplementation (Avenell et 
al., 2014).  
1.8. The association between vitamin D and skeletal muscle  
Evidence of the relationship between skeletal muscle and vitamin D is emerging and, 
as such, is not as well understood as the long-standing association between bone 
and vitamin D. Currently, this evidence is four-fold, as described by (Bischoff-Ferrari, 
2012); i) a myopathy is observed in cases of vitamin D deficiency which is reversed 
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upon treatment, ii) vitamin D receptors (VDRs) are present in skeletal muscle 
providing evidence for a direct relationship with vitamin D, iii)  observational data 
report 25(OH)D concentration is correlated with muscle strength and function in older 
adults and iv) interventional data provides evidence of benefit of vitamin D 
supplementation on muscle strength, balance, falls and function. 
1.8.1. i) Vitamin D deficient myopathy 
Vitamin D deficiency is known to be associated with muscle myopathy, myalgia and 
changes in gait; symptoms which are reversed upon treatment (Ziambaras and 
Dagogo-Jack, 1997). Early clinical observations recorded muscle weakness in 
association with vitamin D deficiency and osteomalacia (Schott and Wills, 1976). 
Myopathy was also observed independent of osteomalacic diagnosis (Glerup et al., 
2000a), and severe deficiency resulted in restricted activities of daily living, such as 
difficulties rising from a chair or ascending stairs, and wheelchair use in 55% of 
participants in one study (Al-Said et al., 2009). A clinical observation study reported 
severe proximal muscle weakness, chronic pain and difficulty walking short distances 
in association with severe vitamin D deficiency in 3 adults over 65 years. All 3 
patients were treated with 50,000 IU vitamin D, and within 8 weeks regained 
strength, experienced reduced pain, improved mobility and were able to discard their 
wheelchair (Prabhala et al., 2000). 
 Alongside myopathy, myalgia, that is, chronic musculoskeletal pain, is known to be 
associated with hypovitaminosis D, with particular reference made to immigrants to 
western countries as a group at risk documented in the literature due to skin 
pigmentation, sun exposure and diet (Prabhala et al., 2000). For instance, veiled 
Arab women exhibited significantly lower serum 25(OH)D than Danish controls and, 
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subsequently, significantly more muscle pain, cramps, functional impairments and 
changes in gait than controls (Glerup et al., 2000c). 
Misdiagnosis of vitamin D-deficient myalgia is common, due to the non-specific 
nature of the symptoms (Glerup et al., 2000a); for example, in a Swiss study 
involving 33 female asylum seekers complaining of musculoskeletal pain, 90.9% of 
patients received an alternative diagnosis, and reported symptoms for a mean 
duration of 2.53 years before severe vitamin D deficiency was confirmed (de La Jara 
et al., 2006). A cross-sectional study of patients presenting with non-specific 
musculoskeletal pain reported a 100% deficiency rate in immigrant participants, 
although this rate was similarly high in all participants (93%) (Plotnikoff and Quigley, 
2003).  
1.8.2. ii) VDR and skeletal muscle 
Evidence supporting the direct effect of vitamin D on muscle was provided by the 
discovery of the VDR in the skeletal muscle tissue of animals (Simpson et al., 1985), 
cloned (Costa et al., 1986), and later, in-situ, human skeletal muscle tissue biopsies 
(Bischoff et al., 2001). 1,25(OH)2D3 is bound with high affinity to the VDR (Holick, 












The genomic actions of vitamin D are slow acting; in the muscle cell nucleus, the 
1,25(OH)2D3-VDR complex stimulates both protein synthesis and transcription (via 
the formation of the heterodimer retinoic X receptor (RXR)), increasing calcium 
uptake and muscle proliferation and differentiation (Ceglia, 2008). Non-genomic 
actions are more rapid, including the transportation of calcium into the muscle cell 
following contraction (Halfon et al., 2015b). 
Animal studies have shown that the deletion of VDR gene in mice results in abnormal 
muscle development; VDR-null mice skeletal muscle cell diameters were 20% 
smaller in comparison to wild-type mice (Endo et al., 2003). In humans, certain VDR 
polymorphisms have been shown to influence muscle strength; for example, the bb 
Reproduced with permission (Halfon et al., 2015a). CC by 3.0 license.  
MAPK: MAP Kinase; PLC: Phospholipase C; VDR: Vitamin D receptor; RXR: 




Bsml genotype expressed in non-obese older women was significantly associated 
with an increase in quadriceps (+23%) and handgrip strength (+7%) in comparison to 
older women expressing the BB VDR genotype (Geusens et al., 1997). 
Additionally, serum 25(OH)D and VDR concentrations have been shown to be 
significantly associated, with muscle biopsies of vitamin D sufficient older men and 
women exhibiting higher VDR concentrations than those who were insufficient or 
deficient (Pojednic et al., 2015); however, this finding was in opposition to (Bischoff‐
Ferrari et al., 2004). 
VDR expression in skeletal muscle tissues has been shown to be significantly 
reduced with age (Bischoff‐Ferrari et al., 2004). Over time, this is thought to 
contribute towards impaired protein synthesis in muscle cells (Costa et al., 1986); 
primarily affecting type II muscle fibre atrophy, notably the fibres first recruited to 
prevent a fall (Sato et al., 2005a), and which may account for the increased risk of 
falls in vitamin D deficient older adults (Visser et al., 2006).  
The mechanism for the decrease in VDR expression with age is not yet established; 
it has been suggested depleted levels of vitamin D frequently demonstrated in older 
adults (Holick, 2006) may result in a downregulation of the receptor through lack of 
stimulation (Bischoff‐Ferrari et al., 2004). Indeed, muscle samples from older 
sarcopenic patients (mean age 63 years) retrieved during distal radius fracture 
surgery exhibited a significant under-expression of VDR and myogenin and an over-
expression of myostatin in comparison to age-matched controls (Roh et al., 2019). 
Although vitamin D status was not reported in this study, one further study reported 
that vastus lateralis muscle biopsies of older women (mean age 78.5y) supplemented 
with 4000 IU per day vitamin D3 for 16 weeks displayed a significant increase in VDR 
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gene expression in comparison to age-matched women supplemented with a 
placebo (Pojednic et al., 2015). 
1.8.3 iii) Vitamin D and musculoskeletal health; observational evidence 
Observational studies provide overwhelming evidence suggesting that serum 
25(OH)D concentration is associated with muscle strength (Glerup et al., 2000a, 
Zivelonghi et al., 2002, Gerdhem et al., 2005, Cherubini et al., 2007, Mastaglia et al., 
2011a), power (Bischoff et al., 1999), function (Boeke et al., 2007, Andersen et al., 
2009, Dam et al., 2009, Okuno et al., 2010b, Cherubini et al., 2007, Mastaglia et al., 
2011a, Zivelonghi et al., 2002, Glerup et al., 2000b), frailty , rate of falls (Stein et al., 
1999) and fractures. 
Muscle strength has also been found to be associated with vitamin D status by 
several studies; the InCHIANTI study (n = 976) reported that handgrip strength was 
significantly reduced in both men and women aged over 65 years with serum 
25(OH)D concentration < 25nmol/L and also < 50nmol/L (Cherubini et al., 2007). 
Additionally, serum 25(OH)D concentration < 30nmol/L have been associated with 
significantly reduced knee flexion (Gerdhem et al., 2005) and extensor strength 
(Gerdhem et al., 2005, Zivelonghi et al., 2002, Mastaglia et al., 2011a, Glerup et al., 
2000a), hip flexion and extensor strength (Mastaglia et al., 2011a) and arm strength 
(Zivelonghi et al., 2002) in women over 65 years. Leg extension power was found to 
be reduced in men and women with hypovitaminosis D (< 30nmol/L), and a modest 
but significant correlation between 25(OH)D and muscle strength was observed in 
older men of mean age 76 years (Bischoff et al., 1999). 
Musculoskeletal function and its association with vitamin D status has been widely 
reported; several studies have concluded that SPPB score was significantly lower in 
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older adults with serum 25(OH)D  < 50nmol/L (Mastaglia et al., 2011a, Cherubini et 
al., 2007), with functional decline at 3 year follow up significantly higher in these 
participants, independent of age, sex, BMI and chronic disease (Boeke et al., 2007). 
A study of the Rancho Bernardo cohort (n = 1065) found the TUG and timed chair 
stand times to be highest, and functional decline after 2.5 years greatest, in women 
in the lowest quartile of 25(OH)D (< 80nmol/L) compared to the highest quartile (< 
337.5nmol/L); this relationship was independent of several covariates, including age 
and physical activity (Dam et al., 2009). Interestingly, in a study of 80 women aged 
over 65 years attending 3 months of weekly exercise sessions, those in the highest 
quartile for 25(OH)D (> 67.5nmol/L) made significantly greater improvements in the 
TUG, 5 meter walk, functional capacity, balance and alternate step tests than those 
in the lowest quartile (< 47.5nmol/L). Women in this group made no significant 
improvements, although there were no significant differences in baseline scores for 
the tests (Okuno et al., 2010b). 
Conversely, one study reported no association between serum 25(OH)D status, loss 
of muscle strength and risk for onset of new disability in 628 moderately to severely 
disabled, independent-living women over 65 years. Although there was a significant 
decline in hip flexion, knee extension and handgrip strength, walking speed and the 5 
timed chair stand test after 3 year follow up, this decline was not associated with 
25(OH)D (Verreault et al., 2002). 
A cohort of 1005 men and women (average age = 74.2 and 75.6 years) from the 
InCHIANTI study for whom frailty (defined using 5 domains) and serum 25(OH)D 
data were available, concluded that men with serum 25(OH)D concentrations < 
50nmol/L had a 4.94 -fold greater risk for frailty than those men with serum 
concentrations  >50nmol/L; no association was observed in women (Andersen et al., 
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2009). Falls and fracture rate has been associated with vitamin D status; a study of 
83 elderly nursing home residents (median age = 84 years) reported that fallers had 
significantly lower serum 25(OH)D concentrations and higher parathyroid hormone 
(PTH) concentrations than residents who did not report a fall (Stein et al., 1999). The 
OPRA study reported that women over 75 years (n = 986) with serum 25(OH)D 
concentrations < 50nmol/L were 2.04 times more likely to sustain at least one low-
energy fracture during the 3 year follow up period than women with levels > 50nmol/L 
(Gerdhem et al., 2005). Interestingly, there was also a significant association 
between self-assessed physical activity and 25(OH)D concentration, with higher 
25(OH)D concentrations associated with more time spent outside and higher activity 
levels (Gerdhem et al., 2005).  
Conversely, relatively little evidence exists documenting the relationship between 
vitamin D status and muscle mass. Vitamin D status has been associated with 
muscle mass and sarcopenia; The Longitudinal Aging Study Amsterdam reported 
that sarcopenia was 2.57 times (based on grip strength) and 2.14 times (based on 
muscle mass assessed by DXA) more likely to be experienced by a large cohort (n = 
1008) of men and women over the age of 65 years with serum 25(OH)D < 25nmol/L 
than those with serum concentrations > 50nmol/L (Visser et al., 2003c). Additionally, 
the odds of incident sarcopenia, defined using the more conservative Foundation for 
the National Institutes of Health (FNIH) criteria (grip strength <27kg in men, <16kg in 
women; ASM <19.75KG in men, <15.02kg in women (Studenski et al., 2014)), were 
significantly and independently increased in a cohort of 1705 older men over 70 
years (mean age = 77.8 years) in the lowest quartiles of baseline 25(OH)D (<40 
nmol/L) and 1,25(OH)D (<62 nmol/L) after a 2 and 5 year follow-up period (25(OH)D 
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OR = 2.53, 95% CI 1.14, 5.64 and 1,25(OH)D OR = 2.67, 95% CI 1.25, 5.60) (Hirani 
et al., 2017). 
1.8.4. iv) Vitamin D and musculoskeletal health; interventional evidence 
Evidence for the effect of vitamin D supplementation on musculoskeletal health is 
mixed, which is surprising considering the decisiveness of available observational 
data, although comparison between studies has proved difficult due to high 
heterogeneity and variations in methodological quality (Beaudart et al., 2014b). 
 Systematic reviews and meta-analyses investigate the effect of vitamin D 
supplementation on muscle strength and function (Muir and Montero-Odasso, 2011, 
Stockton et al., 2011, Beaudart et al., 2014b, Rosendahl‐Riise et al., 2017), with an 
emphasis on the role of baseline serum 25(OH)D. 3 meta-analyses (n = 12,966) 
concluded that vitamin D supplementation had significant, positive effects on lower 
limb muscle strength (Beaudart et al., 2014b), hip muscle strength (Stockton et al., 
2011), postural sway, TUG time and knee extensor strength (Muir and Montero-
Odasso, 2011). These effects were dose, baseline serum 25(OH)D, living situation 
and age dependent; a greater effect was shown in participants supplemented with 
>800IU per day (Muir and Montero-Odasso, 2011), with baseline 25(OH)D 
concentrations <30nmol/L (Beaudart et al., 2014b) or <25nmol/L (Stockton et al., 
2011), those who were institutionalized rather than community-dwelling (Beaudart et 
al., 2014b) and with one study reporting a significant improvement in muscle strength 
only in adults >65 years (Beaudart et al., 2014b).  
Conversely, further systematic reviews and meta-analyses reported no significant 
effect of vitamin D supplementation on muscle strength (Latham et al., 2003b, 
Rosendahl‐Riise et al., 2017) or falls (Latham et al., 2003b). In the earlier study, 
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(Latham et al., 2003b) examined the effect of vitamin D supplementation with and 
without calcium supplementation in a small number of trials (13 trials, n = 2496) 
including older adults (mean age = 60). No trials supplementing with vitamin D alone 
were found to affect muscle strength or physical performance, which were analysed 
using a narrative analysis due to the low quality and differences in measurement 
methodology, however, meta-analyses demonstrated a small effect of combined 
vitamin D and calcium supplementation on the number of people who fell. Of note, 
the authors highlighted the poor quality of the data included; small sample sizes, a 
high number of drop outs and use of poorly validated measurement techniques 
influenced quality (Latham et al., 2003b). The more recent study included 15 trials of 
older men and women over 65 years (n = 2866) and concluded there was no 
improvement in hand grip strength with vitamin D supplementation, both with and 
without additional calcium supplementation, however, there was a small significant 
improvement in TUG time with vitamin D supplementation (Rosendahl‐Riise et al., 
2017). Again, this review included a small number of studies in the meta-analysis, 
reported high heterogeneity and the authors noted the outcomes were measured 
using different devices and protocols, therefore adopting a random-effects model to 
account for this variety.  
The systematic review including younger adults included 5 trials of “excellent” or 
“good” quality (assessed via the PEDro scale), examining the effect of vitamin D 
supplementation on muscle strength in young healthy athletes (aged 18 – 45 years). 
Interestingly, the studies using vitamin D2 supplementation reported no effect on 
muscle strength, however, all studies supplementing with vitamin D3 reported a 
positive effect of supplementation on strength; 2 studies reached significance and 2 
studies demonstrated trends for increased muscle strength, improvements ranged 
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from +1.37% to +18.75% (Chiang et al., 2017). The variety of different measurement 
methodologies utilised to assess the outcome measures was listed as a limitation of 
the review, with the authors stating that this may have effected the “reliability and 
accuracy” of the results (Chiang et al., 2017). 
1.9. Combined RET and vitamin D supplementation  
Evidence for the effectiveness of a combined intervention on parameters of 
musculoskeletal health is not conclusive, nor is its relationship to sarcopenia.  
Although some data are suggestive of an association between serum 25(OH)D 
concentration and muscle weakness (Visser et al., 2003a), this association is not 
causal, and considering the individual benefits of RET and vitamin D3 on muscle1.7., 
a number of research groups have proposed a plausible additive effect may exist if 
the 2 interventions were combined, optimizing the potential for healthy ageing 
muscle, and have advocated the need for additional data to help draw conclusions 
(Daly, 2010, Robinson et al., 2012b, Daly et al., 2014, Denison et al., 2015, Agostini 
et al., 2018). 
To date very few studies have been suitably designed to test the combined effects of 
vitamin D and exercise in older adults, and of the few studies which have, poor 
exercise compliance (Bunout et al., 2006b) and small sample sizes (Agergaard et al., 
2015b) are reported.  A recent systematic review and meta-analysis concluded that 
vitamin D supplementation and exercise training significantly improved muscle 
strength within the lower limb in comparison to exercise training alone (SMD 0.98, 
95%CI 0.73, 1.24, p<0.001) (Antoniak and Greig, 2017). However, the limitations of 
the review serve to highlight the lack of knowledge within this area; only 3 studies 
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were included for this analysis, and the high weighting of one particular study with a 
moderate sample size means that any conclusion drawn can only be tentative.  
Of the sparse available data in other population groups, results are similarly mixed; 
23 overweight and obese younger adults (mean age = 26.1 years) took part in 40 
minutes of RET, 3 days per week for 12 weeks and were supplemented with either 
4000IU vitamin D3 and 500mg calcium per day or placebo and 500mg calcium per 
day. Exercise (97%) and supplement (93%) compliances were high, and muscle 
strength (sum of chest press, leg press, and leg curl 1RMs) increased significantly in 
both groups, although no between group differences were observed (Carrillo et al., 
2012). A group of Chronic Obstructive Pulmonary Disease (COPD) patients referred 
for rehabilitation aged >50 years (mean age = 67 years) were randomized to 
complete 3 months of rehabilitation exercises, 3 times per week incorporating 90 
minutes of aerobic and strength training plus either 100,000IU vitamin D or placebo 
per month for 1 year. Vitamin D deficiency is highly prevalent in this group, as is 
skeletal muscle weakness, which was one of the main reasons for rehabilitation 
referral (Hornikx et al., 2012). Isometric quadriceps strength (assessed via 
dynamometer) was most improved in the vitamin D group, but did not reach 
significance (+15Nm Vs + 7Nm, p = 0.121), similarly, 6m walking distance was most 
improved in the vitamin D group, but again did not reach significance (40m Vs 11m, p 
= 0.130); in neither outcome were effects more pronounced in participants with 






1.10. Aims and objectives of the thesis: 
1. Systematically review the available literature to determine the effect of combined 
resistance exercise training and vitamin D3 supplementation on musculoskeletal 
health and function in older adults. 
2. Complete a secondary data analysis of the Vitamin D, Food Intake, Nutrition and 
Exposure to Sunlight in Southern England (D-FINES) study data set to determine 
the relationship between serum 25(OH)D concentration and muscle mass in older 
men and women 
3. Produce a working protocol for a randomized controlled trial of resistance exercise 
training and vitamin D3 supplementation 
4. Conduct a randomized controlled trial of resistance exercise training and vitamin 
D3 supplementation to determine:  
i) Is vitamin D3 supplementation any more effective in improving musculoskeletal 
function when combined with exercise training compared with exercise training 
alone?  
ii) The seasonal variation in serum vitamin D3 in a population of frailer older 
adults, both free-living and those living in supported housing.  
iii) The association between serum vitamin D3 and physical activity (measured 
using accelerometry) at baseline and responsiveness to RET. 
iv) Between-group differences with respect to changes in falls as events and 
quality of life (QoL).  
v) Between-group differences with respect to changes in fractures as events.  
vi) Whether RET influences serum inflammatory markers in frailer older adults.  
vii) The influence of RET on serum stress markers (serum cortisol/ DHEAS) in 











 THE EFFECT OF COMBINED RESISTANCE EXERCISE TRAINING 
AND VITAMIN D3 SUPPLEMENTATION ON MUSCULOSKELETAL 
HEALTH AND FUNCTION IN OLDER ADULTS: A SYSTEMATIC 





This chapter is taken verbatim (with the exception of the 2019 update) from the 
following publication in which I am principal author: 
Antoniak, A.E. and Greig, C.A., 2017. The effect of combined resistance exercise 
training and vitamin D3 supplementation on musculoskeletal health and function in 










In older adults there is a blunted responsiveness to resistance training and reduced 
muscle hypertrophy compared with younger adults. There is evidence that both 
exercise training and vitamin D supplementation may benefit musculoskeletal health 
in older adults, and it is plausible that in combination their effects may be additive. 
The aim of this systematic review was to evaluate the effectiveness of combined 
resistance exercise training and vitamin D3 supplementation on musculoskeletal 
health in older adults. 
Data sources 
A comprehensive search of electronic databases, including Science Direct, MedLine, 
PubMed, Google Scholar and Cochrane Central Register of Controlled Trials 
(Cochrane CENTRAL accessed by Wiley Science). Eligible studies were randomized 
controlled trials including male and/or female participants (aged ≥65 years or mean 
age ≥ 65 years); enlisting resistance exercise training (RET) and vitamin D3 
supplementation; including outcomes of muscle strength, function, muscle power, 
body composition, serum vitamin D/calcium status or quality of life (4) comparing 










7 studies were included, with a total of 792 participants aged 65 years or over (or 
mean age ≥65 years). Studies were categorized into two groups; group 1 compared 
vitamin D3 supplementation and exercise training versus exercise alone (describing 
the additive effect of vitamin D3 supplementation when combined with resistance 
exercise training) and group 2 compared vitamin D3 supplementation and exercise 
training versus vitamin D3 supplementation alone (describing the additive effect of 
resistance exercise training when combined with vitamin D3 supplementation).  
Meta-analyses for group 1 found muscle strength of the lower limb to be significantly 
improved within the intervention group (0.98, 95% CI 0.73, 1.24, p<0.001); all other 
outcomes showed small but non-significant positive effects for the intervention group. 
The Short Physical Performance Battery (SPPB), Timed Up and Go (TUG), muscle 
strength of the lower limb and femoral neck Bone Mineral Density (BMD) all showed 
significantly greater improvements in the intervention group for group 2 comparisons.  
Conclusions 
This review provides tentative support for the additive effect of resistance exercise 
and vitamin D3 supplementation for the improvement of muscle strength in older 
adults. For other aspects of musculoskeletal function, such as SPPB and TUG, no 
additional benefit beyond exercise was shown.  Further evidence is required to draw 
firm conclusions or make explicit recommendations regarding combined exercise and 






Strengths and Limitations of this study 
• To the best of our knowledge this study represents the first review evaluating 
the combined effects of vitamin D3 supplementation and exercise in older 
adults 
• Generally, outcome measure data could be graded as representing moderate 
quality 
• Only seven studies were found to be eligible for inclusion, highlighting the lack 
of literature available on the topic 
• The inclusion of one high risk study (as determined during the risk of bias 
analysis due to handling of missing data) was deemed necessary due to the 


















Sarcopenia, originally defined as the age related loss of muscle mass (Rosenberg, 
1989), now also encompasses low muscle strength and/or muscle function (Cruz-
Jentoft et al., 2010b). The efficacy of resistance training in preventing or alleviating 
age-related musculoskeletal loss is well established; cited as the most promising 
intervention for improving symptoms of sarcopenia (Kosek et al., 2006).  
Clear evidence exists demonstrating an association between resistance exercise 
training (RET) and muscle hypertrophy, which is maintained in older age (Henwood 
and Taaffe, 2005, Kosek et al., 2006, Stewart et al., 2014). However, in older adults 
there is a blunted responsiveness to RET in comparison with younger adults; a 
blunted muscle protein synthetic rate in response to a single bout of resistance 
exercise has been reported (Kumar et al., 2009), and others demonstrate a reduction 
in muscle hypertrophy in comparison to younger adults (Welle et al., 1996, Häkkinen 
et al., 1998, Raue et al., 2009, Greig et al., 2011b). This ’anabolic resistance’ may be 
due to changes in gene expression and anabolic signalling; an attenuated anabolic 
hormone response to resistance exercise is observed in comparison to younger 
adults (Hameed et al., 2003).  
Losses in muscle strength are associated with losses in functional ability, 
independence and increases in frailty, falls, and disability in older adults (Roubenoff, 
1999, Janssen et al., 2002, Visser et al., 2002, Landi et al., 2012); therefore, there 
may be merit associated with a combination of interventions to boost responsiveness 
of older muscle to resistance exercise and combat anabolic resistance.  
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Vitamin D3 supplementation in humans has been shown to positively influence 
musculoskeletal health in older adults: increases in relative number and cross-
sectional area (CSA) of muscle fibres (type II in particular) has been reported 
(Sørensen et al., 1979, Sato et al., 2005b, Ceglia et al., 2013), and muscle strength 
increased and fall rates decreased after treatment with vitamin D3 (Sato et al., 
2005b). Vitamin D receptor (VDR) concentration significantly increased with vitamin 
D3 supplementation (Ceglia et al., 2013); conversely, supplementation conferred no 
benefits on strength, functioning and balance (Latham et al., 2003a, Lips et al., 2010, 
Uusi-Rasi et al., 2015). Moreover, a systematic review examining the effects of 
vitamin D3 supplementation in vitamin D replete adults aged over 18 years found no 
significant effect on grip or proximal lower limb muscle strength; however, pooled 
data including vitamin D deficient participants (serum 25(OH)D <25 nmol.l-1) 
demonstrated a large effect on hip muscle strength (Stockton et al., 2011).  
There is conflicting evidence surrounding the efficacy of vitamin D3 supplementation 
alone or in combination with exercise on musculoskeletal health, with no clear 
consensus regarding the management or prevention of sarcopenia.  Although 
epidemiological data suggest a relationship between vitamin D3 and muscle 
weakness (Visser et al., 2003a), this association is not well understood, and 
evidence in published literature is lacking and contradictory. Considering the 
beneficial effects of both RET and vitamin D3 on muscle tissue, it is plausible an 
additive effect would exist if combined, optimizing the potential for healthy ageing 
muscle (Robinson et al., 2012b). Thus, the aim of this study was to assess the 
combined effect of RET and vitamin D3 supplementation on musculoskeletal health 




2.3. MATERIALS AND METHODS 
 
A systematic review of peer-reviewed literature relating to the effect of RET and 
vitamin D3 supplementation on musculoskeletal health in older adults was conducted 
in accordance with a study protocol registered on the PROSPERO database (record 
number CRD42015020157). The protocol was informed by the Cochrane Handbook 
for Systematic Reviews of Interventions (Higgins and Green, 2011), and reporting 
conformed to the Preferred Reporting Items for Systematic Reviews and Meta-
analysis (PRISMA) statement (Moher et al., 2009).  
2.3.1. Eligibility Criteria  
Randomized controlled trials were sought for this study. Journal studies included: (1) 
male and/or female participants (aged ≥65 years or mean age ≥ 65 years) (2) 
enlisted RET and vitamin D3 supplementation (studies utilising vitamin D3 and 
calcium supplementation were included) (3) included measures of muscle strength, 
function, muscle power, body composition, serum vitamin D/calcium status or quality 
of life (4) compared results with a control group (no exercise/usual care/no vitamin 
D3 supplementation). Articles were excluded if participants were supplemented with 
additional protein or any supplement/medication with a known anabolic effect on 
muscle tissue. 
2.3.2. Search methods for identification of studies 
Articles published before March 2016 were included. A computerised search of 
Science Direct, MedLine, PubMed, Google Scholar and Cochrane Central Register of 
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Controlled Trials (Cochrane CENTRAL accessed by Wiley Science) databases was 
conducted. Table 1 shows the Medline search strategy, devised by AEA and LH. 
2.3.3. Data items and collection 
Data were extracted independently by 2 reviewers (AEA and ASA) using a 
standardised data extraction sheet; any disagreements were discussed and resolved 
with a third person (CAG). The inter-rater reliability assessed using Cohen’s Kappa, 
was found to be excellent (86% agreement) (Hsu and Field, 2003). Data items 
including general information, participant characteristics and details of the 
intervention were extracted. For key outcomes the definition used by the authors, 
methodology, results, mean differences and the presence/absence of statistical 













(65 adj2 (years or age* or old*)) 
 
4 
(old* adj (adult* or people or person* or population* or men or women)) 
 
5 (elder* or senior* or geriatric* or ?enarian or ag?ing) 
 6 
((age* or aging or old* or elder*) adj1 (musc*)) 
  
7 1 or 2 or 3 or 4 or 5 or 6 
  
 8 Vitamin D/ 
 9 (cholecalciferol* or calciferol* or ergocalciferol*) 
 10 (supplements or dietary supplements) 
 11 ((vitamin D* or cholecalciferol or calciferol* OR ergocalciferol) adj supplementation  














(skeletal muscle mass or size or fibres or fibers or area) 
 
18 
(musc* adj2 (function* or power or strength)) 
 
19 
(musc* adj2 (grow* or hypertrophy or size or mass or csa or cross sectional area or volume)) 
 
20 Body Composition/ 
 21 (lean adj3 mass) 
 22 
(protein adj2 (turnover or synthesis or breakdown)) 
 
23 (nitrogen adj2 (balance or turnover or synthesis or breakdown or retention or loss or retain*)) 




13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 
 
26 Exp exercise/ 
 27 (resistance exercise or resistance exercise training) 
 28 ((resistance or strength or weight or cardio or aerobic) adj3 (train* or condition* or exercise* or lift*)) 
 29 (physical adj3 (activit* or exercise* or train* or exertion* or endurance* or therap* or conditioning or 
fitness)) 
 30 (exercise adj3 (train* or intervention* or protocol* or program* or therap* or regim* or activit*)) 
 31 26 or 27 or 28 or 29 or 30 
 32 7 and 12 and 25 and 31   
 33 Limit 32 to humans 
 34 Remove duplicates from 33 
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2.3.4. Risk of bias analysis 
2 reviewers (AEA and CAG) independently assessed the validity of included studies, 
with provisions for moderation from a third reviewer. The Cochrane Collaboration’s 
tool for assessing risk of bias was utilised, as described in the Cochrane Handbook 
for Systematic Reviews of Interventions (Higgins and Green, 2011); the use of scales 
for assessment is explicitly discouraged (Moher and Olkin, 1995, Moher et al., 1996). 
Pre-specified consensus points were devised and agreed by reviewers to ensure 
consistency. It was acknowledged that by nature of design, blinding of participants 
and personnel would be difficult in certain studies; therefore grading was based on 
the likelihood that outcome measures were influenced by the potential lack of 
blinding (Higgins and Green, 2011).  
2.3.5. Grading the quality of evidence 
The Grading of Recommendation, Assessment, Development, and Evaluation 
(GRADE) handbook (Schünemann et al., 2009) was used to evaluate the quality of 
evidence of outcomes assessed within the meta-analyses. The GRADE approach 
utilises systematically produced questions to reach conclusions on degree of 
confidence in the estimate of the effect, with explicit and comprehensive criteria for 
up- or downgrading quality and multiple reviewers minimising individual grader bias.  
GRADE assesses patient important outcomes across five areas; risk of bias, 
inconsistency, indirectness, imprecision and publication bias, and grades outcomes 






2.4.1. Study selection: 
7 studies were included within the review; Agergaard et al., 2015 (Agergaard et al., 
2015b), Bunout et al., 2006 (Bunout et al., 2006b), Drey et al., 2011 (Drey et al., 
2011), Gianoudis et al., 2014 (Gianoudis et al., 2014), Jessup et al., 2003 (Jessup et 
al., 2003), Uusi-Rasi et al., 2015 (Uusi-Rasi et al., 2015), and Verschueren et al., 

















Upon reading full text articles, it became clear that there were 2 separate groups of 
interventions; group 1, in which all participants took part in RET and the intervention 
arm was supplemented with vitamin D3 (describing the additive effect of vitamin D3 
supplementation when combined with resistance exercise training), group 2 in which 
all participants were supplemented with vitamin D3 and the intervention arm took part 
in RET (describing the additive effect of resistance exercise training when combined 
with vitamin D3 supplementation); and studies using a combination of the 2 
interventions (Table 2.2). 
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Table 2.2: Demographics of included studies  



























3x per week 
& 
1920 IU D3 + 
800mg Ca/day  
RET 






Progressed to 6 
– 8 repetitions 
of 80 – 85% 1 
RM  
Group 2: All participants received vitamin D supplementation; intervention group exercised 
Drey et al., 









2x 60 mins per 
week 
& 
>20 ng/ml = 1000 
IU D3/day 




>20 ng/ml = 1000 
IU D3/day 





6 – 15 
repetitions. 
Intensity 
ranged 10 – 16 













3x per week 
& 









5 – 12 
repetitions. 
Intensity 
ranged 5 - 8 on 
Borg scale 
 
Jessup et al., 
2003 (Jessup 







3x 60-90 mins per 
week 
& 




400 IU D3 + 











et al., 2011 
(Verschueren 













3x per week 
&  




= 800 IU D3/day      




1600 IU  
Or 
Conventional 
dose = 800 IU 
D3/day    
+  1000mg 
Ca/day   
6 months 




Rest period 60 
– 5s 
Vibration 
duration: 1 – 12 
mins 
 
Assigned to Group 1 & 2: Participants took part in a combination of exercise and vitamin D interventions 
Bunout et al., 
2006 (Bunout 








2x 1.5h per week 
Or No exercise 
& 
400 IU D3 + 
800mg Ca/day  
RET 
2x 1.5h per week 
























RET 2x/week for 
12 months, 
1x/week for next 
12 months Or   
No exercise 
& 
800 IU D3/day  
RET 2x/week for 
12 months, 
1x/week for next 







from 1.6 to 5.6 
METS. 
Weights: 60 – 
75% 1 RM 
target 
 
RCT:  Randomized Controlled Trial, RET: Resistance Exercise Training, IU: International Units, Ca: Calcium, HV-PRT: High-
Velocity Progressive Resistance Training; RM: Repetition maximum; Hz: Hertz; m: month; s: seconds 
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2.4.2. Study demographics 
7 eligible studies included a total of 792 participants of mean age 72.8 years (Table 
2.2). Of these, 1 included only males (Agergaard et al., 2015b) and 3 included only 
females (Jessup et al., 2003, Uusi-Rasi et al., 2015, Verschueren et al., 2011). All 
studies included healthy participants living independently, except for 2 studies; 
(Jessup et al., 2003) included participants living within a retirement community and 
(Verschueren et al., 2011) included institutionalized participants living in nursing 
homes, service flats or cloistered communities.  
2.4.3. Interventions 
Studies assigned to group 1 included Agergaard et al., 2015 (Agergaard et al., 
2015b); Bunout et al., 2006 (Bunout et al., 2006b) and Uusi-Rasi et al., 2015 (Uusi-
Rasi et al., 2015). In group 1, all participants took part in RET; incorporating a warm-
up and strengthening exercises utilising commercial weight machines (Agergaard et 
al., 2015b, Uusi-Rasi et al., 2015) or Thera-bands (Agergaard et al., 2015b). 2 
studies included balance challenging aspects (Bunout et al., 2006b, Uusi-Rasi et al., 
2015). All studies included supervised, progressive exercise sessions; progression 
was monitored by a 5 rep max (RM) test (Agergaard et al., 2015b), Borg scale 
(Bunout et al., 2006b) or metabolic equivalents (METs) (Uusi-Rasi et al., 2015). Total 
number of sessions delivered ranged from 36 (Agergaard et al., 2015b) to 156 (Uusi-
Rasi et al., 2015), over a duration of 16 weeks (Agergaard et al., 2015b) to 24 
months (Uusi-Rasi et al., 2015). All administered a vitamin D3 supplement, orally in 
tablet form; doses ranged from 400IU (Bunout et al., 2006b) to 1920 IU (Agergaard et 
al., 2015b) per day; in 2 studies participants were supplemented with 800mg calcium 
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per day (Agergaard et al., 2015b, Bunout et al., 2006b) and 1 study supplemented 
the control group with a placebo (Uusi-Rasi et al., 2015). 
6 studies assigned to group 2 included; Bunout et al., 2006 (Bunout et al., 2006b), 
Drey et al., 2011 (Drey et al., 2011) Gianoudis et al., 2014 (Gianoudis et al., 2014), 
Jessup et al., 2003 (Jessup et al., 2003), Uusi-Rasi et al., 2015 (Uusi-Rasi et al., 
2015) and Verschueren et al., 2011 (Verschueren et al., 2011). Within group 2, all 
participants took a vitamin D3 supplement, orally in tablet form. Doses ranged from 
400 IU (Bunout et al., 2006b, Jessup et al., 2003) to 2000 IU (Drey et al., 2011) per 
day; 1 study monitored serum 25(OH)D at baseline to determine supplement dosage 
(Drey et al., 2011). In 4 studies (Bunout et al., 2006b, Gianoudis et al., 2014, Jessup 
et al., 2003, Verschueren et al., 2011) all participants were supplemented with 
calcium; doses ranged from 700mg (Gianoudis et al., 2014) to 1000mg (Jessup et 
al., 2003, Verschueren et al., 2011) per day. The intervention group took part in RET. 
Studies utilised machine weights and pulleys (Drey et al., 2011, Gianoudis et al., 
2014, Jessup et al., 2003, Uusi-Rasi et al., 2015), Thera-bands (Bunout et al., 
2006b), weighted vests (Jessup et al., 2003) and Whole Body Vibration (WBV) 
machines (Verschueren et al., 2011) for resistance. 5 studies included balance 
challenging aspects (Bunout et al., 2006b, Drey et al., 2011, Gianoudis et al., 2014, 
Jessup et al., 2003, Uusi-Rasi et al., 2015). All studies employed supervised, 
progressive exercise sessions monitored via a Borg scale (Bunout et al., 2006b, Drey 
et al., 2011, Gianoudis et al., 2014), addition of weights to weighted vests (Jessup et 
al., 2003), estimation of METs or individual ability (Verschueren et al., 2011). Total 
number of sessions delivered ranged from 24 (Drey et al., 2011) to 156 (Uusi-Rasi et 
al., 2015), over a  duration of 12 weeks (Drey et al., 2011) to 24 months (Uusi-Rasi et 
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al., 2015). Note that 2 studies included comparators which allowed allocation to both 
groups (Bunout et al., 2006b, Uusi-Rasi et al., 2015). 
2.4.4. Outcome measures 
All outcomes are listed in Table 2.3. Group 1 studies had few outcomes in common; 
however, all measured muscle strength (Agergaard et al., 2015b, Bunout et al., 
2006b, Uusi-Rasi et al., 2015); isometric knee extensor strength was measured using 
a strain gauge (Agergaard et al., 2015b, Uusi-Rasi et al., 2015) and isometric 
quadriceps strength was measured using a quadriceps table (Bunout et al., 2006b). 
Hand grip strength was measured using a hand grip dynamometer (Bunout et al., 
2006b). Magnetic resonance imaging (MRI) was used to measure the CSA of the 
quadriceps (Agergaard et al., 2015b), whilst (Bunout et al., 2006b) analysed fat and 
lean mass using dual-energy X-ray absorptiometry (DXA). 2 studies measured timed-
up and go (TUG), femoral neck and spine bone mineral density (BMD) (Bunout et al., 
2006b, Uusi-Rasi et al., 2015). 1 study analysed fibre type and muscle quality 
(Agergaard et al., 2015b).  
Of group 2 studies, (Bunout et al., 2006b, Gianoudis et al., 2014, Uusi-Rasi et al., 
2015, Verschueren et al., 2011) assessed lower limb strength, and (Bunout et al., 
2006b, Jessup et al., 2003) measured grip strength. Muscle power was measured as 
sit-to-stand transfer power (Drey et al., 2011) and the stair climb test (Gianoudis et 
al., 2014). The short physical performance battery (SPPB) was assessed by (Bunout 
et al., 2006b, Gianoudis et al., 2014), and the TUG by (Bunout et al., 2006b, 
Gianoudis et al., 2014, Uusi-Rasi et al., 2015). BMD of the femoral neck (Bunout et 
al., 2006b, Gianoudis et al., 2014, Jessup et al., 2003, Uusi-Rasi et al., 2015, 
Verschueren et al., 2011) and spine (Bunout et al., 2006b, Gianoudis et al., 2014, 
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Jessup et al., 2003, Uusi-Rasi et al., 2015) were measured using DXA. Lean mass 
was measured using DXA (Bunout et al., 2006b, Drey et al., 2011, Gianoudis et al., 
2014) and X-ray computed tomography (CT) (Verschueren et al., 2011). Balance was 
assessed via the Romberg ratio (Bunout et al., 2006b), four square step test 
(Gianoudis et al., 2014), an AccuSway platform (Jessup et al., 2003) and backwards 
walking (Uusi-Rasi et al., 2015). Other outcomes included endurance (12-minute 
walk (Bunout et al., 2006b)), the 30 second sit-to-stand test (Gianoudis et al., 2014), 

























Table 2.3: Summary of included study outcome measures and significant results 
 










Isometric knee extensor (strain gauge) 
 
MRI of quadriceps muscle (6mm thick) 
 
Muscle strength/CSA 
Muscle strength – Increased (p<0.0001) but no between-group difference 
(1.24% Vs 0.70% per week) 
Muscle CSA – Increased (p=0.001) but no between-group difference (0.41% 
Vs 0.71% per week)Muscle quality – N/S   
 
 Bunout et al., 
2006  









Quadriceps (table) & hand grip 
strength (dynamometer) 
SPPB, TUG 
Femoral neck & spine (DXA) 
Romberg ratio 
Distance walked in 12 minutes 
Muscle strength – Increased with exercise (p<0.001), no effect of vit D 
(0.46% Vs 0.59% per week)  
Muscle function – SPPB (p=0.002) no effect of vit D (0.41% Vs 0.29% per 
week) TUG: Increased in both groups (p=0.004) (0.07% Vs 0.18% per week) 
BMD – Femoral neck increased with vit D, decreased without (p=0.006) 
(+0.03% Vs -0.03% per week). Spine was N/S 
Body sway – Lower with vit D than without (p=0.05) (-0.08% Vs +0.48% per 
week) 
Endurance – N/S 
 
      Drey et al., 
2011 













Muscle power - Increased with vit D intake (p=0.017). (+0.01% Vs 0.002%) 
(0.69% Vs 0.21% per week) 
Muscle function – SPPB increased with exercise (p=0.009) (0.86% Vs -
0.05%) (+0.85% Vs -0.43% per week), SF-LLFDI was N/S 
Body composition – aLM was N/S 
 
 











Lower limbs (bilateral leg press) and 
back (seated row) 
Timed stair climb test 
30 second sit-to-stand test, TUG 
Femoral neck & spine (DXA) 
Total body lean & fat mass (DXA) 
Four Square Step Test 
Muscle strength- Exercise increased strength by +3% (p<0.05) (0.47% Vs 
0.29% per week) 
Muscle power – Exercise increased power by +5% (p<0.05) (0.21% Vs 
0.14% per week) 
Muscle function – Exercise improved Sit-to-stand by +16% (p<0.001) (0.35% 
Vs 0.05% per week). TUG -N/S 
BMD – Exercise increased femoral neck & spine BMD by +0.1% (p<0.05) 
(FN: +0.01% Vs -0.01%; spine: 0.03% Vs 0.01% per week) 
Body composition – Lean & fat mass – N/S 
Dynamic balance – Exercise improved by +6% (p<0.01) (-0.24% Vs -0.12% 
per week) 
 





Table 2.3: Summary of included study outcome measures and significant results continued 
 
 Outcome measures Significant results 
Jessup et al., 
2003 






Hand grip (dynamometer), mean of 8 
tests (stack machine) 
Femoral neck & spine (DXA) 
 
AccuSway force platform 
 
Muscle strength – increased with exercise (p=0.0156). No effect of vit 
D (0.57% Vs 0.19% per week) 
BMD femoral neck – increase with exercise (p=0.00001), increase with 
vit D (p=0.016) (0.30% Vs -0.17% per week) 
Spine – increase with exercise (p=0.0094), vit D supplementation N/S 
(0.39% Vs -0.03% per week) 
Body sway – N/S 










Max isometric leg extensor strength at a 
knee angle of 110° 
SPPB, TUG 
Femoral neck & spine (BMD) 
Backwards walking  
Muscle strength – increased with exercise (p<0.001). Vit D 
supplementation N/S (0.15% Vs 0.13% per week) 
Muscle function – SPPB = N/S. TUG improved in vitamin D and 
exercise group (p=0.01) (-0.02% Vs +0.01% per week) 
BMD – Femoral neck – Vit D maintained BMD (p=0.02) as did exercise 
(p=0.01) (-0.01% Vs -0.01% per week). Spine – N/S 
Dynamic balance – Improved with exercise (placebo: p=0.001, vit D: 
p=0.03). No additive effect of vit D (0.25% Vs 0.25% per week) 
    Verschueren et 
al., 2011 
(Verschueren 






Isometric & dynamic knee extensor 
strength 
Femoral neck (DXA) 
Mass of upper leg (Multi-slice CT) 
 
Muscle strength – Isometric: N/S. Dynamic: improved in all groups. Vit 
D=no effect (0.48% Vs 0.05% per week) 
BMD – Improved in all groups. No difference between training of vit D 
groups (0.03& Vs 0.03% per week) 




CSA: Cross-sectional Area, MRI: Magnetic Resonance Imaging, ELISA: Enzyme-linked Immunosorbent Assay, BMD: Bone Mineral Density, SPPB: 
Short Physical Performance Battery, TUG: Timed Up and Go, DXA: Duel-energy X-ray Absorptiometry, SF-LLFDI: Short Form of the Late Life Function 




Figure 2.2: Summary of risk of bias analysis for included studies 
 
Risk of bias domains of assessment. 1: Random sequence generation, 2: Allocation concealment, 3: 
Blinding of participants and personnel, 4: Blinding of outcome assessment, 5: Incomplete outcome 
data, 6: Selective reporting, 7: Other sources of bias.  Judgements possible: H – High risk of bias, U – 
Unclear risk of bias, L – Low risk of bias 
 
2.4.5. Risk of bias within studies 
For all studies, a high proportion of components were assigned an unclear risk of 
bias due to insufficient information and the unknown effect on study outcome 
measures. Many studies reported insufficient information on concealment and 
blinding procedures, or whether procedures were in place in the event of unblinding. 
In total, 6 studies were judged to have an unclear risk of bias (Agergaard et al., 
2015b, Bunout et al., 2006b, Drey et al., 2011, Jessup et al., 2003, Uusi-Rasi et al., 
2015, Verschueren et al., 2011).  Component 1 was assessed as having a low risk of 
bias for all studies. 1 study was assessed as having an overall high risk of bias 
(Gianoudis et al., 2014) due to component 5, as no data were entered into the 












2.4.6. GRADE analysis  
The GRADE summary of findings table for groups 1 and 2 are shown in Tables 2.4 and 2.5.  
Table 2.4: GRADE analysis of Group 1 measurement outcomes included in the quantitative synthesis 
Quality Assessment Summary of Findings 
Outcome Included 
studies  

























Undetected^ 131/135 0.98 
(Interventio
n) 














line of no 
effect/ OIS 
not reached) 
Undetected^ 124/125 0.37 
(Interventio
n) 














line of no 
effect/ OIS 
not reached) 
Undetected^ 124/125 0.02 
(Interventio
n) 
















line of no 
effect/ OIS 
not reached) 
Undetected^ 124/125 0.02 
(Interventio
n) 




ROB: Risk of Bias; TUG: Timed Up and Go; RCT: Randomized Controlled Trial; CI: Confidence Interval; BMD: Bone Mineral Density; OIS: Optimum Information Size. 






Table 2.5: GRADE analysis of Group 2 measurement outcomes included in the quantitative synthesis 
 
Quality Assessment Summary of Findings 
Outcome Included 
studies  







Significance 95% CI Quality 







No serious imprecision Undetected^ 45/46 1.09 
(Intervention) 
p = 0.02 (0.15,2.03) ⊕⊕⊕⊕ 
High 







No serious imprecision Undetected^ 124/126 -1.57 
(Intervention) 













No serious imprecision Undetected^ 124/126 2.69 
(Intervention) 
p = 0.002 (0.96,4.42) ⊕⊕⊕○ 
Moderate 
 Hand grip 
strength 








(CI cross line of no 
effect, OIS not 
reached) 
Undetected^ 31/33 0.85 
(Intervention) 
p = 0.55 (-1.93,3.63) ⊕⊕⊕○ 
Moderate 







(CI cross line of no 
effect, OIS not 
reached) 
Undetected^ 112/114 -0.12 
(Intervention) 
p = 0.37 (-0.38,0.14) ⊕⊕○○ 
Low 









(CI cross line of no 
effect, OIS not 
reached) 
Undetected^ 103/105 0.02 
(Intervention) 
p = 0.98 (-1.31,1.35) ⊕⊕○○ 
Low 







(CI cross line of no 
effect, OIS not 
reached) 
Undetected^ 103/105 -0.39 
(Intervention) 
p = 0.76 (-2.82, 2.05) ⊕⊕○○ 
Low 






No serious imprecision Undetected^ 124/126 0.04 
(Intervention) 
p = 0.002 (0.01,0.06) ⊕⊕⊕○ 
Moderate 








(CI cross line of no 
effect, OIS not 
reached) 
Undetected^ 124/126 0.02 
(Intervention) 
p = 0.24 (-0.001,0.05) ⊕○○○ 
Very low 




Within group 1, all studies were evaluated as moderate quality of evidence; no 
serious risk of bias was detected. Due to the nature of the studies included within this 
review, no serious indirectness was detected; all outcomes were measured directly 
without the use of a surrogate. Publication bias was not detected, and due to the 
number of studies included, it was not possible to produce funnel plots for any 
outcomes. Although publication bias was “not detected”, it is difficult to conclude that 
there was a complete absence of bias since studies with significant results are more 
likely to be published than those reporting null or non-significant results (Higgins and 
Green, 2011) Published, peer-reviewed articles were included in this review, since 
the Cochrane Handbook for Systematic Reviews of Interventions further suggests 
that the inclusion of unpublished studies may introduce additional bias, as these 
studies have not been strengthened by the peer-review process and may be of lower 
methodological quality (Higgins and Green, 2011). Reasons for downgrading the 
quality of evidence included serious inconsistency due to substantial heterogeneity, 
and serious imprecision due to confidence intervals crossing the line of no effect. 
Within group 2 studies, 5 outcomes were graded as high to moderate quality of 
evidence (SPPB, TUG, muscle strength of the lower limb, hand grip strength and 
BMD of the femoral neck). Remaining outcomes were graded as low or very low 
quality, meaning that one could have little or very little confidence in the effect 
estimate. Common reasons for downgrading outcomes included a combination of 
serious risk of bias (due to the inclusion of study (Gianoudis et al., 2014)), serious 





2.4.7. Results of individual studies and synthesis of results 
Results of the 2 groups of studies are reported separately. Qualitative syntheses 
were conducted for studies with similar interventions and outcomes measures using 
RevMan 5.3 software. Study outcomes reporting results in the same units were 
pooled using a fixed-effect meta-analysis. Effect sizes are expressed as percentage 
mean differences or standardized mean differences (when outcomes were measured 
utilising different methods), with 95% confidence intervals. Higher weighting was 
assigned to studies with smaller standard deviations and a larger sample size 
(Higgins and Green, 2011). Analyses were completed from extracted data; where 
necessary data were estimated from statistics or figures, or requested from the 
authors of the article. Heterogeneity was assessed via the chi squared test (Figures 
2.3 – 2.15 and Tables 2.4 and 2.5). Article (Verschueren et al., 2011) was not 
included in any of the quantitative analyses since the exercise intervention modality 
was considered to be too dissimilar to compare to the other included articles. Within 
each group, there were outcomes unsuitable for quantitative synthesis, due to a lack 
of studies with common outcomes or aspects of studies too dissimilar for comparison; 
therefore, a narrative analysis was utilised. 
2.4.8. Quantitative synthesis 
Outcomes compared for group 1 included muscle strength of the lower limb, TUG 
and BMD of the femoral neck and spine (Figures 2.3-2.6). Only muscle strength of 
the lower limb was found to be significant, with a large effect size in favour of the 




Figure 2.3: Group 1 analysis of muscle strength of the lower limb 
 
 
Figure 2.4: Group 1 analysis of the TUG test 
 
 
Figure 2.5: Group 1 analysis of BMD of the hip 
 
Figure 2.6: Group 1 analysis of BMD of the spine 
 
Group 2 comparisons included the SPPB (Figure 2.7), TUG (Figure 2.8), muscle 
strength of the lower limb (Figure 2.9), hand grip strength (Figure 2.10), weight 
(Figure 2.11), lean mass (Figure 2.12), fat mass (Figure 2.13), BMD of the femoral 
neck (Figure 2.14) and spine (Figure 2.15). Of these outcomes, hand grip strength, 
weight, lean mass, fat mass and the BMD of the spine were found to be non-
significant. However, SPPB score was more improved in the intervention group (1.09, 
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95% CI 0.15, 2.03. p = 0.02), with a significant and large effect. Similarly, TUG was 
significantly reduced within the intervention group (-1.57, 95% CI -2.50, -0.64. p = 
0.0010). The results of the quantitative analysis also supported the combined 
intervention for muscle strength of the lower limb (2.69, 95% CI 0.95, 4.42). p = 
0.002), and BMD of the femoral neck (0.04, 95% CI 0.01, 0.06. p = 0.002).  
 
Figure 2.7: Group 2 analysis of the SPPB test 
 
 
Figure 2.8: Group 2 analysis of the TUG test 
 
 
Figure 2.9: Group 2 analysis of muscle strength of the lower limb 
 
 





Figure 2.11: Group 2 analysis of total body weight 
 
Figure 2.12: Group 2 analysis of lean mass 
 
 
Figure 2.13: Group 2 analysis of fat mass 
. 
 
Figure 2.14: Group 2 analysis of BMD of the hip 
 
 





2.4.9. Qualitative synthesis  
Referring to the narrative synthesis guidelines provided by the Cochrane Consumers 
and Communication Review Group (Ryan.R, 2013), it was appropriate to apply 2 
steps listed; developing a preliminary synthesis and exploring the relationships within 
and between studies. To develop a primary synthesis, results were systematically 
tabulated to identify patterns across studies (Appendices A-C). Exploring the 
relationships between and within studies for group 1, the control group in study 
(Agergaard et al., 2015b) demonstrated a significant percentage increase in CSA of 
the quadriceps from baseline in comparison to the intervention group (+8.46% versus 
+4.94%, p < 0.05).  
Comparing primary outcomes for group 2, the percentage increase in isometric knee 
extensor strength for study (Verschueren et al., 2011) was greater in the intervention 
group (+3.01% versus +0.11%), although not statistically significant. Muscle power 
was compared in studies (Drey et al., 2011) and (Gianoudis et al., 2014), expressed 
as sit-to-stand transfer power and functional stair climbing muscle power 
respectively. Both studies reported a significant percentage increase in muscle power 
within the intervention groups, and smaller, non-significant increases within the 
control groups (sit-to-stand transfer power intervention group +8.00% versus +2.61%, 
p = 0.017; functional stair climbing muscle power intervention group +10.51% versus 
+7.32%, p < 0.05).  
The 30 second sit-to-stand test showed significant favourable results for the 
combined intervention of exercise and vitamin D3 (+10.40% versus +6.20%, p<0.05). 
Within study (Uusi-Rasi et al., 2015), normal walking speed and the 5-time chair 
stand time deteriorated non-significantly in both groups. The 12-minute walk test in 
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study (Bunout et al., 2006b) was further improved within the control group, although 
this did not achieve statistical significance. The four square step test, body sway and 
backwards walking were significantly more improved in the intervention groups. Only 
Romberg ratio showed the greatest improvement within the control group; Romberg 
ratio was decreased in comparison with the intervention group, although the results 
were non-significant (+2.8% versus -0.60%). 
For group 2 secondary outcomes, small and non-significant gains in appendicular 
lean mass were demonstrated in the intervention group of study (Drey et al., 2011). 
In study (Verschueren et al., 2011), muscle mass of the upper limb decreased non-
significantly in both the intervention and control groups, although to a lesser extent in 
the intervention group. BMD of the femoral neck was gained in both groups, although 
by a higher percentage in the control group; both trends were non-significant.  
In summary, meta-analyses for group 1 found muscle strength of the lower limb to be 
significantly improved within the intervention group (0.98, 95% CI 0.73, 1.24, 
p<0.001). All other outcomes showed small but non-significant positive effects for the 
intervention group. The SPPB, TUG, muscle strength of the lower limb and femoral 
neck BMD all showed significantly greater improvements in the intervention group for 
group 2 comparisons. 
The narrative analysis revealed significant differences in body composition, muscle 
power, muscle function and balance. A significant percentage increase in quadriceps 
CSA was observed in the control group of study (Agergaard et al., 2015b). The 
combined intervention of RET and vitamin D3 supplementation resulted in a greater 
percentage increase in muscle strength and power, and a greater improvement in the 
30 second sit-to-stand test, the four-square step test, body sway and backwards 
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walking. However, vitamin D3 supplementation alone resulted in a greater 




The aim of this systematic review was to assess the combined effect of RET and 
vitamin D3 supplementation on musculoskeletal health in older adults. Only 7 studies 
were eligible for inclusion, with a total of 792 participants, highlighting the lack of 
available literature on the topic. Studies were categorised into 2 groups; studies in 
which all participants took part in RET and the intervention group was supplemented 
with vitamin D3, or studies in which all participants were supplemented with vitamin 
D3 and the intervention group took part in RET. 2 studies were categorized into both 
group 1 and group 2. 
2.5.1. Quantitative analysis 
Data analysis conducted for this review included meta-analyses and narrative 
reviews. Meta-analyses for group 1 included muscle strength of the lower limb, TUG 
and BMD of both the femoral neck and spine. Evidence of additional benefit was 
shown for all outcomes within the intervention group; however, the effect size was 
small and non-significant for TUG and BMD of the femoral neck and spine. Muscle 
strength of the lower limb was the only significant outcome of group 1, with a large 
effect size observed within the intervention group (0.98, 95% CI 0.73, 1.24. 
p<0.00001). Although numerous studies have demonstrated the beneficial effect of 
RET on muscle strength in older adults (Henwood and Taaffe, 2005, Kosek et al., 
2006, Stewart et al., 2014), this result provides evidence that vitamin D3 
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supplementation may enhance these effects in older adults. Skeletal muscle 
myopathies associated with vitamin D deficiency are well documented (Smith and 
Stern, 1967), and symptoms of significant muscle weakness are reversed with 
treatment of the deficiency (Glerup et al., 2000c). A systematic review and meta-
analysis reported a gain in lower extremity strength with vitamin D supplementation 
only in vitamin D deficient older adults; no effect was observed in replete adults 
(Stockton et al., 2011). Similarly, no effect of vitamin D3 supplementation on 
isometric quadriceps strength was demonstrated after 6 months in vitamin D replete 
older adults (Grady et al., 1991). Interestingly, although the studies included within 
group 1 (Agergaard et al., 2015b, Bunout et al., 2006b, Uusi-Rasi et al., 2015) did not 
specify serum 25(OH)D concentration as inclusion/exclusion criteria, baseline and 
post-intervention serum 25(OH)D were within the ‘sufficient’ range (>30 nmol.L-1). A 
greater increase of muscle strength in replete older adults represents a novel finding 
of this review. Preliminary support for combined vitamin D supplementation and RET 
was demonstrated in a 3-month longitudinal study examining the effect of serum 
25(OH)D and exercise training on functional performance in older men and women 
aged 65 years and over. No significant improvements in function were reported in 
participants with lower serum 25(OH)D (<47.5 nmol.L-1), however higher serum 
25(OH)D (>67.5 nmol.L-1) was associated with greatest improvements in functionality 
and muscle strength (Okuno et al., 2010a). 
This finding must be considered within the context of the risk of bias and GRADE 
analyses. The risk of bias analysis showed an overall unclear risk of bias for the 
included studies, and the GRADE analysis concluded that the evidence was of 
moderate quality; however, serious inconsistency due to moderate heterogeneity (I2 
= 70%) was detected. This heterogeneity may have been due to the differing duration 
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of interventions (12 weeks to 24 months), differences between measurement 
methodologies, differences between exercise regimens (although all adopted 
progressive RET), doses of vitamin D3 (400 IU to 1920 IU per day), or may indicate 
that these studies were unsuitable for comparison.  
Significant effects for the SPPB, TUG, muscle strength of the lower limb, and the 
BMD of the femoral neck were observed within the intervention groups of group 2 
studies; unsurprisingly, RET was found to have a positive influence. In a recent 
systematic review and meta-analysis, exercise significantly increased SPPB score 
and decreased TUG time, with large effect sizes (1.87 and -2.47 respectively (Giné-
Garriga et al., 2014b)); similar results are reported within this review. Vitamin D is a 
regulator of BMD, proliferating calcium and phosphate absorption in the intestine and 
acting directly on bone cells (Lips et al., 2006). Vitamin D has previously been shown 
to influence BMD, fracture rate and risk (Brincat et al., 2015); studies of patients who 
have sustained a hip fracture typically demonstrated low serum vitamin D (≤30.0 
nmol.L-1; (LeBoff et al., 1999)). Supplementation of vitamin D and calcium has been 
shown to significantly decrease the rate of bone loss in the hip and spine (Tang et al., 
2007). GRADE analyses for these outcomes concluded the quality of evidence to be 
high (SPPB and TUG) or moderate (muscle strength of the lower limb and BMD of 
the femoral neck). 
Closer examination of the control groups within significant outcomes for group 2 was 
undertaken to evaluate the effect of vitamin D3 supplementation alone. Intriguingly, 
although the intervention groups (RET and vitamin D3 supplementation) showed 
evidence of benefit in number of outcomes, the control groups (vitamin D3 
supplementation alone) showed mixed, or even negative impacts on the same 
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outcomes. SPPB score was decreased post-intervention compared with baseline by 
0.30% and 0.50% in the control groups of studies (Bunout et al., 2006b) and (Drey et 
al., 2011) respectively. Muscle strength of the lower limb and BMD of the femoral 
neck showed mixed results for the intervention groups, with some studies reporting 
small increases and others reporting small losses (non-significant). Previous reports 
of the effect of vitamin D supplementation on muscle strength and physical 
functioning are mixed; the InCHIANTI study of people aged 65 years or over reported 
a significant association between serum 25(OH)D <25 nmol.L-1 and SPPB score 
(Houston et al., 2007a). Similarly, a large prospective cohort of older adults aged 65 
years or over found those with low (<25 nmol.L-1) 25(OH)D were significantly more 
likely to experience losses in grip strength and higher rates of appendicular lean 
mass loss compared to those with higher (>50 nmol.L-1) 25(OH)D(Visser et al., 
2003a). Conversely, another large, prospective study found no association between 
serum 25(OH)D, walking speed and time for repeated chair stands (Verreault et al., 
2002). The TUG test time was actually significantly increased within the control group 
of study (Bunout et al., 2006b), and increased by a smaller, non-significant amount in 
study (Uusi-Rasi et al., 2015). Again, participants included in studies (Bunout et al., 
2006b) and (Uusi-Rasi et al., 2015) had sufficient serum 25(OH)D levels, indicating 
that supplementation in replete older adults may not confer additional benefits to 
neuromuscular function unless combined with exercise. 
2.5.2. Narrative analysis 
Studies in group 1 (Agergaard et al., 2015b, Bunout et al., 2006b, Uusi-Rasi et al., 
2015) had few body composition outcomes in common, therefore a narrative analysis 
was conducted. The CSA of the quadriceps was analysed within study (Agergaard et 
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al., 2015b), and results showed that although the intervention group did experience a 
+4.94%, increase from baseline, the control group (not supplemented with vitamin 
D3) actually showed a significantly higher increase in quadriceps CSA (+8.46%, 
p<0.05).  
These results do not provide evidence for the additive effects of combined exercise 
training and vitamin D3. Other study groups have reported changes in muscle CSA 
consequent to RET which are both smaller (Häkkinen et al., 1998, Trappe et al., 
2002) and comparable (Ferri et al., 2003) to those reported in study (Agergaard et 
al., 2015b). Interestingly, a study (Agergaard et al., 2015b) also assessed “muscle 
quality” (muscle strength/CSA); although non-significant, the intervention group 
improved their muscle quality to a greater degree than the control group (+9.61% 
versus +0.66% change from baseline). The intervention and control groups both 
increased their muscle strength to a similar degree, and there was no significant 
difference between these changes; however, the control group (as previously 
mentioned) demonstrated a larger increase in their muscle CSA. This shows that the 
gains in muscle strength in the intervention group surpassed the improvements made 
in muscle CSA, indicative of an increased functionality of the muscle to produce 
force; conceptually more relevant in combatting the effects of sarcopenia than 
muscle size and strength alone (Fragala et al., 2015).  
Results of the narrative analysis for group 2 showed that the combined intervention 
of RET and vitamin D3 supplementation was significantly more beneficial than 
vitamin D3 supplementation alone for sit-to-stand transfer power, functional stair 
climbing muscle power, 30 second sit-to-stand, 5-time chair stand, the four square 
step test, body sway and backwards walking. Only body sway was negatively 
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affected by vitamin D3 supplementation, although the within group change was non-
significant. Other outcomes of interest included normal walking speed, which 
deteriorated in both groups, the distance walked in 12 minutes and Romberg ratio, in 
which the control groups made the most improvement, although not significantly. 
2.5.3. Limitations 
Few published studies were eligible for inclusion within this review, although this 
serves to highlight the knowledge gap with respect to this topic. The inclusion of a 
high risk study was deemed necessary due to the lack of available literature, 
although this had a negative effect on the perceived quality of evidence for the 
outcomes in which it was reported. Generally, outcome measure data could be 
graded as representing moderate quality, although there were several outcome 
measures graded as low or very low quality, due to the high variability of participant 
numbers, duration of interventions, exercise methodologies or differing vitamin D3 
doses and period of supplementation employed within the studies. Furthermore, data 
produced from meta-analyses including study (Uusi-Rasi et al., 2015) may have been 
skewed due to the high weighting assigned for this study as a result of the large 
number of participants recruited. 
Of the individual studies included within this review, none reported 
inclusion/exclusion criterion for vitamin D status, and although at baseline serum 
vitamin D was not significantly different between the groups in 5 studies (Uusi-Rasi et 
al., 2015, Agergaard et al., 2015b, Bunout et al., 2006b, Drey et al., 2011, 
Verschueren et al., 2011), 2 studies reported no data for serum vitamin D  pre or 
post-intervention (Gianoudis et al., 2014, Jessup et al., 2003). Additionally, analysis 
methods used within 5 studies included did not account for confounding factors 
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(Agergaard et al., 2015b, Bunout et al., 2006b, Drey et al., 2011, Gianoudis et al., 
2014, Verschueren et al., 2011), and participants were not stratified on the basis of 
any characteristics in 3 studies (Agergaard et al., 2015b, Jessup et al., 2003, Uusi-
Rasi et al., 2015), although these were single-sex studies. Unfortunately, several 
outcome measures were unsuitable for inclusion within the qualitative analysis due to 




This review provides tentative support for the additive effect of combined RET and 
vitamin D3 supplementation for the improvement of muscle strength in older adults. 
For other aspects of musculoskeletal function, such as SPPB and TUG, no additional 
benefit beyond that gained from exercise training was found. This review showed no 
evidence of benefit of vitamin D3 supplementation alone, however, few studies were 
identified during the literature search, highlighting that further evidence is required to 
draw any firm conclusions or make explicit recommendations regarding vitamin D3 










2.7. 2019 Update 
 
The systematic review search strategy was re-applied to electronic databases on 
02/09/19; the search identified several studies of interest, the majority of these 
studies included participants <65 years of age (Carrillo et al., 2013, Ebid et al., 2017, 
Jung et al., 2018, Lithgow et al., 2018) and one study lacked a true control group 
(Mieszkowski et al., 2018), therefore making them ineligible for inclusion. However, 
one study would be eligible for inclusion (Aoki et al., 2018). 
Only one study reported an association between vitamin D3 supplementation and 
muscle mass; 4000 IU/d vitamin D3 significantly increased total muscle mass and leg 
lean mass in comparison to 800 IU/d vitamin D3 supplementation and exercise 
training in older adults who were vitamin D insufficient at baseline (Mieszkowski et 
al., 2018). Finally, vitamin D3 supplementation significantly improved postural and 
anteroposterior steadiness (Aoki et al., 2018) in comparison to exercise training or 







Table 2.6: Characteristics and results of ineligible and relevant studies to the systemic review 2019 update, continued 
 Baseline characteristics Groups  










Intervention Control Results and comment 
 Mieszkowski 
et al, 2018 
42 69.0 100 47.6 Oct-Jan 1) 4000 IU D3/d + high-intensity Nordic walking 
(high-dose) 
2) 4000 IU D3/d + moderate-intensity Nordic 
walking (high-dose) 
3) 800 IU D3/d + high-intensity Nordic walking 
(low-dose) 
4) 800 IU D3/d + moderate-intensity Nordic 
walking (low-dose) 
All for 2 hours per session, 3x/wk for 12 wks 
- Skeletal muscle mass (+4% vs +2%) and leg lean mass 
(+4% vs +0%) significantly increased in the high-dose vitamin 
D groups in comparison to the low-dose groups. 
- There was a significant effect of exercise intensity (MI-NW) 
and vitamin D dose (high-dose) on peak knee torque flexion 
(p = 0.0327). 
- Elbow extension (p = 0.0001) and flexion (p = 0.0231) 
significantly increased by 11% in the HI-NW group regardless 
of vitamin D dose. 
         Aoki et al, 
2018 
148 70.5 78.5 29.0 Nov ’14 – 
March 
‘16 
1) Exercise + 1000 IU D3/d for 24wks 
2) Exercise alone for 24 wks 
3) 1000 IU D3/d for 24 wks 
Exercise was single-leg stand (3 x/d for 1 
minute) and single-leg squat (18 reps) daily 
- Lower limb muscle mass (bioelectrical impedance), knee 
extensor and flexion strength (dynamometer) and muscle 
power (sit-to-stand test) increased significantly in all groups 
with no between-group differences. 
- Postural steadiness (single-leg stance) was significantly 
improved only in the exercise and vitamin D group. 
- Anteroposterior stability (functional reach test) improved 
significantly only in the vitamin D group 




















IS SERUM 25(OH)D CONCENTRATION ASSOCIATED WITH LEAN 
MASS AND STRENGTH AND IS SARCOPENIC STATUS SEASONAL-
DEPENDENT IN SUBGROUP OF POSTMENOPAUSAL WOMEN FROM 





















Vitamin D deficiency is known to be associated with myopathy and myalgia. Older 
adults are at an increased risk for both vitamin D deficiency and sarcopenia (loss of 
muscle mass and function). The role of vitamin D in regulating muscle mass and 
strength is not well established, with previous studies reporting conflicting and 
inconclusive results.  Since 25(OH)D status is known to be season-dependent, there 
is a rationale to suggest that aspects of muscle health, including sarcopenia, may 
also vary by season. The aim of the current study was to assess the relationship 
between serum 25(OH)D concentration, lean mass and muscle strength. The 
secondary aim was to establish whether sarcopenic status was season-dependent.  
Methods 
This was a secondary data analysis of a subgroup of 188 postmenopausal women 
participating in the 2006-2007 D-FINES (Vitamin D, Food Intake, Nutrition and 
Exposure to Sunlight in Southern England) study. The cohort was assessed as a 
whole group and 2 subgroups; postmenopausal women <65 years (n = 139) and 
postmenopausal women ≥ 65 years (n = 49). Outcome measures included lean mass 
(DXA), muscle strength (handgrip dynamometry) and serum 25(OH)D concentration 
(enzymeimmunoassay). Derived outcomes included appendicular skeletal muscle 
mass and appendicular skeletal muscle index. Sarcopenic status was assessed 
using the European Working Group on Sarcopenia in Older People 2018 criteria. 
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Non-parametric partial correlation using BMI as a covariate was used to evaluate 
the study aims. 
Results 
There was no association between total lean mass and ASM in any group at any 
seasonal timepoint. Following adjustment for BMI, relative appendicular skeletal 
muscle index was positively and significantly associated with 25(OH)D concentration 
for the whole cohort in autumn (rs = 253. 95% CI 0.08, 0.42), p = 0.002), however, 
this relationship was not observed in either subgroup nor in the spring months. A 
small but significant negative relationship between seasonal change in total lean 
mass and change in 25(OH)D (rs = -.211. 95% CI -0.39, -0.03), p = 0.018) was 
observed for the whole cohort. Muscle strength was positively associated with 
25(OH)D concentration at all seasonal timepoints for all groups, with significance 
observed during the summer and autumn months for the whole cohort and 
postmenopausal women <65 years after adjustment for seasonal BMI. Sarcopenia 
prevalence was highest in women ≥ 65 years and varied by season in both 
postmenopausal groups. Serum 25(OH)D concentration was lower in sarcopenic 
women.  
Conclusions 
Sarcopenic status appeared transient and season-dependent, with the highest 
percentage of sarcopenic women observed in the spring. As the sample of 
sarcopenic participants was small, further research investigating year-round 






Vitamin D deficiency is highly prevalent and has been recently described as a “global 
pandemic” (Pludowski et al., 2018), with older adults being a group particularly at risk 
(van Schoor and Lips, 2018) due to factors including a decreased cutaneous capacity 
to synthesise vitamin D (MacLaughlin and Holick, 1985) and limited sun exposure 
due to physical inactivity and reduced time spent outdoors (Kühn et al., 2018). 
Additionally, it is well established that serum 25(OH)D concentration is known to vary 
by season (Christensen et al., 2010, Bird et al., 2012, Darling et al., 2014a, Elizondo-
Montemayor et al., 2017), although it has been suggested that this variation is 
minimal (Lagunova et al., 2009) or not present (Pourhassan and Wirth, 2018, Vallejo 
et al., 2018) in older adults.  
There is evidence for a plausible link between vitamin D and skeletal muscle 
function; the discovery of the vitamin D receptor (VDR) and the reduction in its 
expression in skeletal muscle tissue with age suggests a direct effect of vitamin D on 
muscle (Bischoff‐Ferrari et al., 2004). In an animal study, murine C2C12 cells treated 
with 25(OH)D and 1,25(OH)2D exhibited an increase in VDR and CYP24AA1 
expression and a downregulation of the skeletal muscle growth and development 
inhibitor myostatin, providing support for the theory that vitamin D has a direct effect 
on proliferation, differentiation and a potential anabolic effect on myotube size (Girgis 
et al., 2014). Additionally, case-report and observational studies have shown that 
vitamin D deficiency is associated with myopathy and myalgia (Ziambaras and 
Dagogo-Jack, 1997) which are reversible upon correction of the deficiency 
(Ziambaras and Dagogo-Jack, 1997, Glerup et al., 2000a).  
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Age related losses in muscle mass, strength and function (sarcopenia) (Cruz-Jentoft 
et al., 2018) are associated with poor quality of life (Beaudart et al., 2015a) and are 
prevalent in fallers and those at risk of falling (Barnes et al., 2018). A recent study 
concluded that individuals with a combination of low muscle mass and function were 
predicted to be 12.28 times (95% CI: 7.95,18.96) more likely to lose their 
independence at 90 years of age (dos Santos et al., 2017). Although vitamin D may 
play a role in the regulation of muscle mass and/or muscle strength, this relationship 
is not currently well understood, and the role of serum 25(OH)D concentration in 
relation to muscle mass and strength in adults remains inconclusive. While some 
studies report a positive association between 25(OH)D and muscle mass (Szulc et 
al., 2004, Tieland et al., 2013, Ito et al., 2014) and strength (Visser et al., 2003b, 
Gerdhem et al., 2005, Mastaglia et al., 2011b, Grimaldi et al., 2013, Beaudart et al., 
2014a, Carson et al., 2018), others report no effect on muscle mass (Marantes et al., 
2011, Beaudart et al., 2014a, Carson et al., 2018) or strength (Marantes et al., 2011). 
Additionally, to the best of our knowledge, there has been no investigation to date to 
determine if sarcopenia status is season-dependent; should muscle mass and 
strength, components of sarcopenia classification, be associated with serum 
25(OH)D concentration, which are known to be affected by season (Darling et al., 
2013, Serdar et al., 2017, Klingberg et al., 2015), it is plausible to suggest that 
sarcopenic status, calculated at different seasonal timepoints throughout the year, 
may vary. This may have important implications for the treatment and diagnosis of 
sarcopenia. 
Therefore, the primary aim of the present study was to cross-sectionally analyse data 
obtained from a large cohort of postmenopausal women and investigate associations 
between serum 25(OH)D concentration and lean mass and strength and whether 
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these associations are influenced by season. The secondary aim was to investigate 




Data were obtained and analysed from a total of n = 188 postmenopausal women, 
comprising n = 139 postmenopausal women <65 years and n = 49 women ≥ 65 years 
who participated in the 2006-2007 D-FINES, a single-centre cohort study 
investigating the vitamin D status and bone health of pre- and postmenopausal 
Caucasian and Asian women (Vitamin D, Food Intake, Nutrition and Exposure to 
Sunlight in Southern England) study (Darling et al., 2013). The study was conducted 
in accordance with the 1964 Declaration of Helsinki and received ethical approval 
from the relevant Research Ethics Committees (National Health Service NHS REC 
06/Q1909/1 and University of Surrey EC/2006/19/SBMS). Written informed consent 
was obtained from all participants. 
Recruitment and data collection methodologies are presented in detail elsewhere 
(Darling et al., 2013). Briefly, the D-FINES study recruited 365 women from General 
Practitioner (GP) surgeries in the southeast of England (Surrey, Hampshire, 
Berkshire and outer London). Exclusion criteria included any conditions resulting in 
a disorder of calcium homeostasis, currently taking medications affecting bone, 
calcium or vitamin D metabolism, supplemental use of vitamin D or cod liver oil and 
abnormal liver, thyroid or renal function (assessed via blood test) or use of hormone 
replacement therapy within the previous year. Participants were invited to attend 
the University of Surrey Clinical Investigation Unit on 4 separate occasions; during 
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the summer, autumn and winter of 2006 and in the spring of 2007. Summer was 
defined as falling between the dates of 21/06/2006 and 20/09/2006, autumn 
between the dates of 21/09/2006 and 20/12/2006, winter as falling between the 
dates of 21/12/2006 and 20/03/2007 and spring as falling between the dates of 
21/04/2007 and 20/06/2007. Postmenopausal status was defined as not 
menstruating for over 3 months. During each of these visits, anthropometric data 
including height, weight and grip strength were collected, along with venepuncture 
to measure serum 25(OH)D concentration. Additionally, during the autumn of 2006 
and the spring of 2007 visits, body composition was estimated using Dual X-ray 
Absorptiometry (DXA). 
3.3.2. Serum 25(OH)D concentration measurement 
Fasting venous blood samples were taken from consenting participants during each 
of the 4 seasonal assessment points by phlebotomists at the Clinical Investigation 
Unit at the University of Surrey. Samples were analysed by the Vitamin D Research 
Group laboratory based at the Manchester Royal Infirmary, which is certified by the 
International Organization for Standardization (ISO 9001:2000 and ISO 13485:2003) 
and participates in the Vitamin D quality assurance scheme (DEQAS). Serum 
25(OH)D concentration was measured using a manual enzymeimmunoassay 
(Immunodiagnostic Systems Ltd, Boldon, Tyne and Wear, UK) following 
manufacturer guidelines. Manufacturer reference ranges for 25(OH)D were 19-58 
ng/mL (48-144 nmol/L, with some seasonal variability), sensitivity was 2 ng/ml (5 
nmol/L), intra- and inter-assay coefficients of variation were 6% and 7%, respectively.  
Although seasonal variation in serum 25(OH)D concentration has previously been 
reported within the D-FINES cohort (Darling et al., 2013, Darling et al., 2014b), 
subgroups of postmenopausal women younger and older than 65 years have not 
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previously been studied. The D-FINES cohort and its longitudinal nature provided a 
unique opportunity to explore seasonal changes in both muscle function and serum 
25(OH)D and whether they were associated. 
3.3.3. Muscle strength measurement 
Handgrip strength was measured at all 4 time points (autumn, winter, spring and 
summer) using a JAMAR® hydraulic hand dynamometer (J. A. Preston Corporation, 
Clifton, NJ, USA), which has previously been shown to demonstrate excellent 
reliability for isometric grip strength (ICC = 0.947) (Hogrel, 2015). Measurements 
were taken while the participant was seated, forearms resting on the arms of the 
chair with their wrists just over the end of the chair’s arm and their feet flat on the 
floor. Comfort was assessed and the size of the handle adjusted if necessary. Mean 
maximal grip strength, expressed in kilograms, was calculated from a set of 3 
measurements on each hand (left and right) from which a mean value for each hand 
was calculated.  
3.3.4. Lean mass assessment 
Total body lean mass was assessed at the Guildford Nuffield Hospital via Dual X-ray 
Absorptiometry (DXA) using a Hologic QDR 4500 (Hologic Inc, USA) machine in 
autumn 2006 and spring 2007. Mean difference in lean mass estimates between 
operators of +0.58 (0.47) kg and an interrater coefficient of variation of 1.9% have 
been reported previously in 22 human cadavers (22% female, mean age = 79.6 
years, mean weight = 69.59 kg), repositioned and scanned 3 times (Scafoglieri et al., 
2011). DXA, computerised tomography (Levine et al., 2000) and magnetic resonance 
imaging (Maden-Wilkinson et al., 2013) estimates of lean mass correlate highly. DXA 
is considered a reference standard for lean mass estimation (Buckinx et al., 2018b) 
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and is recommended by the European Working Group on Sarcopenia in Older 
People, 2018 (EWGSOP2) (Cruz-Jentoft et al., 2018). 
3.3.5. Derived muscle outcomes 
Appendicular skeletal muscle mass (ASM) was calculated as the sum of the total 
lean mass of the arms and legs in kilograms. ASM was divided by height squared 
(relative appendicular skeletal muscle index); this variable is suggested by multiple 
consensus groups as a method to quantify relative muscle mass by controlling for 
body size (Cruz-Jentoft et al., 2010a, Fielding et al., 2011, Chen et al., 2014, Cruz-
Jentoft et al., 2018). Sarcopenia was defined according to the EWGSOP2 2018 
criteria for women (Cruz-Jentoft et al., 2018); grip strength of the right hand <16kg 
and low muscle mass, categorised as ASM <15kg, and sarcopenic status were 
assessed in autumn and spring. Sarcopenic status and subsequent analyses 
involving sarcopenic participants were calculated only for participants with available 
ASM and grip strength data for both the autumn and spring timepoints to accurately 
reflect any seasonal changes in status. 
3.3.6. Statistical analysis 
All statistical analyses were performed using IBM SPSS Statistics for Windows, 
version 26.0 with statistical significance set at an α-level of p = 0.05. Normality 
checks revealed significant deviation from the normal distribution for some outcomes 
and therefore log transformation was attempted. With log transformation unable to 
normalise all outcome variables, all data were maintained in their original non-
transformed form.  
 The relationship between seasonal total lean mass and ASM and 25(OH)D 
concentration was assessed using Spearman correlation. The Spearman’s Rho 
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correlation coefficient was interpreted in the following way; <0.4 as weak, 0.4 – 0.69 
as moderate and 0.7 to 1.0 as strong (Schober et al., 2018).  
Non-parametric partial correlation using BMI as a covariate (confirmed before 
analyses) was used to assess cross-sectional associations between serum 25(OH)D 
concentration and relative appendicular skeletal muscle index (since both ASM and 
BMI variables account for height) and muscle strength outcomes throughout the 
seasons. BMI has previously been utilised as a covariate in similar studies due to the 
known influence of BMI/body size on serum 25(OH)D concentration and strength 
(Bean et al., 2003, Visser et al., 2003b, Cruz-Jentoft et al., 2018). Differences 
between sarcopenic and non-sarcopenic participants were assessed using the Mann-
Whitney U test. Chi-squared tests were used to analyse differences between groups 
in categorical variables. The cohort of postmenopausal women was analysed as 
three groups: the whole group plus two sub-groups; postmenopausal women <65 
years of age and postmenopausal women ≥65 years of age, as age is a major risk 
factor for sarcopenia (Tournadre et al., 2019) and contributes to aspects of its 
aetiology, such as declining anabolic hormone concentration (Brook et al., 2016), 




3.4.1. Participant characteristics 
Data from 188 postmenopausal women were analysed, including 139 
postmenopausal women aged <65 years (mean age 58.68 (standard deviation (SD) 
3.23 years; age range = 48 to 64 years) and 49 postmenopausal women aged ≥65 
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years (mean age 76.59 (2.51) years; age range = 65 to 79); participant 
characteristics are shown in Table 3.1. Mean serum 25(OH)D concentration and 
percentage of participants considered vitamin D adequate, insufficient and deficient 
for all groups by season are presented in Table 3.2. Briefly, mean serum 25(OH)D 
concentration ranged from 38.79 – 60.22 nmol/L and the percentage of the cohort 
considered to be vitamin D deficient ranged from 10.0 – 35.6%, dependent on 
season; as expected, serum 25(OH)D concentration was highest in the summer and 
thus this was the season with the lowest percentage of participants considered to be 
vitamin D deficient. Surprisingly, the group of postmenopausal women < 65 years 
exhibited the lowest mean serum 25(OH)D concentration (in the winter) and the 
group of postmenopausal women > 65 years exhibited the highest mean serum 
25(OH)D concentration (in the summer).  
On average, the cohort of women were overweight based on BMI (25.0 to 29.9 kg.m-
2) and there were no significant differences in height, weight, BMI, total lean mass 
and seasonal serum 25(OH)D concentration between postmenopausal women <65 
years and postmenopausal women aged ≥65 years. Postmenopausal women aged 
≥65 years exhibited significantly lower mean grip strength at all seasonal time points 
compared with postmenopausal women aged <65 years; this difference was most 
marked during the winter period (21.80 (5.20) kg vs 18.90 (4.73) kg, p = 0.001), 







Table 3.1: D-FINES study participant characteristics 
 All postmenopausal women Postmenopausal women aged <65 years Postmenopausal women aged ≥65 
years 
 
 N Mean (SD) N Mean (SD) N Mean (SD) P 
Age (years) 188 61.00 (4.97) 139 58.68 (3.23) 49 76.59 (2.51) <0.001 
 Height (cm) 173 160.77 (6.56) 130 160.86 (6.89) 43 160.50 (5.52) 0.731 
 Ethnicity 188 77% white, 19% South 
Asian, 4% other 
134 74% white, 21% South Asian, 
5% other 
49 84% white, 9% South 
Asian, 2% other 
0.088 
 Autumn weight (kg) 173 69.80 (12.94) 130 70.47 (13.71) 43 67.77 (10.16) 0.236 
 Autumn BMI (kg.m-2) 173 27.10 (5.35) 130 27.34 (5.66) 43 26.37 (4.23) 0.306 
 Autumn total lean mass (kg) 171 39.78 (5.19) 129 39.93(5.39) 42 39.33 (4.52) 0.512 
 Spring weight (kg) 166 70.21 (13.12) 125 70.77 (14.04) 41 68.51 (9.74) 0.341 
 Spring BMI (kg.m-2) 166 27.30 (5.50) 125 27.53 (5.89) 41 26.59 (4.06) 0.341 
 Spring total leam mass (kg) 166 40.12 (5.29) 125 40.24 (5.56) 41 39.75 (4.39) 0.609 
 Summer HGS (kg) 
 
179 20.90 (5.27) 134 21.38 (5.38) 45 19.45 (4.69) 0.033 
 Autumn HGS (kg) 
 
174 21.18 (4.90) 130 21.84 (4.86) 44 19.25 (4.54) 0.002 
 Winter HGS (kg) 
 
168 21.03 (5.23) 124 21.80 (5.20) 44 18.90 (4.73) 0.001 
 Spring HGS (kg) 169 20.95 (5.15) 126 21.50 (5.33) 43 19.34 (4.26) 0.017 
 BMI: Body mass index; HGS: Handgrip strength 




Table 3.2: Seasonal 25(OH)D concentrations and corresponding vitamin D status of all postmenopausal women and women <65 years and ≥65 years subgroup 
 All postmenopausal women Postmenopausal women aged <65 years  Postmenopausal women aged ≥65 years 




























Summer 176 56.29 
(23.03) 
60.8 23.9 15.3 128 54.81 
(22.36) 
60.15 21.88 17.97 48 60.22 
(24.56) 
62.5 27.1 10.4 
  Autumn 162 50.40 
(21.65) 
26.8 37.6 35.6 122 49.75 
(21.61) 
48.36 29.51 22.13 40 52.38 
(21.94) 
50.0 40.0 10.0 




26.8 37.6 35.6 112 37.84 
(16.95) 
25.00 37.50 37.50 37 41.68 
(16.97) 
32.4 43.2 24.3 
  Spring 147 40.64 
(19.22) 
27.2 41.5 31.1 113 40.44 
(19.74) 
29.20 38.05 32.75 34 41.31 
(17.62) 
20.6 52.9 26.5 




3.4.2. Serum 25(OH)D concentration and lean mass and strength  
 
There were no statistically significant associations between 25(OH)D concentration 
and total lean mass or ASM during the autumn or spring in any of the 3 groups 
(Table 3.3). Relative appendicular skeletal muscle index was negatively associated 
with 25(OH)D concentration in all groups and at all timepoints, significantly so in 
postmenopausal women <65 years in the autumn (rs = -.221. 95% CI -0.42, -0.04, p = 
0.018) and spring (rs = -.218 95% CI -0.39, -0.05, p = 0.026). Following adjustment 
for corresponding seasonal BMI, significance was only observed in the whole cohort 
(rs = .253. 95% CI 0.08, 0.42, p = 0.002). Change in serum 25(OH)D between autumn 
and spring was significantly and negatively associated with the change in total lean 
mass in the whole cohort, with an increase in lean mass associated with a decrease 
in 25(OH)D.  
Handgrip strength was significantly associated with 25(OH)D concentration within the 
whole cohort and in postmenopausal women <65 years and in the summer within 
postmenopausal women ≥65 years. Following adjustment for corresponding seasonal 
BMI, muscle strength was significantly associated with 25(OH)D concentrations 
during the summer and autumn months for the whole cohort and the postmenopausal 
women <65 years, whilst a weak non-significant relationship was observed in the 
winter and spring months for these groups. Postmenopausal women ≥65 years 
demonstrated a positive association between 25(OH)D concentration and muscle 




Table 3.3: Associations between serum 25(OH)D concentration and lean mass and muscle strength  
 
 All postmenopausal women Postmenopausal women aged <65 years Postmenopausal women aged ≥65 
years 






p N rs 
(95% CI) 
p 




0.170 117 .115 
(-0.06, 0.29) 
0.219 37 .083 
(-0.22, 0.38) 
0.079 
  25(OH)D x Total lean mass Spring 140 .050 
(-0.11, 0.22) 
0.559 108 .040 
(-0.14, 0.21) 
0.684 32 .193 
-0.18, 0.49) 
0.290 
  25(OH)D x ASM Autumn 148 .037 
(-0.12, 0.19) 
0.655 114 .032 
(-0.13, 0.21) 
0.731 34 .050 
(-0.32, 0.42) 
0.778 
  25(OH)D x ASM Spring 139 -.061 
(0.09, -0.02) 
0.474 108 - .073 
(0.05, 0.35) 
0.455 31 .049 
(-0.32, 0.43) 
0.491 
 25(OH)D x relative appendicular 





0.002 111 -.019 
(-0.22, 0.19) 
0.839 31 .263 
(-0.11, 0.59) 
0.139 
1011 25(OH)D x relative appendicular 




0.173 103 -.083 
(0.28, 0.11) 
0.402 28 -.145 
(-0.61, 0.39) 
0.443 
 Change in total lean mass x 
change in serum 25(OH)D 
Autumn to Spring 
125 -.211 
(-0.39, -0.03) 
0.018 101 - .032 
(-0.90, -0.04) 
0.051 24 -.362 
(-0.69, 0.07) 
0.082 
  25(OH)D x HGS Summer* 164 .240 
(0.10, 0.37) 
0.002 120 .272 
(0.12, 0.41) 
0.002 40 .278 
(-0.03, 0.52) 
0.075 
  25(OH)D x HGS Autumn* 148 .182 
(0.01, 0.35) 
0.026 111 .226 
(0.05, 0.39) 
0.016 34 .128 
(-0.25, 0.49) 
0.458 
  25(OH)D x HGS Winter* 142 .157 
(-0.01, 0.31) 
0.059 105 .175 
(-0.01, 0.35) 
0.072 33 .196 
(-0.15, 0.51) 
0.259 
  25(OH)D x HGS Spring* 135 .116 
(-0.01, 0.29) 
0.176 103 .129 
(-0.01, 0.33) 




  *Model is adjusted for BMI; all other variables are unadjusted. 
ASM: Appendicular skeletal muscle mass; Relative appendicular skeletal muscle index is ASM/h2 HGS: Handgrip strength. 
p relates to the Spearman Correlation analysis 
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3.4.3. Seasonal sarcopenia classification  
Seasonal sarcopenia classification is shown in Table 3.4. Only the women with ASM and handgrip strength data available for both 
the autumn and spring timepoints were included in this analysis.  The percentage of women classified as sarcopenic was higher in 
the spring when compared with autumn in all 3 groups.  Sarcopenia status appeared transient for 5 women in total, which meant 
that their status may be season-dependent.  
 
  
Table 3.4: Seasonal sarcopenia classification  
 
 N participants  N classified as 
sarcopenic in 
autumn (%) 







only in autumn 
Sarcopenic 
only in spring 
All postmenopausal women 154 
 
7 (4.55) 10 (6.49) 6 1 4 
 Postmenopausal women aged 
<65 years 
118 6 (5.08) 7 (5.93) 5 1 2 
 Postmenopausal women aged 
≥65 years  
36 1 (2.78) 3 (8.33) 1 0 2 
 Sarcopenia classification based on the EWGSOP2 criteria of combined low muscle mass and strength, which for women is handgrip strength <16kg and 
ASM <15kg (Writing Group for the European Working Group on Sarcopenia in Older People 2  et al., 2018). Number of included participants are those with 





The scale and longitudinal nature of the D-FINES study provided a unique 
opportunity to retrospectively assess aspects of skeletal muscle health and function 
and their association with serum 25(OH)D status. Serum 25(OH)D concentration 
followed the anticipated seasonally-dependent pattern, with peak concentration 
observed during the summer period and lowest concentration observed during the 
winter and spring months for both the whole cohort and the postmenopausal 
subgroups. Serum 25(OH)D concentration was higher within postmenopausal 
women ≥65 years compared with postmenopausal women <65 years at all seasonal 
timepoints, although these differences were not statistically significant. One 
explanation for this finding is that the postmenopausal women <65 years included a 
higher percentage of Asian women and a lower percentage of Caucasian women 
than the postmenopausal women ≥65 years (21% vs 9% and 74% vs 84%, 
respectively). As with premenopausal women in the D-FINES cohort (Darling et al., 
2013), postmenopausal Asian women in the present study presented with 
significantly lower mean 25(OH)D concentration than postmenopausal Caucasian 
women and could be classified as vitamin D deficient at all seasonal time points 
(summer: 63.83 nmol/L vs 27.22 nmol/L, autumn: 57.51 nmol/L vs 22.06 nmol/L, 
winter: 43.35 nmol/L vs 22.06 nmol/L, spring: 45.43 nmol/L vs 23.11 nmol/L, all p < 
0.001).  
Overall, the cohort had sufficient serum 25(OH)D concentration during the summer 
and autumn months, but were classified as insufficient during the winter and spring 
months. Mean 25(OH)D concentration during the summer months was higher than 
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previously reported in community-dwelling older women in a UK population study; 
age-matched women participating in the Health Survey for England, 2000 presented 
with serum 25(OH)D concentration that were 17.97% lower than those observed in 
postmenopausal women ≥65 years within the D-FINES cohort, which did not vary 
seasonally (Hirani and Primatesta, 2005).  
The prevalence of vitamin D deficiency, defined as serum 25(OH)D concentration 
<30 nmol/L, was higher within this cohort than previously reported at all seasonal 
timepoints. A study of worldwide vitamin D status in adults aged 50 to 105 years 
found that 10% of adults in England had a serum 25(OH)D concentration of <30 
nmol/L (Palacios and Gonzalez, 2014). However, the percentage of postmenopausal 
women within the D-FINES cohort considered to be vitamin D insufficient (<50 
nmol/L) was lower than previously reported in the above studies (Hirani and 
Primatesta, 2005, Palacios and Gonzalez, 2014), meaning that women in the D-
FINES cohort were more likely to be categorized into one of the 2 extremes of 
25(OH)D concentrations (sufficiency or deficiency), again, perhaps due to the high 
prevalence of deficiency observed in the Asian participants.  
Postmenopausal women ≥65 years were significantly weaker than postmenopausal 
women <65 years at all seasonal timepoints, which is consistent with longitudinal 
reports of an age related decline in muscle strength (Hughes et al., 2001). Although 
women ≥65 years were 9.92% weaker than women <65 years during the summer 
period, this difference is smaller than expected based on previously demonstrated 
losses of handgrip strength per decade of 16.67% in a cohort of 1314 men and 1315 
women aged ≥20 years who participated in the North West Adelaide Health study 
(Massy-Westropp et al., 2011), particularly as the mean ages of the 2 
postmenopausal groups were almost 2 decades apart (handgrip strength assessed in 
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both hand using a Jamar Analogue Hand Dynamometer from a seated position, with 
the elbow at the participant’s side, flexed at 90°). More modest losses in grip strength 
have been reported in a recent Australian study of 378 health adults aged 20 to 95 
years without musculoskeletal deficits; an average loss of 12.78% grip strength was 
observed between the age ranges of 40 – 59 years and 60 – 69 years and a loss of 
grip strength of 10.83% observed between 60 – 69 years and 70 – 79 years (Ingram 
et al., 2019).  
Comparing muscle strength of the D-FINES cohort to British handgrip strength 
normative data taken from 130 men and 130 women (age range = 15 to 92 years), 
postmenopausal women <65 years were 28.16% weaker and the muscle strength of 
the postmenopausal women ≥65 years was comparable to women of a similar mean 
age during the summer months. Dominant hand handgrip strength during this study 
was assessed using a B+L hydraulic pinch gauge, with the participant seated and the 
arm in the 90° flexion position (Gilbertson and Barber-Lomax, 1994). Again, the 
handgrip strength of the Caucasian participants was significantly higher than 
observed in the Asian participants in both subgroup and at all seasonal timepoints 
with the exception of the summer months in postmenopausal women ≥65 years; the 
previous British study did not provide details of participant ethnicity, making a direct 
comparison difficult. 
However, the muscle strength of both postmenopausal subgroups was below the 
average expected for age-matched women in a more recent study; handgrip strength 
data collated from 12 British population studies which enrolled a total of 49,964 
participants (26,687 females) showed that the mean handgrip strength of the 
postmenopausal women <65 years fell between the 10th and 25th centiles and the 
postmenopausal women ≥65 years fell between the 25th and 50th centiles of the 
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corresponding age group normative data measuring dominant hand handgrip 
strength using a number of brands of dynamometer from a seated position (Dodds et 
al., 2014). Relating the D-FINES cohort to the handgrip strength reported in a further 
study, all 3 of the D-FINES groups (whole postmenopausal cohort and both 
postmenopausal subgroups) displayed grip strength values that were below the 10th 
centile of age-matched females in the previous Australian study measuring dominant 
hand grip strength with a Jamar+ Digital dynamometer from a seated position (arm at 
the participant’s side, bent at 90°)  (Ingram et al., 2019).  
Neither the whole cohort nor the postmenopausal subgroups could be defined as 
having clinical muscle weakness at any seasonal timepoint, based on group mean 
values, as defined as handgrip strength <16kg (McLean et al., 2014, Cruz-Jentoft et 
al., 2018). However, further analysis of individual data revealed that 12.23% to 
16.55% of postmenopausal women <65 years and 16.33% to 22.45% of 
postmenopausal women ≥65 years did have muscle weakness, which varied with 
season (lowest percentage in the summer and highest in the autumn). Observing 
individual participant data, postmenopausal women ≥65 years consistently 
demonstrated a higher percentage of participants with clinical muscle weakness, 
most apparent during the autumn months.  
Neither the whole D-FINES cohort nor the 2 subgroups could be described as having 
low muscle quantity, based on group mean values, defined using either the 
Foundation for the National Institutes of Health (FNIH) (ASM <15.02 kg) (McLean et 
al., 2014) or the EWGSOP2 (ASM <15.00 kg) (Cruz-Jentoft et al., 2018) criteria. 
However, assessing individual participant data, 30.22% to 30.94% of 
postmenopausal women <65 years and 20.41% to 24.49% of postmenopausal 
women ≥65 years were found to have low muscle quantity, which varied seasonally, 
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with postmenopausal women <65 years demonstrating lower ASM compared with 
postmenopausal women ≥65 years, most apparent in the autumn.  
There was no significant association between serum 25(OH)D concentration and 
total lean body mass or ASM in the autumn and spring in any of the groups. Although 
the unadjusted relative appendicular skeletal muscle index in the D-FINES cohort 
was significantly and negatively associated with serum 25(OH)D concentrations in 
the autumn and spring in postmenopausal women <65 years (Appendix D); following 
adjustment for corresponding seasonal BMI, this relationship was no longer 
significant, suggesting that the significance observed was due to variation in BMI in 
this group. After adjustment for corresponding seasonal BMI, only the relative 
appendicular skeletal muscle index of the whole cohort in the autumn was 
significantly associated with 25(OH)D concentration (rs = .253. 95% CI 0.08, 0.42, p = 
0.002). Serum 25(OH)D and muscle mass is a contentious subject, with no clear 
consensus on the role of vitamin D in muscle hypertrophy, although the findings here 
do not support previous findings of an association (Szulc et al., 2004, Tieland et al., 
2013, Ito et al., 2014). Of these studies, one reported a significant association in men 
only (Szulc et al., 2004), one recruited only frail older adults (mean age = 79 years) 
based on the Fried criteria (Tieland et al., 2013) and the final study observed a 
significant relationship between serum 25(OH)D and skeletal muscle index only in 
participants with low muscle mass at baseline (average ASM at baseline could be 
classified as low muscle quantity by the FNIH and EWGSOP2 criteria listed above) 
(Ito et al., 2014).  
The current finding of no association between appendicular lean mass and serum 
25(OH)D concentration is in agreement with conclusions drawn from a previous study 
of 356 women (mean age = 57 years), in which no association was found between 
123 
 
any quartile of 25(OH)D concentration and ASM assessed via DXA (p = 0.511); this 
persisted after adjustment for age, height physical activity, season and fat mass (p = 
0.237) (Marantes et al., 2011). However, these conclusions were drawn from a US 
population of 667 adults, including 356 women (mean age = 57 years); the main 
difference with the D-FINES cohort was that although reflective of the community 
enrolled, 98% of participants were Caucasian, meaning that black and Asian 
participants were substantially underrepresented (Marantes et al., 2011). A more 
recent study in 51 Northern Irish COPD patients (including 23 females, mean age = 
68.7 years) with serum 25(OH)D concentrations comparable with the D-FINES cohort 
found no association between fat-free mass (assessed by bioelectrical impedance) 
and 25(OH)D concentrations during the winter (R = 0.089, p = 0.588) or summer (R = 
0.270, p = 0.092) months (Carson et al., 2018).  
Surprisingly, between the autumn and spring seasons a small but significant negative 
association between change in total lean mass and serum 25(OH)D concentration 
was observed within the whole cohort of postmenopausal women (rs = -.211. 95% CI 
-0.39, -0.03), p = 0.018). Lean mass estimated in the spring was significantly higher 
than that estimated in the autumn (Z = -3.25, p = 0.001), with the reverse true for 
serum 25(OH)D concentration (Z = -6.78, p <0.001). A longitudinal study of 125 
healthy postmenopausal women (mean age = 62.5 years) found that total and 
regional lean body mass estimated by DXA varied seasonally, with a larger 
percentage change than observed within the D-FINES cohort; whole body lean mass 
was significantly lower in the period of December to June than throughout June to 
December (-2.04 (0.24)%, p <0.001) of the previous year (Dawson-Hughes and 
Harris, 1992).  A previous study has shown that serum 25(OH)D concentrations in 
women were significantly and negatively associated with ASM/height2 in a group of 
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195 older women (mean age = 75 years) who were considered vitamin D sufficient 
(25(OH)D = 57.67 nmol/L) with adequate muscle quantity (ASM = 15.20 kg) 
(Iannuzzi-Sucich et al., 2002). Although total body lean mass has been shown 
previously to vary seasonally, it is also important to consider that the very small 
change in lean mass (+0.34 kg) for the D-FINES cohort was within the variability 
reported for the DXA model utilised (Scafoglieri et al., 2011), and therefore although 
statistically significant, may not be a reliably meaningful change. 
In the initial, unadjusted analyses (Appendix D), muscle strength assessed via grip 
strength was significantly associated with serum 25(OH)D concentration at all 
seasonal timepoints for the whole cohort and postmenopausal women <65 years; 
significant associations were observed in the summer months for the 
postmenopausal women ≥65 years. After adjusting for the BMI of each corresponding 
season, the association between handgrip strength and seasonal 25(OH)D 
concentration remained significant for the summer (rs = .240. 95% CI 0.01, 0.37, p = 
0.002), autumn (rs = .182. 95% CI 0.01, 0.35, p = 0.026) and borderline for the winter 
months (rs = .157. 95% CI -0.01, 0.31, p = 0.059) in all postmenopausal women. For 
postmenopausal women <65 years, a significant association remained during the 
summer (rs = .272. 95% CI 0.12, 0.41, p = 0.002) and autumn months (rs = .226. 95% 
CI 0.05, 0.39, p = 0.016), however for postmenopausal women ≥65 years, no 
associations remained significant. Within the D-FINES cohort, BMI was negatively 
and significantly associated with both serum 25(OH)D concentration and handgrip 
strength at all seasonal timepoints, as has been demonstrated in previous studies 
(Parikh et al., 2004, Kull et al., 2009, Massy-Westropp et al., 2011). Controlling for 
BMI accounted for some of the variation in the range of observable BMIs (range in 
the whole cohort = 16.87 to 52.73 kg.m-2 across the 4 seasons), therefore reducing 
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the strength of the relationship between BMI and muscle strength and resulting in 
some significant associations becoming non-significant.  
 The positive association observed between serum 25(OH)D concentration and 
muscle strength is consistent with a large evidence base of previous studies to the 
same effect (Visser et al., 2003b, Gerdhem et al., 2005, Mastaglia et al., 2011b, 
Grimaldi et al., 2013, Beaudart et al., 2014a, Carson et al., 2018). Muscle strength 
has also previously been shown to vary seasonally; in a group of 88 community-
dwelling older adults (mean age = 69.2 years), ankle dorsiflexion strength, measured 
5 times over 1 year, was shown to significantly vary by season, with the highest ankle 
strength observable in the summer months, although was not significantly associated 
with 25(OH)D concentration (Bird et al., 2012). The relationship between 25(OH)D 
concentration and handgrip strength has also been shown to vary seasonally; a 
significant association between 25(OH)D and handgrip strength was observable in 
the summer months (R = 0.334, p = 0.024) but not the winter months (R = 0.191, p = 
0.243) in a group of 51 COPD patients (mean age = 68.7 years) living in Northern 
Ireland (Carson et al., 2018).  
The lack of association between serum 25(OH)D concentration and parameters of 
skeletal muscle mass but positive association, albeit small, with muscle strength is 
suggestive that vitamin D may play a role in muscle strength and/or functioning rather 
than hypertrophy. In a longitudinal analysis of the relationship between changes in 
muscle mass and strength, although positively related to knee extensor and flexor 
strength, muscle mass explained only 5% of the decline in strength and was  
significant only for knee flexor strength in women (Hughes et al., 2001).  
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Regarding sarcopenia prevalence, the rates within the total D-FINES cohort, which 
ranged from 4.55% to 6.49%, dependent on season, were within or below the ranges 
previously reported; a systematic review of 252 studies of sarcopenia prevalence 
based on the EWGSOP criteria (Cruz-Jentoft et al., 2010a) reported prevalence rates 
of 1% to 29% in community-dwelling adults aged >50 years (Cruz-Jentoft et al., 
2014b). Another study reported a prevalence rate of 14% to 27.6% assessed using 
DXA to estimate ASM in 250 older adults (62.8% women, mean age = 74.1 years) 
using the EWGSOP criteria to diagnose sarcopenia (Beaudart et al., 2015b). Within 
the D-FINES cohort, 2.78% to 8.33% of postmenopausal women ≥65 years were 
considered to be sarcopenic in the autumn and spring months, respectively. During 
both the autumn and spring, 100% of sarcopenic participants identified in this group 
were Caucasian. 5.08% to 5.93% of postmenopausal women <65 years were 
considered to be sarcopenic in the autumn and spring months, respectively. In this 
group, 50% of identified sarcopenic participants were Caucasian and 50% were 
Asian during the autumn. During the spring, 57.14% of postmenopausal women <65 
years were Caucasian and 42.86% were Asian. A higher prevalence of sarcopenia in 
postmenopausal women ≥65 years compared with postmenopausal women <65 
years was expected since sarcopenia prevalence has been shown to increase with 
age (Volpato et al., 2013).  
Comparing non-sarcopenic participants with participants identified as sarcopenic 
during either the autumn, spring or both seasonal timepoints, ASM, total lean mass 
and handgrip strength were significantly lower in sarcopenic participants than non-
sarcopenic participants (all p <0.005), as would be expected. Serum 25(OH)D 
concentration was lower and less variable in sarcopenic participants than in non-
sarcopenic participants at each seasonal timepoint, although no statistical 
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significance was observed at any timepoint. Serum 25(OH)D concentrations at each 
seasonal timepoint in non-sarcopenic vs sarcopenic participants were as follows; 
summer: 56.70 (23.13) vs 49.35 (21.27) nmol/L, autumn: 50.95 (21.90) vs 42.76 
(16.85) nmol/L, winter: 38.86 (16.88) vs 37.85 (19.25) nmol/L and spring 40.70 
(19.38) vs 39.86 (17.73) nmol/L. This finding is in agreement with a previous study 
comparing 66 sarcopenic with 66 non-sarcopenic older adults (mean age = 71 
years); 25(OH)D concentration was significantly lower during the “summer” period of 
June to November and lower, albeit not significantly, throughout the “winter” period of 
December to May (p = 0.017) (Verlaan et al., 2017). 
A finding novel to the current study was evidence that sarcopenia classification may 
be transient and season-dependent, although it is important to note that this was 
concluded from a relatively small number of participants (7 in the autumn and 10 in 
the spring). The percentage of participants classified as sarcopenic based on the 
EWGSOP2 criteria (Cruz-Jentoft et al., 2018) differed from autumn to spring, with the 
highest percentage of sarcopenic women identified in the spring for both 
postmenopausal groups. A total of 5 women from the available cohort were found to 
present a transient sarcopenic status, with 4 of the 5 women (80%) found to be 
sarcopenic only in the spring. More women found to be sarcopenic only in the spring 
than only sarcopenic in the autumn in all 3 groups compared; 2 of the 3 
postmenopausal women <65 years (66.67%) were sarcopenic only in spring and all 
postmenopausal women ≥65 years (2 women) with transient sarcopenic status were 
observed in spring.  
Of participants with ASM and handgrip data available for both the autumn and spring 
months, ASM in the spring was significantly higher than in the autumn (16.28 kg vs 
16.15 kg, Z = -2.55, p = 0.011); however, both handgrip strength (21.20 kg vs 21.52 
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kg, Z = 1.07, p 0.284) and serum 25(OH)D concentrations (42.83 nmol/L vs 51.18 
nmol/L, Z =6.41, p < 0.001) were lower in the spring. Although ASM, muscle strength 
and serum 25(OH)D concentrations have been found to vary seasonally in this study, 
other factors including parathyroid hormone concentration have been associated with 
sarcopenia (Visser et al., 2003b) and have been found to vary with season (Dawson-
Hughes et al., 2014). Furthermore, physical activity is known both to be associated 
with sarcopenia and vary seasonally (Scott et al., 2010) with outdoor physical activity 
positively influencing cutaneous production of vitamin D and therefore 25(OH)D 
concentrations (Orces, 2019). In the autumn, non-sarcopenic participants spent more 
time per day walking than sarcopenic participants (98.52 minutes vs 76.09 minutes, p 
= 0.504), although the reverse was true in spring (92.90 minutes vs 106.88 minutes, 
p = 0.716). 
The D-FINES cohort presents a large and rich data set; however, findings of the 
current study should be interpreted within the context of some limitations. Firstly, the 
use of correlation to assess association means that causality cannot be inferred. The 
number of sarcopenic participants was small, relative to the whole cohort, meaning 
that the subgroup of sarcopenic participants within the current study may not be 
representative of the general sarcopenic population within the UK. Dietary intake of 
vitamin D was not assessed or included within any analyses within the current study, 
which, although the relative dietary contribution to overall vitamin D status is lower 
than cutaneous production (<20% total annual intake; (Macdonald et al., 2011a)) 
does represent a limitation of the current study.  
One further limitation of the study is the definition of menopausal status; women were 
determined to be postmenopausal following 3 months of amenorrhea, although it is 
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widely accepted that postmenopausal status be defined as 12 months of amenorrhea 
following the final menstrual period (Soules et al., 2001). 
Unfortunately, appropriate measures of muscle function were not available at 
timepoints corresponding with lean mass and strength assessments, therefore it was 
not possible to categorise the severity of sarcopenia observed in this cohort. Thus, 
the seasonal variability of sarcopenia severity was not investigated in the current 
study, but would be of future interest alongside a potential transient sarcopenia 
diagnosis throughout the year, as it was only possible to assess sarcopenic status in 
the autumn and spring seasons.  
Handgrip strength may not present a true reflection of total body strength, since 
upper body strength loss is slower than upper body strength loss; in 68 women of 
ages ranging from 46 to 78 years followed up after an average of 9.7 years, knee 
extensor strength was shown to decline by an additional 5.6% per decade than elbow 
flexion strength (p <0.001) (Hughes et al., 2001). Furthermore, handgrip strength is 
vulnerable to the methodology selected, particularly elbow positioning. Although the 
current study followed the American Society of Hand Therapists recommended 
positioning (seated participant with elbow flexed at 90°) (Fess, 1981), grip strength 
has previously been shown to be significantly greater when assessed from a 
standing position with the elbow fully extended (Liao et al., 2014) 
Additionally, lower extremity muscle power may be a more appropriate outcome 
when assessing sarcopenic status, since muscle power is a superior predictor of 
functional status than muscle strength (Suzuki et al., 2001, Byrne et al., 2016) and 
more relevant to activities of daily living such as stair climbing, walking and standing 
from a seated position (Foldvari et al., 2000). In the Longitudinal Aging Study 
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Amsterdam cohort of 449 older men and women (mean age = 75 years), lower 
extremity performance, assessed as the sum of a 3-meter timed walk test and a 5-
time chair rise test, was significantly associated with handgrip strength in men (β = 
0.079, p <0.001) but not in women (β = 0.046, p = 0.100) following adjustments for 
BMI, number of self-reported diseases, physical activity and cognitive function 




This study provides evidence suggesting that there is no association between serum 
25(OH)D concentration and total lean mass, ASM or relative ASM; this finding is 
supported by some previous work but contended by other groups. Although change 
in 25(OH)D concentration from autumn to spring was negatively associated with the 
change total body lean mass, the change in lean mass was within the measurement 
variability for DXA and thus should be interpreted with caution. Muscle strength was 
shown to be positively associated with 25(OH)D at all seasonal timepoints, 
suggesting that serum 25(OH)D concentration is associated with muscle strength 
and functional outcomes rather than muscle hypertrophy. Sarcopenic status was 
shown to be transient and seasonal in a small sample of postmenopausal women; 
confirmation of this finding in a larger and therefore more representative sample 
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Sarcopenia is a progressive loss in muscle mass, strength and function, the adverse 
consequences of which are severe, affecting quality of life and placing an increasing 
burden on social and healthcare systems. Vitamin D status is known to be associated 
with markers of sarcopenia, namely muscle mass, strength and function. Also, 
resistance exercise training (RET) is currently the only proven intervention to treat 
sarcopenia. However, very little data exist on the influence of combining the two 
interventions of vitamin D supplementation and resistance exercise training. 
The aim of the present study was to determine whether vitamin D3 supplementation 
is any more effective in improving musculoskeletal function when combined with 
resistance exercise training (RET) compared with exercise training alone in older 
adults. 
Methods and analysis 
This was a double-blinded randomized placebo-controlled trial that aimed to 
recruit a target of 127 eligible men and women aged ≥65 years living independently 
or in sheltered housing within the Birmingham area and randomized into to 2 groups: 
i) 6 months RET and placebo, or ii) 6 months RET and 800IU/d vitamin D3. Measures 
of body composition (DXA), muscle function (SPPB, TUG), falls and fractures as 
events were assessed. Assessments took place at baseline and post-intervention, 
with intermittent monitoring of bone turnover, calcium and vitamin D. The primary 
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outcome was lower limb extensor power output. Analyses of within-group changes 
and between-group differences in outcome measures were planned. 
Ethics and dissemination 
Ethical approval for the EXVITD study was granted by the Black Country NHS 
Research Ethics Committee (14/WM/1220). The study was conducted according to 
the principles of the Declaration of Helsinki. Trial registration number: NCT02467153. 



















The UK has an ageing population; life expectancy has increased rapidly in the 
previous 2 decades, with life expectancy at birth between 2010 and 2012 reaching 
82.72 for females and 78.85 years for males (Office for National Statistics, 2015). 
Importantly, healthy life expectancy is not keeping pace; adults over 65 years are 
expected to spend approximately 7.9 years in poor health (Office for National 
Statistics, 2014a). Sarcopenia refers to the age-related loss of muscle mass, strength 
and function (Cruz-Jentoft et al., 2018). In the face of an increasing proportion of 
older adults and the dramatic increase in pressure on health and social care 
(Janssen et al., 2004), many are likely to suffer the adverse consequences of 
sarcopenia, namely impaired functional ability, increased frequency of falls and 
fractures, with attendant morbidity and mortality; a higher incidence of 
hospitalizations and longer length of hospital stay (Beaudart et al., 2017). Sarcopenia 
therefore represents a serious and increasing public health problem. The causes of 
sarcopenia are unclear, however, there are numerous factors associated aetiology 
(Bano et al., 2017, Steffl et al., 2017, Robinson et al., 2017, De Spiegeleer et al., 
2018). One such example is vitamin D deficiency; older adults are considered an “at 
risk group”, with prevalence rates of hypovitaminosis d reaching 89% in residential 
care (Schilling, 2012). Consequences of vitamin D deficiency include muscle 
weakness and an increased risk of falls and fractures (Holick and Chen, 2008). While 
it is known that vitamin D is essential for calcium and phosphorous homeostasis and 
bone health (Holick and Chen, 2008), we know relatively little about the direct effects 
of vitamin d on muscle mass and function in humans. The majority of evidence for an 
effect on muscle is based upon animal models, which have reported increases in 
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muscle protein synthesis in response to vitamin d supplementation but which may not 
mimic the human condition (Garcia et al., 2011, Srikuea et al., 2012), and cross-
sectional epidemiology (Wicherts et al., 2007, Visser et al., 2003b, Houston et al., 
2007b) which cannot establish causality. Meta-analyses examining the effect of 
vitamin D supplementation on musculoskeletal parameters report conflicting 
evidence, although supplementation was shown to improve muscle strength, with 
effects more pronounced in older and vitamin d deficient participants (Beaudart et al., 
2014a). 
Another factor associated with sarcopenia is physical activity. Resistance exercise 
training (RET) is the most promising intervention for improving sarcopenia (Kosek et 
al., 2006). We and others have shown that even in very old adults (>75 years), RET 
improves muscle strength and functional outcomes although the hypertrophic ability 
of older muscle is blunted compared with younger adults (Greig et al., 2011a, Raue 
et al., 2009). Therefore, in order to help older adults maintain good musculoskeletal 
health, interventions to optimise responsiveness to physical activity are likely to be 
most effective if they are multimodal and include resistance exercise. One such 
example is the combination of RET with vitamin D supplementation. 
Very few data exist that test the combined effects of vitamin D3 supplementation and 
RET on the musculoskeletal health of older adults, as highlighted by a recent 
systematic review and meta-analysis (Antoniak and Greig, 2017). The review 
concluded vitamin D supplementation and exercise training significantly improved 
muscle strength within the lower limb compared with to exercise training alone (0.98, 
95% CI 0.73 to 1.24, p<0.001) (Antoniak and Greig, 2017). However, the limitations 
of the review serve to highlight the lack of knowledge within this area; only 3 studies 
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were included in this meta-analysis, and the high weighting of one particular study 
meant that only tentative conclusions could be drawn. 
Therefore, the principal aim of the EXVITD study was to determine whether vitamin 
D3 supplementation was any more effective in improving musculoskeletal function 
when combined with RET compared with RET alone. Secondary objectives included; 
(i) determining the seasonal variation of 25(OH)D in a population of frailer older 
adults both free-living and those living in supported housing. (ii) Investigating the 
association between baseline 25(OH)D and physical activity measured using 
accelerometry and responsiveness to RET (iii) Determining between-group 
differences with respect to changes in falls as events and quality of lifel (iv) 
Determining between-group differences with respect to changes in fractures as 
events (v) Determining the influence of RET on serum inflammatory markers (e.g. IL-




4.3.1. Study design 
This study protocol is presented in line with the Standard Protocol Items: 
Recommendations for Interventional Trials (SPIRIT) guidelines. The EXVITD study 
was a two-arm exploratory double-blinded randomized placebo-controlled trial. A 
target total of 127 participants were sought to be identified, recruited and randomized 
1:1 into 2 groups: i) RET and 800IU vitamin D3 per day or, ii) RET and a daily 
placebo for 6 months. Eligibility was assessed at screening and all outcome 
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measures were collected at baseline and 6 months, with venepuncture outcomes 
additionally assessed at months 1 and 3. 
The study was registered as a randomized controlled trial on clinicaltrials.gov 
(NCT02467153). The EXVITD study took place within Birmingham, at both the 
University of Birmingham and the Wellcome Trust Clinical Research Facility at the 
Queen Elizabeth Hospital. Data collection began in July 2017 and collection/analysis 
was completed in October 2019 31/12/2019. 
4.3.2. Study population 
We aimed to recruit 127 men and women aged ≥65 years, who were ambulatory 
(with/without aids) and lived independently or within sheltered housing 
accommodation in Birmingham, West Midlands, UK. We selected this population as 
they are more susceptible to sarcopenia and subsequent functional deficits and 
therefore stand to benefit from interventions aimed to improve musculoskeletal 
health. Eligibility criteria are summarised in Table 4.1. Since confirmation of eligibility 
in this low-risk study did not require the interpretation of medical notes/ history or a 
physical examination, the study Chief Investigator (CI) was suitably qualified to 
confirm eligibility. However, any queries about eligibility were raised with the medical 








Table 4.1: EXVITD study eligibility criteria1 
Inclusion 
criteria 
Aged ≥65 years 
  Ambulatory (with or without walking aids) 
  Living independently or within sheltered housing accommodation  
 Exclusion 
criteria 
History of myocardial infarction within previous 2 years 
  Cardiac illness: moderate/ severe aortic stenosis, acute pericarditis, acute myocarditis, 
aneurysm, severe angina, clinically significant valvular disease, uncontrolled dysrhythmia, 
claudication within last 10 years; thrombophlebitis or pulmonary embolus within last 2 
years 
  History of cerebrovascular disease (cerebrovascular accident (CVA), transient ischemic 
attack (TIA)) within last 2 years 
  Acute febrile illness within the previous 3 months 
  Severe airflow obstruction; uncontrolled metabolic disease (e.g., thyroid disease or cancer) 
  Significant emotional distress, psychotic illness or depression within the previous 2 years 
  Lower limb fracture sustained within the previous 2 years/ upper limb fracture within the 
previous 6 months 
  Non-arthroscopic lower limb joint surgery within the previous 2 years 
  Any reason for loss of mobility for > 1 week in the previous 2 months or > 2 weeks in the 
previous 6 months 
  Resting systolic pressure >200 mmHg or resting diastolic pressure >100mmHg 
  Poorly controlled atrial fibrillation; poor (chronic) pain control 
  Moderate/ severe cognitive impairment (mini mental state examination (MMSE) score <23) 
  Vitamin D deficiency (serum 25(OH)D3 <30nmol/l); current antiresorptive/anabolic 
treatment for osteoporosis 
  Treatment with bisphosphonates for osteoporosis in the past two years 
  Current use of glucocorticoids; known primary hyperparathyroidism 
  Renal impairment (Stage 4 or 5 
1Based on previously published criteria of exercise studies with older adults (Greig et al., 1994) 
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4.3.3. Recruitment  
Recruitment strategies were three-fold and are detailed below. 
i) Primary Care approach 
We worked with the West Midlands Clinical Research Network who assisted with 
recruitment via primary care and helped to identify additional supported housing 
facilities under their aegis. Eligible participants from surrounding areas were 
identified via an electronic practice-based search of registers using the criteria 
described in Table 1. The General Practitioner (GP) reviewed and excluded anyone 
they deemed unsuitable for reasons other than those identified in the protocol (e.g. 
already taking part in another study). 
A Patient Approach letter was sent to patients identified from the GP together with a 
Participant Information Sheet (PIS, see Appendix E), reply form and FREEPOST 
envelope addressed to the study team.  Alternatively, the research team were 
contacted directly by phone or email. Patients not responding to the first invitation 
received one reminder after 3 weeks, including an acknowledgement that the letter 
was to be ignored by those responding to the initial letter. When the study team 
received a signed patient contact agreement consent form, they contacted the 
potential participant via telephone to discuss the study in more detail, go through the 
questionnaire responses and if eligible, obtain written consent. 
ii) Sheltered housing approach 
Sheltered housing managers and head offices were contacted directly, and where 
possible, study information was presented at residents’ meetings, coffee mornings 
and on communal notice boards. Residents could contact the study team directly or 
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through the housing manager. When a response was received, the participant was 
contacted as detailed above. 
iii) Independent living approach 
We recruited older adults living independently via several methods. Study information 
was displayed at appropriate locations, for example seniors’ groups, community 
centres and libraries. Additionally, advertisement was via appropriate and relevant 
websites, print media (e.g. magazines, leaflets, newsletters) and social media. 
Members of the Birmingham 1000 Elders cohort managed by the University of 
Birmingham were also recruited. Study information was presented at seniors’ group 
meetings and direct contact to a member of the study team was answered as 
detailed above. 
4.3.4. Eligibility screening 
The assessments completed during eligibility screening are documented in Table 4.2, 
and were conducted via one of following methods:  
1) For participants identified via the primary care or independent living approach, 
the health questionnaire (see Appendix F) was conducted via telephone, with 
subsequent tests completed at the University of Birmingham. 
 
2) For participants identified via the sheltered housing approach, all eligibility 
screening tests were conducted within the participant’s own home, provided 
health and safety requirements for the blood draw are met (i.e. hand washing 
facilities available nearby and impermeable surfaces). If requirements were 
not satisfied, transport was arranged for the participant and the visit took place 






It was the responsibility of the investigator to obtain written informed consent for each 
participant prior to performing any trial related procedure. A PIS was be provided to 
facilitate this process and the participant was given at least one week to read the PIS 
and discuss participation with others outside the research team. For participants 
recruited via the primary care network approach, a signed patient contact agreement 
consent form was received before any contact was made. 
Investigators ensured they adequately explained the aim, trial treatment, anticipated 
benefits and potential hazards, and the participant was given the opportunity to ask 
questions. Investigators also stressed that participation was voluntary and that the 
participant was free to refuse to take part and could withdraw from the trial at any 
Table 4.2: Eligibility screening assessments  
 Location of assessment Exclusion criterion 
Informed consent At participant’s home or the University of 
Birmingham 
- 
  General health 
questionnaire 
Telephone call, participant’s home or the 
University of Birmingham 
 
Answering “yes” to any 
question outlined in the 
exclusion criteria (Table 3.1) 
  Mini mental state exam 
(MMSE) 
At participant’s home or at the University of 
Birmingham 
 
Score < 23 
 
 
Blood draw assessing 
25(OH)D status 
At participant’s home or at the University of 
Birmingham 
 
Serum 25(OH)D < 30 nmol/L 
 
 Physical activity 
monitoring 
(ActivPAL accelerometery) 






time without it affecting their future care. If interest in participation in the trial is 
confirmed they were asked to sign and date the consent form (see Appendix G). 
At each visit the participant’s willingness to continue in the trial was ascertained. 
Throughout the trial the participant had the opportunity to ask questions about the 
trial.  Any new information that was relevant to the participant’s continued 
participation was to be provided to the study team.  Where new information became 
available which may have affected the participants’ decision to continue, participants 
were given time to consider and if happy to continue were re-consented. Re-consent 
was documented in the medical notes and the participant’s right to withdraw 
remained. With the participant’s consent, their GP was informed of their participation. 
4.3.6. Randomization, allocation and blinding procedures 
Participants were randomised by a University Hospitals Birmingham statistician to 1 
of 2 arms: 1) RET + 800 IU vitamin D3 daily (intervention) or 2) RET + placebo daily 
for six months (control). Participants were stratified on the basis of vitamin D status 
(high≥50nmol/L, low = 30-50nmol/L), physical activity (measured pre-randomisation 
using accelerometery, achieving the minimum recommended step countper day, not 
achieving the recommended step countper day), and sex. “High” vitamin D status 
was defined as ≥50nmol/L as this cut-off point is widely accepted as describing 
vitamin D adequacy; “low” vitamin D status was considered to be between 30 – 
50nmol/L, widely accepted as describing inadequacy (van Schoor and Lips, 2018). 
We declined to include participants with hypovitaminosis D as we felt it unethical to 
withhold treatment from those participants randomized to the placebo group. 
The physical activity cut-off point of 7000 steps per day (averaged from data 
collected using ActivPAL accelerometers worn for 7 days) was chosen based on 
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review evidence recommending older adults achieve between 7000 – 10,000 steps 
per day, or 7100 if averaged over 1 week (Tudor-Locke et al., 2011). This 
recommendation was calculated based on an assumed average adult cadence per 
minute and applied to the Canadian physical activity guidelines recommending that 
older adults achieve 150 minutes of moderate-to-vigorous activity per week 
(Paterson and Warburton, 2010); a variation of both the WHO guidelines (World 
Health Organization, 2010) and the recent UK Chief Medical Officers’ report on 
physical activity guidelines for older adults (Department of Health and Social Care, 
2019). 
Randomisation was computer-generated using the random number function in 
Microsoft Excel with a mixture of block sizes of four and six. Allocation of participants 
into study group and labelling and allocation of the tablets into supplement bottles 
and adherence monitoring was completed within the University of Birmingham, by an 
individual with no other involvement in the study. 
The study team and participants were blinded to group allocation. Randomisation 
codes were kept in individual sealed envelopes to avoid unblinding the whole cohort 
if an individual participant allocation was requested by the study team's medical 
expert. In order to avoid assessor unblinding, all blood results were viewed by the 
study team's medical expert who may have been unblinded as a consequence. 
Unblinding decisions were to be taken by the study medical expert, in consultation 
with the CI. 
Arrangements for emergency unblinding if both the medical expert and CI were 
unavailable were according to established UHB practice embedded within its 
governance structure. The Clinical Research Facility (CRF) does not open 24 hours a 
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day, however the CRF Clinical Manager had 24-hour access to the relevant 








 N = 127 participants to be identified via the primary care, sheltered housing and 
independent living approaches and provided with a copy of the PIS 
RECRUITMENT PHASE 
-56 to -7 days: Screening visit 
Procedures: consent, health questionnaire, MMSE, serum 25(OH)D assessment, physical activity 
monitoring. To take place at the Wellcome Trust Clinical Research Facility or participant’s home 
Participant given 1 week minimum to 
consult the PIS 
Participant contacts the study team 
ENROLMENT PHASE 
-7 to 0 days: Baseline testing 
Procedures: LLEP, DXA scan, TUG, SPPB, chair rise, blood pressure, QoL, VAS pain, food diary 
To take place at the Wellcome Trust Clinical Facility or participant’s home 
BASELINE TESTING PHASE 
Randomization and allocation 
Stratified on the basis of vitamin D status, physical activity and sex 
6 months 
Resistance exercise training 
+ 
800 IU vitamin D3 daily 
6 months 
Resistance exercise training 
+ 
Placebo tablet daily 
Month 6: Follow-up testing 
Procedures: LLEP, DXA scan, TUG, SPPB, chair rise, blood pressure, QoL, VAS pain, food 
diary, activity monitoring 
To take place at the Wellcome Trust Clinical Research Facility or participant’s home 
INTERVENTION PHASE 
FOLLOW-UP TESTING PHASE 
Continuous monitoring of falls and fractures as events Venepuncture assessments 
months 1 & 3 
Fig 4.1: Study timeline schematic 
PIS: participant information sheet, MMSE: mini mental state exam, LLEP: lower limb extensor 
power output, DXA: dual energy X-ray absorptiometry, TUG: timed up and go, SPPB: short 
physical performance battery, VAS: visual analogue scale pain questionnaire 
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4.3.7. Study intervention: Intervention arm 
i)  Resistance Exercise Training 
A rolling group exercise programme with a maximum of 12 participants per group and 
no more than 2 groups running concurrently was established. Group 1 alone ran for 3 
months to check for practical issues. The exercise training intervention was delivered 
by the study team in partnership with a specialist exercise instructor who delivered 
initial training, supervision and regular quality assessment. The specialist exercise 
instructor provided a copy of their Public, Personal Trainer and Coaches liability 
Insurance certificate to the CI. 
The RET programme was developed by our falls prevention nurse specialist and 
approved by the Falls Lead Physiotherapist for UHB and includes; a dynamic warm-
up and aerobic section (approximately 15 minutes), balance and co-ordination 
section (approximately 10 minutes), resistance training section (approximately 20-25 
minutes) and a cool down with stretches (approximately 10-15 minutes). Each 
session lasted for approximately 60 minutes, with 2 sessions per week for 6 months. 
The sessions included elements of current established programmes for falls 
prevention/ core stability (e.g., OTAGO (Robertson et al., 2001)) and was tailored 
and progressed individually to a range of abilities within the target group. The 
resistance training section utilised physiotherapy bands and ankle weights, of which 
a range of colours and weights was supplied. 
Attendance at group sessions was monitored via a register, and participants were 
asked to report any non-attendances to a member of the study team. Progression 
was assessed via the 30 second chair rise test (also a policy of the specialist 
exercise instructor), band colour/ ankle weight utilised and repetitions of resistance 
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exercises. Groups ran throughout the year to mitigate for seasonal variation in 
vitamin D status. Group 1 ran from July to January (summer to winter), Group 2 ran 
from April to December (spring to winter) and Group 3 ran from December to August 
(winter to summer). 
Exercise sessions were held in communal living spaces for participants recruited via 
the sheltered housing route or within the Morris Club Centre, an NHS health, fitness 
and wellbeing centre located on the Queen Elizabeth Hospital campus, for 
participants recruited via the independent living or primary care approach. Pre-payed 
transport to and from the exercise sessions was offered to all participants in order to 
remove a potential barrier to participation and promote participant retention. During 
the study participants were asked not to undertake any additional classes/ 
supplements; after the study was completed a book or DVD of the training exercises 
was given to encourage continued physical activity as a lifestyle choice. 
ii) Vitamin D3 supplementation 
In line with the current Institute Of Medicine (Ross et al., 2011b) and Royal 
Osteoporosis Society (The Royal Osteoporosis Society, 2019b) guidelines, the daily 
dose of vitamin D3 was 800 IU. This was below the UK Food Standards Agency 
publicly stated safe limit for daily vitamin D intake at 1000 IU (Food Standards 
Agency, 2003), although this has been criticised as overly conservative (Vieth, 2006). 
The Institute of Medicine set a Tolerable Upper Intake Level (UL) for vitamin D of 
4000 IU per day (Ross et al., 2011b) and the European Food Safety Agency (EFSA) 
Panel on Dietetic Products, Nutrition and Allergies have set a no observed adverse 
effect level (NOAEL) of 10,000 IU per day (EFSA Panel on Dietetic Products and 
Allergies, 2012). Additionally, hypercalcemia, the hallmark of vitamin D intoxication, 
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has only been consistently observed in anecdotal evidence when 25(OH)D 
concentrations are between 375–500 nmol/L (Jones, 2008). Therefore, assessment 
and monitoring of serum 25(OH)D and calcium occurred throughout the study 
(baseline, months 1, 3 and 6) although we did not anticipate any reason for early 
termination of the study.  
Individual supplies of over the counter vitamin D supplements provided by IVC Brunel 
Healthcare were given to participants in tablet form packed in pots; pots contained a 
4-week supply of supplements (28 tablets) and participants were instructed to take 
one 800 IU tablet per day. Tablets were stored at ambient temperature by the study 
team within the University of Birmingham, and distributed to participants every 4 
weeks. Tablet manufacture was undertaken by Brunel Healthcare in a Medicines and 
Healthcare products Regulatory Agency (MHRA) licensed facility, labelling and 
allocation of tablets into pots took place within the University of Birmingham by an 
individual with no other involvement in the study. Labels contained the following 
information: number of tablets (28); dose (20 μg/800 IU); schedule and directions of 
use; storage information; date; participant ID; batch information; trial name (EXVITD) 
and study team contact number. Compliance was monitored by returning used tablet 
pots, with gentle compliance reminders given to participants during the exercise 
sessions.  
Study intervention: Control arm 
Participants randomized to the control arm of the trial received the RET intervention 
alongside the intervention group and a daily placebo supplement distributed and 





Table 4.3: EXVITD study outcome measures 
  Trial period 
 Enrolment Allocation Post-allocation Follow-up 
 -56 to -7 
days 
(Screening) 









+1 to +7 
days 
Enrolment 
Informed consent1 X X X X X X 
 Health questionnaire X      
 MMSE X      
 Venepuncture X X X X X X 
 Physical activity monitoring 
(accelerometery – ActivPAL) 
X     X 
 Allocation  X     
Interventions 
Resistance exercise training       
 Vitamin D or placebo       
Assessments 
Lower limb extensor power 
(Nottingham power rig) 
 X    X 
 Body composition & BMD 
(DXA) 
 X    X 
 Chair rise (Leonardo force 
plates) 
 X    X 
 Functional ability (SPPB & 
TUG) 
 X    X 
 Blood pressure  X    X 
 Falls as events X X X X X X 
 Fractures as events X X X X X X 
 Quality of life (SF-36)  X     
 Musculoskeletal pain 
questionnaire 
 X    X 
 Food diary  X    X 
1Informed consent form will be signed during the screening visit and will be re-confirmed verbally at 
each following time point. BMD: bone mineral density, DXA: dual energy X-ray absorptiometry, SPPB: 
short physical performance battery, TUG: timed up and go, SF-36: 36 item short form survey. 
placebo tablet was as follows; 73% Sorbitol P60W, 25% sieved Xylitab 300, 2% 
Magnesium Stearate Veg EP. 
4.3.8. Outcome assessments 
A list of scheduled outcome assessments is presented in Table 4.3. Outcome 
measures were assessed by the study team, with the exception of the DXA scan 






4.3.9. Reliability, validity and appropriateness of outcome measure variables to be implemented in the EXVITD study 
 
Table 4.4: Reliability, validity and appropriateness of outcome measure variables to be implemented in the EXVITD study 
Outcome variable Measurement variable Reliability/validity/appropriateness in an older population 
Muscle power LLEP (Nottingham power 
rig) 
The Nottingham Power Rig, manufactured by the Medical Engineering Unit of The 
University of Nottingham, serial number LEPR/08/052 using LegRig Version 2.0 (2003) 
software edition was used to measure explosive power in the dominant leg of 
participants. The test is completed in a seated position, with the participant extending 
their dominant leg in order to depress the foot press as quickly and forcefully as possible. 
The depression of the foot press rotates the flywheel and an optoswitch is used to record 
angular velocity and calculate LEP (Bassey and Short, 1990). This action incorporates 
hip extension, knee extension, and ankle plantar flexion and is considered the “gold 
standard” of power measurement in older adults (Gray and Paulson, 2014). Since the test 
is performed seated, it is considered a safe alternative measure of muscle power to jump 
tests in frail older adults (Lindemann et al., 2003). The measurement of muscle power 
using the Nottingham leg rig has been found to be significantly associated with 
measurement of power using an isokinetic dynamometer (Spearman’s rho = 0.73, 
p<0.001) and two-legged jumps on a force plate (Spearman’s rho = 0.86, 
p<0.001)(Bassey and Short, 1990). The test-retest coefficient of variation has been 
reported as 8% in a population of 419 women aged 63-75 years (Portegijs et al., 2005).  
Muscle power was selected as the primary outcome measure since muscle power is a 
superior predictor of functional status than muscle strength (Suzuki et al., 2001, Byrne et 
al., 2016) and power of the lower limbs has been found to be an independent predictor of 
self-reported functional status in community-dwelling older women (Foldvari et al., 2000). 
Muscle power declines  more rapidly with ageing than muscle strength (Skelton et al., 
1994) and low leg muscle power is associated with a 2-3 fold greater risk of mobility 
limitations compared with low muscle strength (Bean et al., 2003); mobility limitation is an 
independent risk factor for disability, hospitalization and mortality and reduces quality of 





Figure 4.2: The Nottingham Power Rig, reproduced 
with permission from (Barker et al., 2012), 




Outcome variable Measurement variable Reliability/validity/appropriateness in an older population 
Body composition DXA Total body composition and BMD was assessed using a GE Lunar iDXA encore 2011 
running software version 13.60.033. Quality assessment checks are completed 3 times 
per week with the machine switched on and water and encapsulated phantoms provided 
by the manufacturer are used to calibrate the machine 3 times per week. 
DXA differentiates and quantifies different materials in the body using 2 beam energies 
which are attenuated or absorbed in relation to tissue type and amount. DXA 
discriminates between lean and bone materials, and provides estimates of 3 body 
compartments; lean, bone and fat. Since lean and fat masses comprise more water than 
bone, these tissues will attenuate the beam energy to a lesser degree than bone 
(Buckinx et al., 2018a). 
DXA is widely available, produces lower radiation doses and measurements of muscle 
mass and quality are highly correlated with both CT (multi-slice thigh fat-free mass, r2 = 
0.96)(Levine et al., 2000) and MRI (whole body lean mass r = 0.94) (Chen et al., 2007). 
Although DXA does have a number of limitations, such as the inability to measure 
intramuscular fat and differences in results between devices (Buckinx et al., 2018a), it 
has been cited as a reliable method of indirectly estimating muscle mass in older adults 
(Chen et al., 2007). Indeed, DXA is the current “reference technique of choice for 
estimating muscle mass and body composition in research and clinical practice”, and is 
widely used in RCTs to estimate skeletal muscle mass (Buckinx et al., 2018a).  
 BMD DXA BMD is calculated by converting the radiation energy per pixel into areal density, which is 
the number of pixels in the area and the amount of bone in each pixel (Berger, 2002). 
The assessment of BMD to predict fracture risk has limitations,  namely, BMD does not 
fully describe bone strength nor quality, does not account for bone size nor architecture, 
is not a true three dimensional measure and cross-comparison between different DXA 
machines is difficult (Pors Nielsen, 2000). However, from BMD, T and Z scores can be 
calculated, which are used to diagnose osteoporosis(World Health Organization, 1994); 
BMD estimation via DXA has become “universally adopted as a standard to define 
osteoporosis” (Link, 2012). In the EXVITD study, additional images of the hip and spine 
were chosen since these site-specific scans are preferred to diagnose osteoporosis and 
predict fracture risk (Sözen et al., 2017). DXA used to estimate BMD has been described 
as highly precise (with a maximum acceptable precision error of 2-2.5% (Link, 2012)) and 





Outcome variable Measurement variable Reliability/validity/appropriateness in an older population 
Muscle function SPPB The Short Physical Performance Battery test (SPPB) was designed to assess lower 
extremity function in older adults and consists of 3 domains; balance, gait speed and 
chair rise tests (Guralnik et al., 1994). The test has a maximum score of 12 points, with a 
score ≤8 points indicative of poor physical performance (Cruz-Jentoft et al., 2010c). SPP 
score is associated with mobility disability, hospitalization and mortality (Guralnik et al., 
2000, Beaudart et al., 2016b). The SPPB test has been found to be a highly valid and 
reliable measure of function in a variety of older populations (Freire et al., 2012, Gómez 
et al., 2013, Olsen and Bergland, 2017) and also sensitive to change in the event of 
medical events including myocardial infarction, stroke and hip fracture; participants 
experiencing such medical events were significantly more likely to record poorer 
summary performance change scores (Ostir et al., 2002). Therefore, the SPPB test is a 
standard measure of physical performance in older adults in a research and clinical 
setting (Cruz-Jentoft et al., 2010c) and is also a validated test for sarcopenia severity 
diagnosis (Writing Group for the European Working Group on Sarcopenia in Older 
People 2  et al., 2018). 
 Muscle function TUG  The Timed Up and Go test (TUG) is a measure of muscle function developed specifically 
for older adults and is the time (in seconds) taken to stand up from a chair, walk 3 
meters, turn around, return and sit down (Podsiadlo and Richardson, 1991). Aspects of 
the TUG test are characteristic of activities of daily living important for the maintenance of 
physical independence, i.e. the muscle strength to rise from a chair, gait speed, turning, 
and the co-ordination to sit safely from a standing position (Vervoort et al., 2016); poor 
TUG test performance has been associated with mortality (HR = 1.79; 95% CI, 1.33, 
2.42, p <0.001) (Bergland et al., 2017). The TUG test is sensitive and specific when 
identifying older people with sarcopenia (sensitivity = 67%, specificity = 88.7%) (Martinez 
et al., 2015) and those who are prone to falls (sensitivity = 87%, specificity = 87%) 
(Shumway-Cook et al., 2000). Additionally, a high inter-rater reliability has been reported 
amongst community-dwelling older adults (ICC = 0.98) (Shumway-Cook et al., 2000) and 
the TUG test is recommended by both the American and British Geriatrics societies to 
assess gait speed, balance and fall risk in older adults (Panel on Prevention of Falls in 
Older Persons and Society, 2011). The TUG test is recommended by EWGSOP2 to 
assess low physical performance (Writing Group for the European Working Group on 
Sarcopenia in Older People 2  et al., 2018) and a cut-off point of ≥20 seconds for low 













Accelerometry was used to estimate average physical activity over 7 days. The 
activPALTM monitor (PAL Technologies Ltd, Glasgow, Scotland) is a small accelerometer 
device affixed to the anterior midline of the thigh where it is able to determine static and 
dynamic acceleration, classify activities into 3 categories (sitting/lying, standing, stepping) 
and provides an estimation of energy expenditure (EE) expressed in metabolic 
equivalents (METs). Step count, time spent sitting/lying, estimated energy expenditure 
and postural transitions were recorded and a daily average was estimated from the 7-day 
data. PAL Technologies use Intelligent Activity Classification algorithms to translate the 
positional and acceleration data received from the monitor into information about posture 
(i.e, sitting/lying, standing and postural transitions), step count and stepping speed 
(Edwardson et al., 2017). Energy expenditure is indirectly measured using these 
categories of movement, and intensity of exercise inferred using METs (≥3.0 METs 
assumed as moderate-vigorous activity) (Montoye et al., 2017). 
Although subjective measures of activity estimation such as self-report questionnaires 
and activity diaries are more practical for large-scale cohorts (Aguilar-Farías et al., 2015), 
they may overestimate sedentary time in older adults (Van Cauwenberg et al., 2014), 
they reply on participant recall and they can place a high level of burden on the 
participant (Atkin et al., 2012). Conversely, activPAL monitoring has reported excellent 
inter-device reliability (ICC = 0.99) and an overall 95.9% agreement between a second-
by-second observed analysis and the monitor (Grant et al., 2006). Additionally, activPAL 
has been reported to record step count and cadence under 3 treadmill conditions (fast, 
normal and slow speeds) and during a 500 metre outdoor walk to a high degree of 
accuracy (<1% absolute percentage error) in a group of 20 older adults of mean age 71.9 













Outcome variable Measurement variable Reliability/validity/appropriateness in an older population 
Musculoskeletal 
pain 
VAS pain  The visual analogue scale (VAS) for pain is a generic questionnaire for evaluating pain. It 
consists of a coloured scale from 0 to 10 (0 = “no pain”, 10 = “worst imaginable pain”); a 
score <4 indicative of good pain management (Burckhardt and Jones, 2003) and a score 
of ≤2 a cut-off point for “acceptable” pain (Wolfe and Michaud, 2007). The minimum 
change of clinical relevance in a cohort of patients with rheumatoid arthritis was shown to 
be 1.1 points on the 10 point scale, which was the calculated standard error of the mean 
(Wolfe and Michaud, 2007). The questionnaire is completed by the participant, with a line 
drawn perpendicular to their experience of pain both in a seated and standing position for 
the previous 24 hours. The participant burden of completing the questionnaire is low, 
since it can be completed in under 1 minute and the VAS is reported to be sensitive to 
change in clinical trials (Burckhardt and Jones, 2003). Test-retest reliability has been 
reported as r = 0.937 for literate and r = 0.712 for illiterate patients with rheumatoid 
arthritis (Ferraz et al., 1990). Chronic pain assessed by the VAS has been shown to be 
significantly associated with poor self-reported health status, sleep disorders, depression 
and malnutrition in 105 nursing home residents of mean age 82.2 years (Zanocchi et al., 
2008).  

















The general population health questionnaire the Short Form (SF)-36 is a quick and 
comprehensive version of the 149-item health questionnaire developed as part of the 
Medical Outcomes study (Ware Jr and Sherbourne, 1992). The SF-36 questions 
encompass 3 domains of health; functional status, wellbeing and an overall evaluation of 
health. A 2005 review of quality of life assessment in older adults found that the SF-36 
was the most extensively used assessment, with good evidence supporting the 
questionnaire reliability, validity and responsiveness to change, particularly in community-
dwelling older adults with lower levels of morbidity (Haywood et al., 2005). The SF-36 
was completed quickly (median time of 8 minutes) by 195 patients aged 65 years and 
over and the authors remarked questions regarding functional ability made the SF-36 










Outcome variable Measurement variable Reliability/validity/appropriateness in an older population 
Ground reaction 
force & peak 
mechanical power 
of the lower limbs 
Leonardo Mechanograph® 
Ground Reaction Force 
Plate 
The Leonardo Mechanograph® Ground Reaction Force Plate (Novotec Medical, 
Pforzheim, Germany) running the Leonardo Mechanograph® GRFP Research Edition 
Software version 4.2 was used to assess ground reaction force and peak mechanical 
power of the lower limbs. The Leonardo jump plates are calibrated at set up with no 
ongoing checks. 
The Leonardo Force Plate comprises a bench (45cm high) and a force platform 
containing 4 strain gauge force sensors to measure vertical ground reaction force 
(Matheson et al., 2013). The equipment records the maximal total relative power per 
body weight (CRTPrel) and the maximal velocity (CRTv) during standing throughout the 5 
time chair rise test (also performed as part of the SPPB test (Guralnik et al., 1994)). 
The chair rise test was chosen as the single two-legged jump may be contraindicated in 
frail older adults. The chair rise test evaluates an action which is relevant in everyday life 
(Buehring et al., 2015) by assessing the muscle power required to co-ordinate the 
movement of standing from a seated position (Dietzel et al., 2015). 
The Leonardo Force Plate has been found to have excellent test-retest reliability (ICC of 
up to 0.99) in a range of different age groups, including older adults (Rittweger et al., 
2004, Veilleux and Rauch, 2010, Buehring et al., 2015), good inter and intra-rater 
reliability (Matheson et al., 2013) and measurements of lower limb power correlate well 
with the Nottingham power rig (r = 0.6) and isokintetic dynamometry (r = 0.68) 















Figure 4.3: The chair rise test using the Leonardo 
Mechanograph® Ground Reaction Force Plate. 




Outcome variable Measurement variable Reliability/validity/appropriateness in an older population 
Blood pressure Systolic and diastolic blood 
pressure 
Blood pressure is assessed as an exclusion criterion at baseline and also measured at 6 
months using a Welch Allyn vital sign monitor 300 series (WelchAllyn, Inc., Skaneateles 
Falls, NY). The monitor is calibrated and serviced once annually by a medical engineer. 
Blood pressure was measured in accordance with University Hospitals Birmingham 
clinical guidelines; briefly, the procedure was explained to the participant and consent 
was ascertained. The participant was given a minimum of 5 minutes to relax whilst 
seated before the first measurement was taken. After ensuring that no tight items of 
clothing were constricting the arm, the blood pressure cuff was then placed on the arm, 
with the centre directly over the brachial artery. The arm was supported at the level of the 
arm with a pillow before the first seated reading was taken. Directly after this 
measurement was recorded, the participant was asked to stand, and their standing blood 
pressure measurement was recorded. Each sitting and standing measurement was 
repeated 3 times, with a 5 minute break in between. High blood pressure was an 
exclusion criterion for the EXVITD study, with high blood pressure categorised as a 
resting systolic pressure >200 mmHg or resting diastolic pressure >100mmHg. 
High systolic and diastolic blood pressures have been shown to be positively associated 
with cardiovascular health outcomes such as stroke (MacMahon et al., 1990), coronary 
heart disease and an increase in long-term mortality (van den Hoogen et al., 2000). The 
Welch Allyn vital sign monitor has been shown to give highly accurate measures of 
systolic and diastolic blood pressures across a range of different pulse rates (40 – 200 
beats per minute) (Davis et al., 2005). The accuracy of 5 units of Welch Allyn vital sign 
monitors were assessed using an oscillometric non-invasive blood pressure stimulator 
(Biotek BP pump); 93% of the 150 measurements taken on the Welch Allyn vital sign 
monitor showed an absolute mean difference between the Biotek simulator below 
5mmHg, with an absolute mean bias of 0.7±2.4 mmHg and no clinically relevant precision 
error between monitors; this resulted in the Welch Allyn vital signs monitor being 
assigned an A/A rating according to the European Society of Hypertension criteria 
(O'Brien et al., 2002).   
LLEP: Lower limb extensor power; LEP: Leg extensor power; DXA: Dual-energy X-ray absorptiometry; BMD: Bone mineral density; CT: 
Computerised tomography; MRI: Magnetic resonance imaging; RCT: Randomized controlled trial; HR: Hazard ration; CI: Confidence interval; 
ICC: Intraclass correlation 
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4.3.10. Sample size calculation 
We estimated n=114 participants would give 80% power at the 5% level (two-sided 
test) to detect an additional 19% improvement in the primary outcome measure 
(lower limb power output) above that expected as a result of RET alone (i.e., 29%, 
assuming standard deviations of 26% and 43% in the two groups). This represented 
a gain of over 10 'mobility years' assuming an annual loss of power of 1.5%.  This 
sample size also allowed detection of a 1.0-point increase on the SPPB score over 
and above an assumed 1.5-point increase due to exercise training alone. These 
calculations are based on a combination of our own pilot data and previously 
published data (Greig et al., 2011a, Skelton et al., 1995, Young et al., 1983, Perera 
et al., 2006). Informed by our experience of exercise interventions with older adults 
and patient groups we added 13 participants to cover an anticipated 10% drop-out 
rate. 
4.3.11. Statistical analysis 
All data was entered into a database and analysed using IBM SPSS Statistics for 
Windows, version 25.0; data analysis was conducted on both an intention to treat 
and per protocol basis. Normality was assessed by visual inspection of Q-Q plots and 
the characteristics of participants at baseline were summarised using means and 
standard deviations, medians and quartiles or counts and percentages, as 
appropriate. The comparison of primary interest was the difference at baseline and 6-
month follow-up between the intervention and control groups. A small number of 
variables were found to be non-normally distributed; they were significantly skewed 
and kurtotic, demonstrated significant Kolmogorov-Smirnov/Shapiro-Wilk results and 
deviations on the normal Q-Q plots. A number of log transformations were attempted, 
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however, no one transformation was able to normalise all outcome variables and so 
data was maintained in its non-transformed form. When assessing within-group 
changes, the Wilcoxon Signed Ranks Test was utilised for these variables and paired 
T-tests were implemented for normally distributed variables. 
Between-group comparisons, adjusted for baseline results, were assessed by 
analysis of covariance (ANCOVA) for primary and secondary outcome measures, 
using the Bonferroni correction to control for type I errors arising from multiple 
comparisons. Covariates applied to the analysis included sex, physical activity and 
baseline serum 25(OH)D; variables used to stratify participants. Biomarkers at 
baseline, months 1, 3 and 6 were compared using a repeated-measures analysis of 
variance (ANOVA). All statistical tests conducted were two-sided with an alpha level 
of p = 0.05. Little’s Missing Completely At Random (MCAR) test was non-significant 
and thus missing data was addressed using multiple imputation as suggested by the 
study statistician; this was due to the risk of bias, potential loss of precision and 
power of excluding individuals with missing data from analyses by using exclusion 
methods such as pairwise or listwise (Sterne et al., 2009). 96.77% of variables at 
baseline were complete, with 85.48% of all values found to be complete. 5 
imputations were calculated using the automated method with minimum/maximum 
constraints set for variables; linear regression modelling was utilised by SPSS.  
4.3.12. Data collection, management and monitoring 
All personal data was handled and stored with the strictest confidence and in 
accordance with the Data Protection Act 2018. Personal details such as home 
address, name, date of birth and contact number were provided by the participant in 
the signed participant contact agreement form or in person during an introductory 
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meeting, with the purpose of future contact. Potential participants were made aware 
that personal data collected during the study would be kept confidential and stored 
securely at the University of Birmingham in a locked cabinet accessible only to 
members of the study team. Additionally, participants were aware that relevant 
sections of medical notes and data collected during the study may be looked at by 
responsible individuals from the University Hospitals Birmingham NHS Foundation 
Trust. 
Once allocated to one of the study groups, participants were assigned a unique 
personal identification code, which was used from that point onwards to identify them 
in all documentation, correspondence between the participating sites and the case 
report form (see Appendix H). In the case of specific issues and/or queries from 
regulatory authorities, it would be necessary to have access to the complete trial 
records, provided that participant confidentiality was maintained. Personal data will 
be kept for 10 years after the last data capture in line with University of Birmingham 
policy to allow for verification.  
4.3.13. Missing data 
Data reported on each case report form was consistent with the source data and any 
discrepancies were explained. All missing and ambiguous data was queried. 
Individual data sets were checked by the CI at regular intervals and discrepancies 
highlighted and listed. These were viewed and discussed by the Trial Management 
Group if and when they arose. 
4.3.14. Storage and analysis of samples 
In total, 5 blood samples (10mL) were taken from participants completing the study; 
timepoints are shown in Table 3.3. The samples were analysed at the Queen 
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Elizabeth clinical haematology laboratory (full blood count, blood biochemistry, liver, 
and renal function, serum 25(OH)D), the University of Birmingham Institute of 
Inflammation and Ageing (stress and inflammatory markers) under the supervision of 
a member of the study team and at the Royal Liverpool Hospital Clinical Laboratories 
(bone turnover markers) following a material transfer agreement. Blood analysed at 
the Queen Elizabeth hospital was sent for processing immediately, bloods analysed 
by the University of Birmingham and the Royal Liverpool Hospital were stored at the 
Wellcome Trust Clinical Research Facility at the Queen Elizabeth hospital at -80°C 
for analysis once data collection was complete. Collection, analysis, storage and 
destruction of residual blood samples was according to local policy and standard 
operating procedures aligned to the University of Birmingham Quality Management 
System. 
Serum 25(OH)D concentrations were analysed at the Queen Elizabeth clinical 
haematology laboratory using a chemiluminescent microparticle immunoassay 
(Alinity i 25-OH Vitamin D Reagent Kit 08P45 by Abbott Laboratories, Illinois, United 
States). The manufacturer’s reference ranges were 6.6 – 53.2 ng/mL (16.6 – 132.9 
nmol/L) varying with season, with a lower limit of detection of 3.5 ng/mL (8.8 nmol/L) 
and a within-laboratory (includes within-run, between-run and between-day) 
coefficient of variation of 3.3 nmol/L (SD = 0.67). The laboratory is a member of the 
National External Quality Assurance Scheme (NEQAS) and is externally accredited 
by the United Kingdom Accreditation Service (UKAS), number 7860 against 
ISO15189.  
Frozen serum samples taken at baseline, months 1, 3 and 6 were transported on dry 
ice to the University of Birmingham Institute of Inflammation and Ageing for analysis 
of inflammatory markers including IL-1β, IL-6, IL-8, IL-10 and TNF-α. The Luminex® 
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MAGPIX® CCD Imager was used with Magnetic Luminex® High Performance Assay 
multiplex kits. Manufacturers report less than 0.5% cross-reactivity and interference 
was observed for all markers. Manufacturer minimum detectable dose (MDD) ranges, 
intra- and inter-assay precision, recorded as coefficient of variation (CV), for each of 
the markers measured are as follows; IL-1β: MDD = 0.164 – 0.820 pg/mL, intra-
assay precision = 1.9% and inter-assay precision = 12.5%; IL-6: MDD = 0.200 – 1.24 
pg/mL, intra-assay precision = 2.5% and inter-assay precision = 13.9%; IL-8: MDD = 
0.163 – 0.923 pg/mL, intra-assay precision = 1.3& and inter-assay precision = 13.7%; 
IL-10: MDD = 1.54 – 10.1 pg/mL, intra-assay precision = 2.5%, inter-assay precision 
= 13.4%; TNF-α: MDD = 0.302 – 2.24 pg/mL, intra-assay precision = 1.9%, inter-
assay precision = 14.1%. 
Frozen serum samples taken at baseline, months 1, 3 and 6 were transported on dry 
ice to The Royal Liverpool Hospital Clinical Laboratories, where carboxy-terminal 
collagen crosslinks (CTX), a degradation product of Type I collagen was analysed as 
a measure of bone resorption and overall bone health. Bone turnover markers, such 
as CTX have been shown to predict BMD change in response to intervention 
therapies for osteoporosis (Greenblatt et al., 2017), with decreases in CTX 
associated with a reduction in spinal fractures and an increase in BMD (Eastell et al., 
2011). CTX was analysed using an electrochemiluminescence immunoassay 
(Elecsys Cobas® β-CrossLaps/serum by Roche Diagnostics, Roche Holding AG, 
Basel, Switzerland). The manufacturer’s reference ranges were 0.299 – 1.008 ng/ml, 
with a lower limit of detection of 0.01 ng/ml and a repeatability and intermediate 




4.3.15. Monitoring and auditing  
This was low-risk single centre trial and thus the study team did not consider the 
support of a Data Monitoring Committee to be necessary; however, monitoring of the 
study by the University of Birmingham Clinical Research Compliance Team, including 
access to source documents as requested, was permitted. 
4.3.16. Ethical considerations 
A favourable opinion was granted by the Black Country NHS Research Ethics 
Committee (REC) in December 2014 (14/WM/1220). All study team members 
received necessary training and conducted the study in accordance with Good 
Clinical Practice guidelines. 
4.3.17. Safety monitoring 
Serious adverse events (SAEs), defined as any event that could be related to the 
study that caused injury or hospitalisation were to be reported to the CI and the 
Clinical Research Facility’s Clinical Manager for review within 24 hours after first 
becoming aware of the event. All SAEs were to be reviewed formally every 2 weeks 
during Clinical Research Facility operations meetings which include representation 
from the Trust Research, Development and Innovation office, however, no SAEs 
occurred during the study period. 
4.3.18. Dissemination policy 
Results of this trial will be submitted for publication in peer reviewed journals. The 
manuscript will be prepared by the study team led by the CI. Authors will 
acknowledge that the trial was performed with the support of the Royal Osteoporosis 





Although exercise is currently the only proven mechanism to improve the symptoms 
of sarcopenia (Offord and Witham, 2017), the anabolic response to RET is blunted in 
older compared to younger adults (Greig et al., 2011a, Raue et al., 2009) and 
strategies to potentially overcome this effect are lacking. A recent systematic review 
highlighted the lack of data in this area (Antoniak and Greig, 2017) and provided 
tentative support for the combined intervention of vitamin D and RET (Antoniak and 
Greig, 2017). Very few studies to date have been appropriately designed to test the 
combined effects of vitamin D and exercise in older adults, and of the studies which 
have, poor exercise compliance (Bunout et al., 2006a) and small sample sizes have 
been reported (Agergaard et al., 2015a), limiting interpretation of the data. 
Therefore, the EXVITD study aimed to address these issues and bridge the gap in 
knowledge regarding the potential enhancement of the effects of RET by vitamin D 
supplementation. A sample size of n=127 represents a substantial addition to the 
current data and as the study team delivered the intervention (both the supplements 
and the RET sessions), adherence was monitored closely (registers of attendees 
were taken at each session by the PhD student or exercise instructor, with weekly 
communications of this information at the end of each week) and encouraged in 
person. A finding that RET and vitamin D supplementation is effective compared with 
RET alone would support the development of future multimodal interventions to 
maintain bone and muscle health in old age and pave the way for further mechanistic 
and intervention studies examining the effects of RET/vitamin D in conjunction with 
other promising anabolic agents. 
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The strengths of this study include the design; a randomized double-blinded placebo-
controlled trial is the most appropriate methodology to utilise to assess the primary 
and secondary outcomes. A range of outcome measures will provide a wealth of 
information regarding the musculoskeletal health of the participants. Additionally, the 
present study aimed to recruit older men and women, meaning that the results of the 
trial will be generalizable with respect to sex. 
One limitation of the study is the lack of a precise and quantifiable measure of 
exertion, exercise progression or muscle loading. Exertion was not be assessed in 
the present study; the use of objective measures such as heart rate monitors or rate 
of perceived exertion scales were rejected due to additional participant burden. 
Exercise progression and muscle loading would be more objectively measured if 
gym-based resistance equipment were to be employed, however, the benefit of using 
body weight, ankle weights and physiotherapy bands is that these equipment will be 
more familiar and readily adapted to daily practice, so that new-found exercise habits 
may be maintained following the close of the study. Additionally, previous studies 
have emphasized benefit of vitamin D supplementation in deficient participants 
(Beaudart et al., 2014a); since vitamin D deficiency is an exclusion criterion, we may 
be less likely to observe meaningful clinical effects of supplementation in our vitamin 









4.5. Personal development and lessons learned 
Table 4.5. Personal reflections 
This is a short reflective section detailing my personal development 
throughout the study and the lesson that I learnt during recruitment and 
through implementing the study. 
The various amendments submitted throughout the EXVITD study are 
displayed in Table 4.6. It took 7 minor and 6 substantial amendments to 
arrive at a working protocol (Version 10.0). The addition of this short reflective 
section within the methods chapter was deemed necessary, as a substantial 
amount of time during the PhD was spent attempting to recruit. Originally, we 
aimed to recruit men and women aged ≥70 years and living in sheltered 
housing accommodation within Birmingham. It was expected that this group 
of older adults would be pre-frail or frail but still able to maintain 
independence and hence an appropriate population to benefit from an 
exercise intervention. 
The reality of the experience was rather different from expected; older adults 
living within sheltered housing accommodation were older and much frailer, 
with many more co-morbidities (such as dementia) than expected. Many of 
the residents considered 3 sessions of exercise per week for 6 months was 
too big a time commitment for them; residents were also wary about taking 
any supplements in addition to their prescribed medications. Moreover, the 
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support we initially received from the Bournville Village Trust (a large housing 
association overseeing 8000 properties in Birmingham) ended when their 
manager left the organisation.  
An additional advantage to targeting sheltered housing accommodation was 
that use of a communal living area for the exercise session would make 
attendance easy for the residents. In practice, it was extremely difficult to gain 
any access to the residents. Supported housing accommodation managers 
acted as “gatekeepers” and access to residents was only permitted if they 
agreed; approximately two thirds of opportunities to discuss the study with 
residents were denied or ignored, therefore, residents were unable to make 
an informed decision about participation in the study. Figure 4.4 displays the 
















 Head offices of sheltered housing organisations were initially contacted, then 
sheltered housing managers. If they agreed, the study was presented at 
resident’s meetings and coffee mornings or the study flyer was displayed on 
communal noticeboards or within newsletters. Of the interested residents, 
only 1 was found to be eligible; the main reason for lack of eligibility was that 
many of the residents were already prescribed or taking supplemental vitamin 
D, which at the time was an exclusion criterion.  
The approval of substantial amendments 2 to 6 meant that we were able to 
recruit and form our first group of participants; via these amendments we 
were able to advertise and recruit more widely without the 
prescribed/supplemental vitamin D exclusion criterion, recruit from a wider 
pool of potential participants by lowering the age entry criterion from 70 years 
to 65 years and also recruiting community-dwelling participants  to participate 
in exercise sessions held in a public space.  The obvious downside to these 
amendments was that we recruited a slightly different group of older adults 
than we were originally aiming to include; our group of participants were more 
independent and functionally able than we planned. Additionally, we did not 
recruit our target number of participants as indicated by the sample size 




Table 4.6: Protocol development 
Amendment type & 
number 
Date New documentation version Reason for amendment 
Initial ethics approval 08/12/14 Protocol V. 1.0 
PIS V. 2.0 
 
 Minor amendment 1 21/08/15 Protocol V.2.0 
 
- Addition of falls & fractures as events 
- Use of CRF instead of health research bus 
- Storage, labelling & allocation of vitamin D at UoB instead of CRF 
- No urine samples to be taken 
 Minor amendment 2 14/12/15 PIS V.3.0 - PIS amended to reflect above changes 
 Minor amendment 3 05/01/16 Protocol V.3.0 
PIS V.4.0 
- Addition of CTX & PTH blood markers 
 Substantial amendment 1 25/01/16 Protocol V.4.0 
PIS V.5.0 
- Additional hip & spine DXA scans 
 Minor amendment 4 11/04/16 Protocol V.5.0 - Updates to protocol: update contact details/co-investigators/change “drug” to 
“supplement” 
- Blood pressure to be measured at baseline  
- Advertise study on Birmingham City Council website 
 Substantial amendment 2 22/07/16 Protocol V.6.0 
PIS V.6.0 
- Lowering of age criterion from 70 years to 65 years 
- Advertise study via the 1000 Elders database/ appropriate websites/ print media 
- Recruit community-dwelling (independent) older adults 
 Substantial amendment 3 01/11/16 Protocol V.7.0 - Removal of daily supplemental vitamin D (>400IU) and/or calcium (>500mg) use 
exclusion criterion 
- Advertisement of study displayed in GP practices 
 Substantial amendment 4 10/02/17 Protocol V.8.0 - Addition of Clinical Research Network and BUPA support for recruitment 
- Use of public spaces to hold exercise intervention 
 Minor amendment 5 12/04/17 Protocol V.9.0 -  Additional 21 days between enrolment and intervention start to allow time to 
conduct multiple screening visits and merge participants into 1 exercise group 
 Minor amendment 6 31/05/17 GP letter V.2.0 - Amend GP letter to reflect the lowering of age criterion and removal of a urine 
sample request 
 Substantial amendment 5  06/07/17 GP summary V.1.0 
Patient invitation letters V.1.0 
- Submission of CRN supporting documentation 
 Substantial amendment 6 04/08/17 Patient contact agreement V.1.0 
Patient reminder letter V.1.0 
- Submission of further CRN supporting documentation 
















 RESULTS OF A RANDOMIZED CONTROLLED TRIAL 
INVESTIGATING THE INFLUENCE OF COMBINED VITAMIN D3 
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5.1. Baseline characteristics 
Participant characteristics at baseline measurement are summarised in Table 5.1; 
median age and interquartile range of the participants in the placebo (n = 12) and 
vitamin D (n = 12) groups were 70.50 ± 5.75 and 68.00 ± 6.50 years, respectively. 
There was a similar distribution of males and females in each group and the mean 
BMI categorised the participants as overweight. Importantly, there were no significant 
differences in stratifying outcomes (sex, serum 25(OH)D and mean step count). 
Mean baseline daily step counts fell below the recommended 7000 – 10,000 steps 
per day for participants in both groups, although was achieved by 41.67% (n=10) of 
all participants. Mean serum 25(OH)D concentrations at baseline were within the 
adequate range for both groups; placebo group = 50.65 ± 14.85 nmol/L and vitamin 
D group = 51.31 ± 18.03 nmol/L. 11 (36.67%) and 19 (63.33%) participants at initial 
screening were considered vitamin D insufficient (<50 nmol/L) and adequate (>50 
nmol/L), respectively. There were significant differences at baseline in height, weight, 
perceived general health assessed by the SF-36 questionnaire and total lean mass. 
The significant differences in total body weight were due to the inclusion of one 
participant with a BMI of over 45 in the placebo group. There were no between-group 
differences in baseline total body weight if this participant were excluded (placebo 
group = 76.97 (14.89) kg, vitamin D group = 72.54 (16.29) kg, t (1,21) = 0.68, p = 
0.505). However, analyses were conducted both including and excluding this 
participant, and their inclusion did not significantly affect any of the results, therefore, 
to keep the sample as representative as possible participants were not removed due 
to outlying data points, alternatively, where appropriate, relative outcome measures 




5.2. EXVITD attrition and compliance 
Of the 24 participants randomized to the intervention, 19 (79.17%) completed the 
study, resulting in an attrition rate of 20.83%. There were 2 dropouts from the 
placebo group and 3 from the vitamin D group; reasons given for withdrawal were ill 
health (n = 3), changing mind about participation (n = 1) and no explanation (n= 1). 
89.08% of prescribed exercise sessions were attended by participants and 
supplement compliance was 92.95% (Appendices J and K). On average, participants 
significantly increased their 30 second chair rise test challenge score by 14 points (t 
(17) = 9.46, p < 0.001, calculated from Appendix I exercise progression log), with no 
significant difference between the groups. The 30 second chair rise test was used as 
a method of assessing progression and was also a policy implemented by Move It Or 
Lose It (company that trained the seated exercise specialist). An increase of 3 
repetitions on the 30 second chair rise test has previously been concluded as a 
clinically meaningful increase in performance (Johansen et al., 2016). 
5.3. Falls and fracture incidence 
A fall, using the generally accepted description, was defined as “an event which 
results in a person coming to rest inadvertently on the ground or floor or other lower 
level” (World Health Organization, 2018). 3 falls occurred throughout the study period 
and all falls occurred at a time outside of the scheduled exercise sessions. None of 
the falls caused serious injury or resulted in a fracture; all fallers recovered from their 
fall within 24 hours, with minor bruising. 2 of the 3 fallers were male and all fallers 
were randomized to the placebo group.
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Table 5.1: Baseline characteristics of EXVITD participants 
 Whole cohort (n = 24)  
Mean (SD) 
Placebo group (n = 12)  
Mean (SD) 





   Demographics 
Sex (% female) 45.83 42.67 50.00 0.682 
 Age (years)¥ 70.00 (6.00)  70.50 (5.75) 68.00 (6.50) 0.443 
 Height (m) 1.66 (0.11) 1.69 (0.11) 1.64 (0.12) 0.006 
 Weight (kg) 74.68 (18.14) 80.76 (18.63) 72.54 (15.71) 0.005 
 BMI (kg.m-2) 27.24 (6.31) 28.52 (7.83) 26.99 (4.82) 0.159 
 SBP (mmHg) 138.06 (21.93) 131.69 (17.66) 132.64 (16.39) 0.740 
 DBP (mmHg) 79.37 (11.35) 78.50 (13.11) 76.67 (6.37) 0.288 
 VAS pain sitting¥ 0.00 (1.00) 0.00 (0.75) 68.00 (6.50) 0.872 
 VAS pain standing¥ 0.00 (1.00) 68.00 (6.50) 68.00 (6.50) 0.932 
  SF-36 Physical function score (%) 75.00 (21.63) 74.17 (19.29) 81.67 (19.46) 0.353 
 SF-36 General health score (%) 73.27 (14.14) 68.75 (10.25) 80.83 (13.62) 0.022 
 MMSE¥ 29.00 (2.00) 29.50 (1.00) 28.50 (2.75) 0.068 
 Average step count 6708.55 (2527.13) 6518 (2577) 6451 (2463) 0.873 
Functional characteristics 
LLEP (W) 128.46 (71.40) 150.75 (70.04) 112.58 (74.22) 0.209 
 SPPB total score 9.85 (2.09) 9.83 (2.37) 9.83 (2.04) 1.000 
 TUG (s) 7.93 (2.58) 7.43 (3.17) 8.23 (2.12) 0.475 
 Peak total power (kW) 0.55 (0.20) 0.56 (0.19) 0.57 (0.22) 0.980 
 5-time CRT time (s) 7.02 (3.10) 7.50 (4.31) 6.42 (1.37) 0.417 
Body composition characteristics 
Total fat mass (kg) 25.72 (10.21) 26.90 (11.90) 24.77 (8.40) 0.216 
 Total lean mass (kg) 46.45 (9.85) 48.98 (8.67) 44.12 (9.12) 0.001 
 Femoral neck BMD (g.cm3) 0.92 (0.14) 0.94 (0.11) 0.93 (0.15) 0.855 
 Lumbar spine BMD (g.cm3) 1.27 (0.23) 1.32 (0.23) 1.28 (0.13) 0.654 
Biochemical characteristics 
Serum 25(OH)D (nmol/L) 50.21 (19.80) 50.65 (14.85) 51.31 (18.03) 0.817 
¥ values shown for non-normal variables are median (interquartile range) 
SD: Standard deviation; BMI: Body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; VAS: Visual analogue scale; SF-36: 
Short form health questionnaire; MMSE: Mini mental state exam; LLEP: Lower limb extensor power; SPPB: Short physical performance battery; TUG: 
Timed up and go; 5-time CRT: Chair rise test completed using Leonardo Mechanography® ; S: seconds. p refers to the difference between the 
placebo and vitamin D groups (independent samples t-test or Mann Whitney-U) 
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5.4. Functional outcomes 
Within-group changes in functional outcomes are displayed in Table 5.2. Absolute 
power output is presented in Tables 5.1, 5.2 and 5.5. Relative power output was also 
analysed as there were significant differences in body weight at baseline, although 
changes in body weight did not significantly differ within- or between-groups. 
Standardising for total body weight did not alter the LLEP output results; there was 
no significant change within the placebo group (+0.23 (0.47) W.kg-1, t (9) = 1.56, p = 
0.153) and the change in relative LLEP within the vitamin D group remained 
significant (+0.31 (0.38) W.kg-1, t (8) = 2.46, p = 0.040). Similarly, there were no 
between group differences in change in relative LLEP; difference in placebo – vitamin 
D pooled mean result at 6 months = -0.008 (0.16), F (1,13) = 0.19, p = 0.674.  
Overall, improvements were observable in all functional outcomes measured, with 
the exception of gait speed. When analysing within-group changes, the vitamin D 
group significantly increased their LLEP by 19.11% (p = 0.038), and the placebo 
increased their power output by 11.35% (not significant). SPPB total score 
significantly increased in the vitamin D group and decreased in the placebo group. 
The 5-time chair rise time was significantly reduced in both groups by 35.60% and 
44.69% in the placebo and vitamin D groups, respectively. The TUG test time was 
faster in both groups at month 6 in comparison to baseline; - 8.16% and - 18.56% in 
the placebo and vitamin D groups, respectively, with statistical significance observed 
in the vitamin D group (p = 0.034). Peak total power significantly increased within the 
whole cohort and the placebo (+27.71%) and vitamin D (+25.93%) groups. The 5-
time chair rise test assessed using Leonardo Mechanography® was significantly 




As with LLEP, relative peak power was calculated to account for body weight. 
Change in peak relative power was significant within the whole cohort (+3.03 (1.85) 
W.kg-1, p <0.0001), placebo group (+3.17 (2.19) W.kg-1, p = 0.002) and vitamin D 
group (+2.86 (1.45) W.kg-1, p = 0.002); there were no between-group differences 
(difference in placebo – vitamin D pooled mean result at 6 months = 0.93 (0.96), F 
























Table 5.2: Within group changes in functional outcomes 
 Whole cohort Placebo group Vitamin D group 
 Baseline 





Change p Baseline 
(n = 12) 
 
Month 6 
 (n = 10) 
 
Change p Baseline 
(n = 12) 
Month 6 
(n = 9) 
 
Change p 



















































































































































Values shown are pooled mean (standard deviation). * N = 16 at month 6 for peak total power and 5-time CRT due to technical issues with the Leonardo 
Mechanography® Ground Reaction Force Plate 
LLEP: Lower limb extensor power; SPPB: Short physical performance battery; TUG: Timed-up and go; 5-time CRT: Chair rise test completed using Leonardo 





5.5. Body composition outcomes 
Within-group changes in body composition outcomes are displayed in Table 5.3. All 
outcomes were found to change non-significantly, with the exception of total lean 
mass, which significantly increased within the placebo group (+ 1.37%). Lean mass 
was shown to increase within the vitamin D group, but by a smaller and non-
significant amount (+ 0.31%, p = 0.678). The changes in bone parameters (femoral 
neck and lumbar spine BMD) were small and non-significant in both groups. A small 
amount of fat mass was lost in the placebo group (- 1.37%) and gained in the vitamin 
D group (+ 0.31%), however both of these changes were non-significant. Within-
group change in ASM and SMI was greater in the placebo group than within the 































Table 5.3: Within group changes in body composition outcomes 
 Whole cohort Placebo group Vitamin D group 
 Baseline 
(n = 24) 
 
Month 6  
(n =19) 
 
Change p Baseline 
(n = 12) 
 
Month 6 
(n = 10) 
 
Change p Baseline 
(n = 12) 
Month 6 
(n = 9) 
 
Change p 
































































































































































Values shown are pooled mean (standard deviation). BMD: Bone mineral density; ASM: Appendicular skeletal muscle mass; SMI: Skeletal muscle index. p refers 




5.6. Physical activity outcomes 
Within-group changes physical activity outcomes are displayed in Table 5.4. No 
significant changes in any of the physical activity outcomes assessed by ActivPAL 
accelerometery were observed. Average daily step count assessed over 7 days 
increased in the whole cohort, as expected (+ 128.07%). The largest increase was 
attributed to the vitamin D group, which increased their average daily step count by 
16.61%. Average time spent sitting/lying increased non-significantly in both groups at 
month 6, consistent with a small decrease in energy expenditure in both groups. 
Average time spent standing and average up/down transitions were also decreased 
in both groups. Average time spent stepping per day decreased marginally in the 
placebo group but was increased by 24.79% within the vitamin D group at month 6, 
























Table 5.4: Within group changes in physical activity outcomes 
 Whole cohort Placebo group Vitamin D group 
 Baseline 
(n = 24) 
 
Month 6  
(n =19) 
 
Change p Baseline  
(n = 12) 
 
Month 6 
 (n = 10) 
 
Change p Baseline 
(n = 12) 
Month 6 




























































































  0.29 
(0.67) 
0.223 
















- 1.60 0.109 















- 0.84 0.401 
Values shown are pooled mean (standard deviation). ¥ Median (interquartile range) and Z-scores are reported from the Wilcoxon Signed Ranks Test for within 
group differences due to non-normal distribution. EE: Energy expenditure; METs: Metabolic equivalents. p refers to the change from baseline to month 6 within 





Table 5.5: Between group comparisons for functional, body composition and physical activity outcomes 
 Adjusted month 6 pooled mean (SE) Pooled mean change (SE) ANCOVA results 
 Placebo group (n = 10) Vitamin D group (n = 9) Placebo - vitamin D F(df) p 
Functional outcomes 
LLEP (W) 154.54 (7.16) 159.74 (7.58) - 5.20 (10.89) 0.12 (1,13) 0.737 
 SPPB total score 9.40 (1.65) 11.62 (1.54) - 2.23 (2.29) 1.21 (1,13) 0.291 
 Gait speed (s) 3.71 (0.30) 3.40 (0.32) 0.31 (0.46) 0.47 (1,13) 0.504 
 5-time chair rise (s) 7.40 (0.73) 6.52 (0.77) 0.88 (1.09) 0.62 (1,13) 0.444 
 TUG (s) 7.09 (0.33) 6.43 (0.35) 0.66 (0.48) 1.87 (1,13) 0.194 
 Peak total power (kW) 1.63 (0.65) 1.13 (0.66) 0.50 (0.93) 0.36 (1,13) 0.557 
 5-time CRT time (s) 3.83 (0.60) 4.59 (0.67) - 0.76 (0.95) 0.46 (1,13) 0.510 
Body composition outcomes 
Total body weight (kg) 80.08 (16.15) 70.57 (13.98) - 0.61 (1.24) 0.21 (1,13) 0.654 
 Total BMC (kg) 2.69 (0.01) 2.66 (0.01) 0.03 (0.02) 2.76 (1,13) 0.121 
 Hip T-score - 0.62 (0.06) - 0.57 (0.07) - 0.05 (0.10) 0.37 (1,13) 0.552 
 Total fat mass (kg) 25.45 (0.37) 25.87 (0.40) - 0.42 (0.57) 0.53 (1,13) 0.481 
 Total lean mass (kg) 46.47 (0.24) 46.13 (0.26) 0.33 (0.37) 0.92 (1,13) 0.355 
 ASM (kg) 21.30 (0.96) 19.03 (1.01) 2.27 (1.43) 2.53 (1,13) 0.136 
 SMI 27.31 (0.73) 26.10 (0.78) 1.20 (1.12) 1.16 (1,13) 0.300 
Physical activity outcomes 
Average daily step count 5972.16 (694.80) 6532.27 (742.10) - 560.11 (1039.04) 0.24 (1,14) 0.633 
 Average time spent sitting/lying 
(hours/day) 
19.20 (1.11) 19.15 (1.17) 0.06 (1.64) 0.01 (1,13) 0.939 
 Average time spent standing (hours/day) 4.17 (0.42) 4.60 (0.46) - 0.43 (0.67) 0.06 (1,13) 0.810 
 Average time spent stepping (hours/day) 1.27 (0.21) 1.54 (0.23) - 0.27 (0.34) 1.04 (1,14) 0.325 
 Average up/down transitions per day 43.34 (3.26) 48.14 (3.47) - 4.80 (4.84) 0.94 (1,13) 0.351 
 Average daily EE (METs) 33.21 (0.72) 33.14 (0.81) 0.05 (1.13) 0.04 (1,11) 0.841 
Model adjusted for baseline value, sex, baseline 25(OH)D and baseline average daily step count. SE: Standard error; LLEP: Lower limb extensor power; SPPB: Short 
physical performance battery; TUG: Timed up and go; BMC: Bone mineral content; ASM: Appendicular skeletal muscle mass; SMI: Skeletal muscle index; EE: Energy 
expenditure; METs: Metabolic equivalents.  p refers to the between group mean difference (ANCOVA) 
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5.7. Between-group comparisons 
 Table 5.5 shows the primary comparisons of interest; between group comparisons 
for functional, body composition and physical activity outcomes. In summary, no 
significant differences between the placebo and vitamin D groups were observable at 
month 6 after the completion of 6 months of RET and vitamin D or placebo 
supplementation daily in any of the outcome measures assessed. For functional 
outcomes, the vitamin D group exhibited higher LLEP and SPPB total score and a 
faster gait speed, 5-time chair rise and TUG time than the placebo group. Peak total 
power was higher and 5-time CRT was faster within the placebo group at month 6. 
With regards to body composition outcomes, ASM, SMI, total lean mass and total 
BMC were all marginally higher within the placebo group at month 6 in comparison to 
the vitamin D group. Hip T-score was marginally higher within the vitamin D group in 
comparison to the placebo group at month 6. Very small between-group changes 
were observable in physical activity outcomes; average daily step count, average 
time spent standing and stepping and the number of up/down transitions were all 
marginally higher within the vitamin D group at month 6. Energy expenditure and 
















Table 5.6: Between-group comparisons in biomarker concentrations at different time points throughout EXVITD 
 Placebo group (n = 9) 
Adjusted pooled mean (SD) 
Vitamin D group (n = 9) 
Adjusted pooled mean (SD) 
Between-group 
comparisons 



















7.21 (1,17) 0.016 
























































0.11 (1,9) 0.752 
Model adjusted for baseline value, sex, baseline 25(OH)D and baseline average daily step count. PTH: Parathyroid hormone; CTX:  
Carboxterminal collagen crosslinks.  p refers to the between group mean difference (ANCOVA) 
Table 5.7: Whole group results and within-group comparisons of inflammatory markers at baseline and 6-months 
 Whole group Placebo group Vitamin D group 
































































5.8. Blood marker outcomes 
Table 5.6 shows the between-group comparisons in biomarker concentrations at 
baseline and months 1, 3 and 6. As expected, the vitamin D group significantly 
increased their serum 25(OH)D concentrations at month 6 from baseline (F (3,24) = 
3.79, p = 0.023); no significant increases in serum 25(OH)D concentration were 
observed within the placebo group (F (3,27) = 1.30, p = 0.294). Additionally, serum 
25(OH)D concentrations were significantly higher at 6 months within the vitamin D 
group in comparison to the placebo group (p = 0.033). PTH, calcium and CTX serum 
concentrations did not significantly differ between the 2 groups.  
Table 5.7 shows the whole cohort, placebo and vitamin D group results and within-
group comparisons of IL-6, IL-8 and IL-10 inflammatory markers at baseline and 6-
months. No significant changes in any of the inflammatory markers were observed in 




















































The primary aim of this study was to determine between-group differences in 
musculoskeletal function and health after 6 months of RET and/or 800 IU vitamin D3 
or placebo supplementation daily. Secondary aims included comparisons within- and 
between groups of body composition, physical activity, blood and bone turnover 
markers (including vitamin D, calcium, CTX), and falls/fractures. 
6.1. Primary outcome measures: Functional outcomes 
In summary, gains in power or improvements in functionally ability were generally 
higher within the EXVITD study compared with previous exercise and vitamin D 
supplementation studies. For example, gains in LLEP, SPPB total score, peak total 
power and TUG time were all greater than previously observed. There were no  
significant between-group differences to support the additive effect of vitamin D and 
RET for any of the outcome measures. However, within-group differences revealed 
the largest changes in functional outcomes were within the vitamin D group and 
several outcomes achieved a statistically significant change within this group only. 
The total study sample size was substantially lower than required, as estimated by 
the sample size calculation, suggesting that the EXVITD study was simply under-
powered to detect any possible between-group differences.  
6.1.1. Lower limb extensor power (LLEP) 
Lower-limb extensor power output (LLEP) was chosen as the primary outcome 
measure for the EXVITD study, since decline in muscle power is known to be 
strongly associated with mobility limitation (Byrne et al., 2016), which in turn is 
associated with reduced quality of life and independence in older adults (Pahor et al., 
2014). Although both the placebo and vitamin D groups improved their LLEP, this 
change reached significance only within the vitamin D group, in which a large effect 
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size was observed (+18.10W or +11.35%, p = 0.153 Vs +21.56W or +19.11%, p = 
0.038, d = 0.83). An estimated additional +19% increase in LLEP (i.e., up to 38%) in 
the vitamin D group would have been needed to detect a significant difference 
between the vitamin D and placebo groups. 
At baseline, the relative LLEP of the whole EXVITD cohort (1.81 (0.91) W.kg-1) was 
precisely equivalent to the 50th percentile of leg power for the 65-74 years age 
category reported by the Allied Dunbar National Fitness Survey (ADNFS) (Sports 
Council and Health Education Authority, 1992), a UK national study of physical 
activity and fitness conducting physical testing in 1318 older adults including LLEP 
via the Nottingham rig. Analysing the baseline relative LLEP of each of the 
intervention groups separately, the placebo group average relative power was 2.06 
(0.97) W.kg-1, placing them above average in comparison to the ADNFS cohort, 
whilst the vitamin D group average relative power was 1.53 (0.80) W.kg-1, placing 
them between the 10th and 50th percentile (1.10 and 1.81 W.kg-1, respectively) 
(Sports Council and Health Education Authority, 1992). By month 6 of the study, the 
placebo group increased their relative power to 2.29 (1.30) W.kg-1, an increase of 
10.04%, and still above average compared to the ADNFS, although this within-group 
change was non-significant (p = 0.153). The vitamin D group significantly increased 
their relative power to 1.84 (0.72) W.kg-1 (an increase of 16.85%, p =0.040), meaning 
that their relative power was now comparable to the 50th percentile reported by the 
ADNFS (Sports Council and Health Education Authority, 1992). There were no 
significant between-group differences (p = 0.674). 
The gains in LLEP within the RET and vitamin D group of the EXVITD study were 
greater than other RET studies not incorporating vitamin D3 supplementation, yet 
baseline power was lower within the EXVITD study in two of the three studies 
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(Vestergaard et al., 2008, Cegielski et al., 2017). A 24 week RET study including 
older women of mean age 67.5 years resulted in a significant +15.7% increase in 
peak knee isometric knee extensor power measured (Edholm et al., 2017). 
Furthermore, other exercise training studies of differing duration report lower muscle 
power gains measured using the Nottingham power rig as follows; + 14.00% in 12 
men and women (mean age = 63 years) after 4 weeks home-based exercise training 
(Cegielski et al., 2017), +10.19% in 650 women (mean age = 81 years) after 24 
weeks home-based exercise video training (Vestergaard et al., 2008) and +15.84% in 
38 men and women (mean age = 76.6 years) after 52 weeks strength training 
(Capodaglio et al., 2007). 
Comparisons with other studies is challenging since muscle power measurement 
methodology, training regimen and duration and participant population group vary; 
additionally, few studies incorporating vitamin D supplementation and RET in older 
adults currently exist, and fewer still assess muscle power over muscle strength. 
However, 2 of the studies included in the systematic review reported in Chapter 2 
measured muscle power. One of these explored the effects of 12 weeks of strength, 
power or no training on 69 older men and women (mean age = 77 years) and 
included a “run-in” phase of 8 weeks prior to training, in which all participants were 
supplemented with 1000 or 2000 IU vitamin D3 daily, dependent on baseline 
25(OH)D status. After the run-in phase of 8 weeks of vitamin D3 supplementation, 
muscle power (measured as sit-to-stand transfer power) was significantly increased 
in the cohort (+3.58%, p = 0.017). Participants were then randomized to 1 of the 3 
groups and completed a 12-week training period; power was measured again and 
was shown to increase in both the strength training (+8.25%) and control (+3.58%) 
groups, although there were no significant between-group differences (p = 0.308) 
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(Drey et al., 2011). In the second study included in the systematic review, functional 
muscle power, assessed using the timed stair climb test, increased significantly after 
12 months of 1000 IU vitamin D3 supplementation per day and RET compared with  
controls in a study of 162 older adults (mean age = 67 years). However, since all 
participants were supplemented with vitamin D3, any changes were attributed to RET 
(+4.5%, p < 0.005) (Gianoudis et al., 2014).  
A more recent study not included in the 2017 published systematic review, which 
reported the effect of vitamin D supplementation and a 24 week exercise intervention 
in older adults (mean age = 68.8 years) demonstrated that muscle power (assessed 
using the 5-time sit-to-stand test) significantly increased in all 3 intervention groups 
(exercise alone, vitamin D supplementation alone and combined exercise and 
vitamin D). As with EXVITD, there were no significant differences between the 
groups, although the within-group change was shown to be highest in the combined 
intervention group, in which 5-time sit-to-stand time improved by 19.41% compared 
with exercise alone (14.69%). Interestingly, vitamin D supplementation alone resulted 
in comparable increases in muscle power (13.68%) (Aoki et al., 2018), although this 
study supplemented with a higher daily dose of vitamin D3 (1000 IU/d) than EXVITD.  
6.1.2. Total SPPB score  
The EXVITD cohort significantly increased their SPPB total score after the 6-month 
intervention, however, this increase could be attributed to the vitamin D group which 
improved their score by an average of 14.45% or +1.67 points, which was statistically 
significant (p = 0.028). The average SPPB score within the placebo group decreased 
by -10.04% (or -0.91 points, p = 0.637), although the between-group difference was 
not significant. The increase in SPPB for the whole cohort is comparable to the 
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findings of a systematic review of physical activity interventions for physical function 
in adults ≥65; evidence from 5 studies (n = 266 men and women) of moderate quality 
evidence and an average duration of 36 weeks, concluded exercise interventions 
resulted in a significant increase in total SPPB score of 1.87 points (95% CI 1.17, 
2.57, p <0.0001) (Giné-Garriga et al., 2014a). A study of 3 sessions of RET per week 
for 5 months in 55 older men and women (mean age = 69.1 years) reported a mean 
increase in total SPPB score of 5.26%, with a large heterogeneity of individual 
responses to the intervention; changes in SPPB score ranged from a ≤ -20% 
decrease and ≥ +20% increase in performance (Chmelo et al., 2015). This study 
serves to highlight that a limitation of some functional tests such as the SPPB and 5-
time chair rise is a ceiling effect and therefore they cannot discriminately assess 
functional change in higher functioning individuals (Sayers et al., 2006); 8 individuals 
(33.33%) taking part in EXVITD scored the maximum 12 points in the SPPB test at 
baseline, meaning that only a decrease in performance would demonstrate any 
change at 6 months. 
Again, the study was under-powered to detect any significant changes in SPPB 
score; it was estimated that an additional 1.0-point increase in total score above the 
1.5 point increase expected with RET alone (i.e. 2.5 points) would need to be 
observed in order to detect a significant between-group difference in the vitamin D 
group; so it is not possible to state confidently that vitamin D3 supplementation 
resulted in the increased SPPB score. However, it is possible to conclude that the 
increase in average SPPB score within the vitamin D group could be classified as a 
clinically meaningful improvement; effect size calculations concluded that an increase 
of 0.71 – 1.50 points on the SPPB test was associated with a substantial increase in 
1-year self-perceived mobility in a group of 424 older adults aged 70 to 89 years 
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(Kwon et al., 2009). Additionally, a further study concluded that a 0.99 – 1.34 point 
increase in total SPPB score was equal to a substantially meaningful change based 
on secondary data analysis of studies involving older adults (mean age range = 69.8 
to 77.6 years) from which an effect size or standard error of measurement was 
calculated (Perera et al., 2006). 
Changes in total SPPB score within the EXVITD study were greater compared with 
one previous exercise and vitamin D supplementation study (although the duration of 
the current study was longer), 12 weeks of exercise training resulted in a 1-point 
increase in SPPB score (+10.20%) in comparison with sedentary controls (p = 
0.009); there was no significant effect of vitamin D supplementation (p = 0.065) (Drey 
et al., 2011).  The change in total SPPB score within a 9-month study randomizing 
into 4 groups (1.RET and vitamin D, 2. RET and placebo, 3. control and vitamin D 
and 4. control and placebo) was significantly higher in trained participants (groups 1 
and 2) than non-trained (groups 3 and 4, p = 0.002) and higher still in the RET and 
vitamin D group than the RET and placebo group (+14.7% and +10.5%) (Bunout et 
al., 2006a). Although the change in SPPB score in the RET and vitamin D group in 
the earlier study was comparable to the change in the vitamin D group of the EXVITD 
study, the placebo group of the EXVITD study exhibited a non-significant decline in 
SPPB score, which does not support the results from the RET and placebo group 
from the earlier study (Bunout et al., 2006a). 
6.1.3. SPPB test components: 5-time chair rise test 
5-time chair rise test time was significantly reduced in the whole cohort and within 
both intervention groups; placebo group: -3.93 seconds (55.29%), p = 0.001 and the 
vitamin D group: -5.56 seconds (80.81%), p<0.001. Between-group comparison was 
190 
 
non-significant (p = 0.444). The changes in the 5-time chair rise test observed in the 
EXVITD study were greater than comparable exercise training studies; 53 older 
women (mean age = 81 years) who completed 3 weekly sessions of home-based 
video exercise training for 5 months significantly improved their 5-time chair rise time 
by 36.88% (p = 0.023), however this was not significantly different from the 
improvements observed within the sedentary control group (Vestergaard et al., 
2008). 
Comparing previous RET and vitamin D supplementation studies, 2 reported the 5-
time chair rise test separately to total SPPB score; one of these studies (Uusi-Rasi et 
al., 2015) reported decreases in 5-time chair rise test in both RET intervention 
groups. Placebo and RET resulted in a 7.80% decrease (p = 0.03) and 100 IU/d 
vitamin D and RET resulted in a borderline significant decrease in 5-time chair rise 
time of 6.95% (p = 0.05); there was no change in 5-time chair rise time associated 
with sedentary groups supplemented with placebo or vitamin D after 24 months 
(Uusi-Rasi et al., 2015). In the other study, a 24-week study combining vitamin D3 
supplementation and RET (Aoki et al., 2018), a 19.41% improvement in 5-time sit to 
stand test time with the combined intervention (p <0.001) was reported; however, this 
was not significantly different from the significant improvements observed with 
exercise alone and vitamin D3 supplementation alone. 
A possible explanation for the large improvements in the 5-time chair rise test is that 
a modified chair rise test, a component of the SPPB test, was included in the EXVITD 
exercise intervention; at each session attended, participants performed a 30 second 
chair rise test which served to increase muscle strength and also to monitor the 
intervention progression (to ensure that the intervention could truly be classified as 
“training”). A small but significant learning effect has been observed with the 30 
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second chair rise test, regardless of rater and with significantly higher repetitions 
after the fourth test in comparison   with the first (Johansen et al., 2016). This was 
also a limitation of an earlier study (Drey et al., 2011), who then performed a sub-
analysis of the SPPB test including only the balance parameters and gait speed (the 
maximum resultant score was therefore 8 points). The same analysis was completed 
with the EXVITD cohort; there were still no between-group differences (F (1,8) = 
2.64, p = 0.143), however the significant improvement within the vitamin D group 
remained (t (8) = 2.40, p = 0.043). Additionally, the within-group change in the 
placebo group remained non-significant (t (9) = 1.08, p = 0.309), although the 
average change in total score increased (+0.40 points, SD = 1.17) rather than 
decreased after 6 months. 
One further limitation of this test may have been that chair height was not adjusted 
for the lower limb length of each individual participant. Although most reports of the 
chair rise test do not specify chair height, those which do most frequently report chair 
heights of between 40-4cm (Bohannon, 1995). However, it has been suggested that 
the height of the chair be adjusted dependent on the length of the lower limb of 
participants since this effects the load applied to the lower limb during the test 
(Yamada and Demura, 2004). 
6.1.4. SPPB test components: Gait speed 
Gait speed, a component of the SPPB test, was marginally improved within both 
intervention groups although neither change was significant; placebo group: -0.05 
seconds (1.39%), p = 0.925; vitamin D group: -0.39 seconds (11.08%), p = 0.397.   




Although the changes in gait speed were seemingly small, changes within the whole 
cohort and placebo group could be categorised as a small, clinically meaningful 
change (within the range of 0.04 – 0.06 m/s. Whole cohort = 0.07 m/s, placebo group 
= 0.02 m/s) and the change in gait speed within the vitamin D group was considered 
a substantial, clinically meaningful change (within the range of 008 – 0.14 m/s; 
vitamin D group = 0.13 m/s). This is based on effect sizes calculated to define 
meaningful change in physical function measures during a secondary data analysis 
of 692 older adults (mean age range = 69.8 - 77.6 years) who took part in both 
observational and randomized trials of exercise and stroke rehabilitation (Perera et 
al., 2006). 
One study investigating the mode of exercise intervention and effects in older adults 
concluded that a combination of aerobic and resistance exercise was more effective 
at improving gait speed after 12 weeks in older men and women (n = 84, mean age = 
69.3 years) than aerobic or resistance training alone (16.8%; 95% CI 7.8, 25.6, 
p<0.001), with significant effects observable as early as halfway through the 
intervention (Timmons et al., 2018). Conversely, a systematic review of resistance, 
coordination and multimodal exercise interventions in a total of 1297 older adults and 
their effects on habitual gait speed concluded that all 3 modes of exercise similarly 
increased gait speed by 8.4% (Hortobágyi et al., 2015).  
Of the comparable RET and vitamin D supplementation studies, only one analysed a 
variant of gait speed independent of total SPPB score (Uusi-Rasi et al., 2015). 4 
meter normal walking speed was analysed in 409 women (mean age = 74.1 years) 
who took part in a 2-year study of 800 IU/d vitamin D3 supplementation and exercise; 
walking speed was maintained in both exercise groups (placebo and exercise and 
vitamin D3 and exercise) but declined in both sedentary groups (placebo alone and 
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vitamin D3 alone) (Uusi-Rasi et al., 2015). The effect of exercise on gait speed in 
older adults is not consistent; a systematic review of combined nutritional and 
exercise interventions and muscle outcomes in older adults over 65 years found no 
effect of either exercise or vitamin D supplementation on gait speed (Denison et al., 
2015).  
6.1.5.  Timed up and go test (TUG) 
Within-group comparisons revealed both groups improved their TUG time (placebo 
group 8.88%, p = 0.081; vitamin D group 22.79%, p = 0.034), although this change 
was significant only within the vitamin D group. Between-group comparisons were 
non-significant (p = 0.194).  
The improvement in TUG observed within the vitamin D group was comparable to an 
earlier study which implemented 2 sessions of RET per week for 24 weeks in 63 
older women (mean age = 67.5 years); after the intervention, there was an 
approximate 19.05% improvement in TUG time within the resistance training group 
and an approximate 16.92% improvement within the non-trained control group 
(Edholm et al., 2017). In a further study, 38 older men and women (mean age = 76.6 
years) were randomized to 3 sessions of strength training per week for 1 year or a 
control group; men (18.6%) and women (20.50%) in the strength training group 
significantly improved their TUG, with no significant effect of sex observed, however, 
TUG time within both male (-2.00%) and female (-0.60%) deteriorated (Capodaglio et 
al., 2007). A systematic review including 12 studies of older adults (n = 691 aged ≥60 
years) concluded that progressive RET significantly improved TUG time in 
comparison to controls (mean difference = ‐0.69 seconds, 95% CI ‐1.11 to ‐0.27, p = 
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0.0012); studies conducted 2-3 exercise sessions per week for a range of 2 to 104 
weeks (Liu and Latham, 2009).  
Three RET and vitamin D3 supplementation studies included within the Chapter 2 
systematic review assessed TUG (Bunout et al., 2006a, Gianoudis et al., 2014, Uusi-
Rasi et al., 2015). In a group of 96 older adults (mean age = 77 years) randomized to 
9 months of 1) 400 IU/d vitamin D3 supplementation and RET, 2) RET and placebo, 
3) control and vitamin D3 or 4) control and placebo, TUG time was significantly 
improved in trained participants and supplemented participants improved more than 
participants receiving the placebo (2.4%, p = 0.004) (Bunout et al., 2006a). There 
was no between group difference in TUG time after 12 months between the 
intervention (3 sessions per week of RET combined with 1000 IU/d vitamin D3) and 
control (usual care, general osteoporosis information and 1000 IU/d vitamin D3) 
groups in an earlier study; there was an approximate change of 0% and 3% within 
the intervention and control groups, respectively, although this study implemented a 
secondary cognitive task alongside the TUG (counting backwards from 100 by 3) 
(Gianoudis et al., 2014). A further study found that TUG time improved within the 
exercise and vitamin D group after 24 months (1.75%) and deteriorated within the 
placebo and exercise group (-0.35%), although there was no significant difference 
between the groups (Uusi-Rasi et al., 2015). 
6.1.6. Leonardo Mechanograph® force plate outcomes: Peak total power and 5-
time CRT 
Peak total power increased significantly within both the placebo (+27.71%, p = 0.001) 
and vitamin D (+25.93%, p = 0.008) groups; there were no between-group 
differences (p = 0.557). Similarly, 5-time CRT time improved significantly within the 
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placebo (69.18%, p = 0.006) and vitamin D (73.07%, p < 0.0001) groups with no 
between-group differences (p = 0.510). 
The change in peak total power observed within the control group of a study of 74 
COPD patients after 3 sessions of strength, endurance and squat training for 3 
weeks was +0.61 W (95% CI 0.17, 1.06) (Gloeckl et al., 2017); this was higher than 
the change within both the placebo (0.23 (0.15)) and vitamin D (0.21 (0.14) groups at 
month 6 in the EXVITD study. A further study assessed peak relative power after 3 
sessions of supervised balance and strength training per week for 12 weeks in 66 
older adults (mean age = 73 years) (Lacroix et al., 2016); change in relative peak 
power within the intervention group (+17.30%,  p < 0.017) was lower than observed 
within both the placebo (+28.14%, p =0.002) and vitamin D (+25.63%, p = 0.002) 
groups in the EXVITD study.  
Cross-sectional functional performance was assessed via Leonardo Mechanography 
in 293 community-dwelling older men (mean age = 71.6 years) and women (mean 
age = 71.4 years) from Germany. Reference data reported average 5-time chair rise 
test relative peak power in women (n = 130) to be 8.9 (SD = 2.1) W.kg-1 and 11.1 (SD 
= 2.4) in men (n = 124) (Dietzel et al., 2015). Women within the placebo group of the 
EXVITD study (n = 5) had lower peak relative power at baseline (6.74 (0.83) W.kg-1) 
than reported above (Dietzel et al., 2015), however, at month 6 peak relative power 
was comparable (8.82 (0.32) W.kg-1). Women within the vitamin D group of the 
EXVITD study (n = 6) had similarly lower peak relative power at baseline (6.73 (1.79) 
W.kg-1), however, relative power was higher than the reference data at month 6 (9.45 
(1.77) W.kg) and the within group change for women in the vitamin D group was 
significant (p = 0.041). Men within the placebo group of the EXVITD study (n = 7) 
exhibited lower peak relative power at baseline than previously reported (Dietzel et 
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al., 2015) (8.53 (2.91) W.kg-1), however, at month 6, power was higher than the 
reference data (12.44 (4.91 W.kg-1). Similarly, within the vitamin D group of the 
EXVITD study, men (n = 6) were assessed as having lower peak relative power than 
the reference data above (Dietzel et al., 2015) (8.72 (1.58) W.kg-1), but this value was 
increased to 13.44 (2.11) W.kg-1 at month 6.  
5-time CRT within the EXVITD study was substantially higher than reported in 
exercise studies; for example, after 12 weeks of supervised balance and strength 
training, average 5-time CRT was significantly improved in the intervention group by 
30.29% (p < 0.017) in comparison with the passive control group, which experienced 
a deterioration of 5-time CRT time (-1.20%, non-significant) (Lacroix et al., 2016). A 
further study of 74 COPD patients completing  5 sessions per week of endurance, 
strength and squat training for 3 weeks reported a non-significant improvement in 5-
time CRT time of 1.4 (2.9 – 0.0)% (p = 0.053) (Gloeckl et al., 2017).  
One other study of vitamin D3 supplementation and exercise training study measured 
muscle power utilising a force plate; after 12 weeks of strength training, a cohort of 
69 older adults (mean age = 77 years) did not significantly alter their muscle power 
as assessed by sit to stand transfer power; absolute power at baseline was reported 
as 467 W, with an increase of 42 W after 12 weeks of strength training and also a 12 
W improvement evident within the sedentary control group (p = 0.308) (Drey et al., 
2011). This is much lower than both the baseline (600 W) and change in power (220 
W) measured within the EXVITD cohort, which reported a significant increase in 
power assessed using Leonardo Mechanography within the whole cohort (p < 0.001), 
the placebo (p = 0.001) and vitamin D (p = 0.008) groups, although no between-
group differences were found. The participants within the aforementioned study had 
a lower SPPB score at baseline (8.8 within the strength training group) than the 
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EXVITD cohort (9.85), suggesting that these participants may have been frailer than 
included within the EXVITD study and also the intervention was shorter by 12 weeks.  
The improvement in 5-time CRT time as measured by Leonardo Mechanography in 
the EXVITD study was substantially higher than in previous exercise training studies 
involving older adults, although, as there were no between-group differences, this 
cannot be ascribed to vitamin D supplementation alone.  
As with the chair rise test completed as part of the SPPB test, the large improvement 
in 5-time CRT time measured using Leonardo Mechanography may be due to a 
learning effect; the 30-second sit to stand test was completed at each exercise 
session by all participants as a way to track progression. Task-specific training has 
been shown to significantly improve performance; 161 disabled supported housing 
residents (mean age = 82 years) completing 3 hour-long sessions of task-specific 
bed and chair rise resistance training exercises per week for 12 weeks (e.g. heel 
raise, supine to sit and raise from a chair) incorporating additional weight (weighted 
vest or ankle weights) to increase resistance and challenge balance. Training 
significantly improved the time taken to perform these tasks (11-20%, p < 0.0001) 
and also performed a significantly greater number of bed or chair rises than the 
flexibility control group (p = 0.030) (Alexander et al., 2001). Additionally, technical 
issues with the Leonardo mechanography equipment meant that 3 participants were 
unable to complete their month 6 measurements, further decreasing the 
representativeness of the already small sample.  
Although the Nottingham power rig has been cited as the “gold standard” for muscle 
power evaluation in older adults (Gray and Paulson, 2014), the use of Leonardo 
Mechanography in the assessment of muscle function and power has the potential to 
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be more accurate than other commonly used tests. However, there appear to be no 
examples of direct comparison or validation studies for this specific brand of 
equipment. Other brands of force plates have been shown to be correlated with the 
Nottingham power rig; a sample of 33 older adults (mean age = 67.8 years) 
completed the 5-time chair rise test (a component of the SPPB) and had their muscle 
power evaluated as sit-to stand transfer power utilising a force plate (Soehnle, 
Germany) and power assessed by the Nottingham power rig. Power assessed by the 
force plate and the Nottingham rig showed a moderate association (r = 0.6), 
however, the 5-time chair rise test was poorly correlated with power measured using 
the force plate (r = -0.08) (Lindemann et al., 2003). Within the EXVITD study, relative 
power measured using the Nottingham power rig and Leonardo Mechanography 
showed equal associations at baseline (r = 0.60, p = 0.001) within the whole cohort, 
however, the association between the 2 types of equipment at month 6 was higher (r 
= 0.836, p < 0.001) and comparable to values reported in an earlier study involving 
the two-legged jump (r = 0.86, p<0.001) (Bassey and Short, 1990). The lack of a 
strong correlation between the two measures and the differences in absolute and 
relative power measured by the two techniques within the EXVITD study is most 
probably due to the difference in movements with each test; the Nottingham power 
rig aims to isolate the lower extremities and activate a specific group of muscles 
whilst the power assessed by the chair rise test and Leonardo mechanography 
include upper body muscle activation for balance, stability and co-ordination. 
Additionally the chair rise test is weight-bearing whilst LLEP measured using the 
Nottingham power rig is not; the study previously mentioned reported power values 
measured by the force plate to be twice as large as those measured by the 
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Nottingham rig (Lindemann et al., 2003), although these differences observed within 
the EXVITD study were four-fold greater.  
 In the assessment of muscle power, the Nottingham power rig requires a maximal 
effort from a small group of muscles, i.e. the extremities, but Leonardo 
Mechanography combines this intensity of muscle work with the co-ordination of 
several different muscle groups during both the chair rise test and jump testing; some 
groups suggest this combination is preferable in the assessment of interventional 
effects in older adults (Buehring et al., 2015). Additionally, when assessing the 
reliability of Leonardo Mechanography and common functional tests in 97 older 
adults (mean age = 80.7 years) with multiple tests completed over 3 months, 
Leonardo Mechanography retest reliability (ICC = 0.93) was higher than observed 
with gait speed and the SPPB test (ICC = 0.76 and 0.77, respectively) (Buehring et 
al., 2015). Although the 5-time sit to stand test is similar to the chair rise test 
completed using Leonardo Mechanography, the 5-time sit to stand provides only 
components of muscle power since it is reported in seconds. Additionally, one earlier 
study concluded that the 5-time sit to stand test was poorly associated with power 
assessed by a force plate (r = -0.08), suggesting that this may be due to the “ceiling” 
effect of the test, as discussed earlier (Lindemann et al., 2003). It is possible to 
estimate power from the 5-time chair rise test from participants height, weight and 
height of the chair used, which has been found to be strongly correlated with muscle 
power assessed using a leg press machine (BH Fitness, Serie TR, Spain), r = 0.72, p 
< 0.001 (Alcazar et al., 2018). That said, although non-significant, this method of 
power calculation over-estimated muscle power by an average of 7.0 W in 40 
community-dwelling older adults (mean age = 77.6 years) (Alcazar et al., 2018), with 
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the measurement of each variable required for the calculation introducing an element 
of human error, albeit small (Gómez-Cabello et al., 2012). 
6.2. Secondary outcome measures: Body composition 
In summary, there were no within-group changes in any body composition outcomes, 
with the exception of a significant increase in lean mass within the placebo group; as 
with functional outcomes, there were no between-group differences in any of the 
body composition outcomes assessed. 
6.2.1. Total body weight 
Changes in total body weight within the placebo (-0.82 (4.62) kg or-1.02%)) and 
vitamin D (+0.43 (1.67) kg or +0.61%)) groups were small and non-significant; 
additionally, there were no between group differences (p = 0.654).  
Exercise interventions have previously demonstrated conflicting results regarding 
total body weight. In a study of 91 community-dwelling older adults (mean age = 83 
years) considered mild to moderately frail, total body weight was significantly reduced 
after a period of 9 months of combined RET, balance and endurance training (-0.8kg, 
p = 0.005) but remained unchanged after 9 months of balance and low-intensity 
strength training (-0.0 kg, p = 0.920); as with the EXVITD study, BMI categorized 
participants in both groups as overweight at baseline (Binder et al., 2005). In a 
systematic review and meta-analysis of the effects of exercise (including RET, 
aerobic or both) in sarcopenic obese older adults (mean age range = 66.8 – 81.4 
years) total body weight was marginally and non-significantly reduced as a results of 
the intervention; - 0.29kg (95% CI -1.44, 0.86, p = 0.620) including a total of 258 
participants from 5 studies (Hita-Contreras et al., 2018).  
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4 previous combined RET and vitamin D supplementation studies report total weight 
at baseline and follow-up; 2 studies found no significant change in body weight within 
any of the groups included (Bunout et al., 2006a, Uusi-Rasi et al., 2015), comparable 
with the findings of the EXVITD study. In a study of 18 older women (mean age = 
69.2 years) living in a retirement community in Florida, USA randomized to complete 
3 sessions per week for 32 weeks of exercise training using weighted vests and 400 
IU vitamin D3/day or a sedentary control group also supplemented with 400 IU/d 
vitamin D3, participants in the training group reduced their weight by 5.69% (-4.20 
kg) on average, whilst the control group increased their body weight by 0.71% (+0.20 
kg, between-group difference p = 0.008) (Jessup et al., 2003). Body weight was non-
significantly decreased by -0.2% in the exercise and control groups of a study 
recruiting 162 older adults (mean age = 67 years) randomized to 12 months of RET 
and vitamin D3 supplementation (1000 IU/d) or a control group also supplemented 
with vitamin D3 (Gianoudis et al., 2014).  
One limitation for the measurement of total body weight was that the prandial state 
and the clothing worn during each measurement was not standardised; 
measurements were taken during the morning, but participants were not instructed to 
remain in a fasted state. 
6.2.2. Femoral neck and lumbar spine BMD 
The average change in both femoral neck and lumbar spine BMD within the whole 
cohort, and the individual placebo and vitamin D groups was very small. The only 
gain in BMD was within the placebo group at the lumbar spine (+0.01 g.cm3, p = 
0.647), otherwise BMD was maintained following the 6-month intervention which 
could be attributed to RET rather than vitamin D supplementation, as suggested by 
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the lack of between-group differences. The gain in BMD at the lumbar spine within 
the placebo group was small, but at 3.23%, was higher than the coefficient of 
variation for the model of DXA machine used within the EXVITD study (reported as 
0.56% for BMD by the manufacturer (Toussirot et al., 2007)). 
Systematic reviews and meta-analyses of the effect of exercise training on BMD 
differ in their conclusions; a review of 24 RCT studies including postmenopausal 
women (age range 50.5 to 69.6 years) found that participants in the 14 studies 
involving RET significantly increased both their femoral neck (SMD = 0.303, 95% CI 
0.127, 0.479, p = 0.001) and lumbar spine (SMD = 0.311, 95% CI 0.115, 0.507, p = 
0.002) BMD. However, additional gains were observed in the studies that utilised 
“combined RET” (RET combined with balance and jump exercises, for example) as 
the training method; femoral neck BMD (0.411, 95% CI 0.176, 0.644, p = 0.001) and 
lumbar spine BMD (0.431, 95% CI 0.159, 0.702, p = 0.002) (Zhao et al., 2015). 
Conversely, an earlier systematic review of the effects of exercise on BMD in older 
adults (mean age range = 65 to 83 years) included 19 RCTs with 1577 participants; 
low impact and RET exercise regimens were consistently found to result in no 
positive and non-significant effects on BMD at the lumbar spine, although small, non-
significant gains were observable at the femoral neck (Marques et al., 2012) 
There are some limitations to the conclusions of meta-analyses involving BMD 
measurement; many studies involving bone health and BMD include mainly or solely 
female participants, for example of the 17 studies included within the meta-analysis 
by (Marques et al., 2012),15 included 100% women, 1 did not report the sex of 
included participants and only 1 included an equal spilt of male and female 
participants. Additionally, both of the meta-analyses cited above reported 
intermediate to high levels of heterogeneity, attributed to differences in the exercise 
203 
 
regimens between different studies (i.e. type, intensity, frequency, duration), but also, 
regional BMD estimates have been shown to vary between different DXA models and 
manufacturers (Fan et al., 2010).  
The majority of the studies included within the systematic review in Chapter 2 of the 
thesis reported femoral neck and lumbar spine BMD as outcome measures. Several 
of these studies found gains in femoral neck BMD (Jessup et al., 2003, Bunout et al., 
2006a, Verschueren et al., 2011, Gianoudis et al., 2014), ranging from 0.6% 
(Gianoudis et al., 2014) to 9.46% (Jessup et al., 2003). Additionally, lumbar spine 
BMD was reported by 4 of the studies included within the systematic review in 
chapter 2, with 3 of these studies finding gains in lumbar spine BMD as a result of the 
combined RET and vitamin D3 supplementation intervention (Jessup et al., 2003, 
Bunout et al., 2006a, Gianoudis et al., 2014). The gains observed within the placebo 
group of the EXVITD study were within the range of lumbar spine BMD gains 
reported within the systematic review in Chapter 2 (1.5% (Gianoudis et al., 2014) to 
12.5% (Jessup et al., 2003)).  
Only one study reported an overall loss in BMD following the combined intervention; 
following 12 months of RET and 800 IU/d vitamin D3 supplementation, a group of 
409 older women (mean age = 74 years) lost 0.51% BMD at the femoral neck, 
although this was a significantly smaller loss than experienced by the placebo and no 
exercise group (1.25%, p 0.04) (Uusi-Rasi et al., 2015). Additionally, the same study 
reported small percentage increases in lumbar spine BMD within the combined 
intervention group (0.33%), although this was not significantly different to the placebo 
and no exercise group. 
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Although the majority of comparable RET and vitamin D3 supplementation studies 
reported increased in BMD at the femoral neck and lumbar spine, it is worth 
mentioning that baseline BMD of the participants included within all of the studies 
reporting on BMD included within the systematic review reported in chapter 2 were 
lower than those of the EXVITD cohort; for example, the lowest baseline mean BMD 
of the femoral hip and lumbar spine were reported as 0.63 g.cm3  and 0.77 g.cm3, 
respectively by the same study (Jessup et al., 2003), which was also the study that 
observed the largest increase in both femoral neck and lumbar spine BMD. Baseline 
mean BMD of the femoral neck within the EXVITD cohort was 0.92 g.cm3. This was 
higher than reported in a group of 620 healthy Danish adults (age range = 20 to 89 
years), in which the BMD of the femoral neck was estimated in women aged 60 to 69 
years and 70 to 79 years to be 0.69 (0.11) g.cm2 and 0.61 (0.13) g.cm2, respectively; 
in men of the same age ranges, BMD was reported to be 0.79 (0.12) g.cm2 and 0.73 
(0.09) g.cm2, respectively (Warming et al., 2002). At baseline, the mean BMD of the 
femoral neck in women and men participating in the EXVITD study was 0.88 g.cm3 
and 0.96 g.cm3. Although there were no significant increases in BMD at any site 
observable within the EXVITD study, maintenance of BMD at the femoral neck and 
lumbar spine may be a clinically relevant finding since “normal” bone loss in healthy 
older adults has been determined as 0.002 to 0.006 g.cm2 per year at all sites 
(Warming et al., 2002). 
Additionally, the duration of all studies that reported BMD as an outcome measure 
was longer than the EXVITD study, with the exception of (Verschueren et al., 2011). 
This is important as it has been suggested that the minimum period for RET 
interventions should be 6 months since this is the amount of time taken for bone 
remodelling to be detectable on a DXA scan (Zhao et al., 2015). In addition, follow-up 
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DXA scanning to monitor the response to osteoporosis treatments typically takes 
place a minimum of 2 years after the initial scan, as any changes before this period 
are unlikely to be detectable (The National Osteoporosis Society, 2011). Although the 
precision of the GE Lunar iDXA has been quoted 0.56% for BMD by the 
manufacturer (Toussirot et al., 2007), it is important to consider that these figures are 
for short-term precision calculated from measurements taken within hours or days 
apart; long-term precision of DXA calculated from measurements repeated annually 
over 7 years at the femoral neck and lumbar spine have been reported to be 2.21% 
and 1.12%, respectively, with measurements at year 7 significantly different from 
those taken at baseline for the femoral neck (Patel et al., 2000).  
Regarding markers of bone turnover, CTX was not significantly changed within either 
group following the 6-month intervention, nor were there any between-group 
significances observed. CTX concentration was non-significantly decreased within 
the placebo group and non-significantly increased within the vitamin D group (-
14.29% vs +7.41%, p = 0.752). Baseline CTX concentrations were comparable with 
those previously reported in similar populations (Marques et al., 2013, Gombos et al., 
2016). 
 CTX concentration was not significantly altered in 47 older adults (mean age = 68.2 
years) following 32 weeks of resistance (2 sessions per week) and impact (1 session 
per week) training; mean CTX concentration remained unaltered in the 24 female 
participants, with a small non-significant decrease in CTX concentration observed in 
the 23 male participants (-2.78%, p = 0.722) (Marques et al., 2013). A further study 
assessed the acute responses of CTX concentration in 150 older women (mean age 
= 60.2 years) considered to have low bone mass (mean T-score = -2.1, range = -1.0 
to -4.7) to a single bout of either 30 minutes RET (n = 50), 46 minutes of outdoor 
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walking on a flat surface (n = 50) or a sedentary control (n = 50). A significant 
decrease in CTX concentration was observed within the RET group (-11.11%, p < 
0.01), but the CTX concentration observed within both the walking and control groups 
remained unaltered (Gombos et al., 2016). 
Regarding falls as events, 3 falls occurred throughout the study period and all falls 
occurred at a time outside the scheduled exercise sessions. None of the falls caused 
serious injury or resulted in a fracture; all fallers recovered from their fall within 24 
hours, with minor bruising. 2 of the 3 fallers were male and all fallers were 
randomized to the placebo group. One limitation of the study was that previous falls 
history was not collected, and so analyses could not be conducted to assess the 
effects of the intervention, if any, on this parameter.  
6.2.3. Total fat mass 
Total fat mass was not significantly altered as a result of the EXVITD study; the 
placebo group lost 0.25 (1.13) kg on average (p = 0.509), which was equivalent to 
0.90% of their total fat mass and the vitamin D group gained 0.34 (1.26) kg of fat 
mass (p = 0.448), equivalent to 1.40% of their total fat mass. There were no 
between-group differences in change in fat mass (p = 0.481). The changes in fat 
masses within both groups were within the coefficient of variation of the GE Lunar 
iDXA, which has been reported as 0.59% for fat mass (Toussirot et al., 2007). 
One study of 9 months RET in frail older adults reported a decrease in percentage fat 
mass assessed by DXA in both the RET (-1.0 (1.7)%) and flexibility and low-intensity 
strength training control (-0.4 (1.9%) groups with no between-group differences (p = 
0.220) (Binder et al., 2005). A systematic review and meta-analysis of the effects of 
exercise on body composition on older adults with sarcopenic obesity reported small 
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and non-significant losses in both total and percentage fat mass; meta-analysis data 
from 194 participants included in 5 studies found a total fat mass loss of 0.97kg (95% 
CI -2.94, 1.00, p = 0.220) and data from 377 participants from 8 studies concluded a 
percentage fat mass loss of 0.26% (95% CI -0.74, 0.22, p = 0.290) (Hita-Contreras et 
al., 2018).  
Of comparable RET and vitamin D3 supplementation studies, 3 studies reported no 
significant differences between groups in fat mass; 2 studies analysed body 
composition using DXA and merely reported that there were no significant changes in 
any body composition parameters (Bunout et al., 2006a, Uusi-Rasi et al., 2015). 
However, 1 study reported results in more detail. After 12 months of either RET and 
1000 IU/d vitamin D3 supplementation (intervention group) or vitamin D3 
supplementation alone (control group), there were no between-group differences in 
percentage fat mass loss in either the intervention (-0.8%, range = -2.6 – 1.1%) or 
control (-1.00%, range = -3.3 – 1.3%) group; participants were 162 older adults 
(mean age = 67 years) classified as overweight (BMI = 27.4 kg.m-2) (Gianoudis et al., 
2014). 
6.2.4. Total lean mass, ASM and SMI 
Total lean mass differed significantly between the groups at baseline; placebo group 
mean total lean mass was 48.98 (8.67) kg and the vitamin D group average lean 
mass was 44.12 (9.12) kg, p = 0.001. Change in lean mass at 6 months was 
significant within the placebo group (+0.67 (0.61) kg or +1.35%, p = 0.007), but not 
within the vitamin D group (+0.13 (0.91) kg or +0.30%, p = 0.678), although the 
vitamin D groups change in lean mass was within the GE Lunar iDXA precision error, 
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which has been reported as 0.45% for lean mass (Toussirot et al., 2007). There were 
no between-group differences (p = 0.355). 
Exercise studies assessing total lean mass report similar overall changes to the 
EXVITD study; after 9 months of RET, lean body mass estimated using DXA was 
increased by 0.8 (1.4) kg, but was unchanged within the flexibility and low-intensity 
strength training control (0.0 (1.5) kg, between-group difference, p = 0.005) (Binder et 
al., 2005). In a meta-analysis examining the influence of RET on lean body mass, 49 
studies were eligible for inclusion, including 1328 older adults (mean age = 65.5 
years) completing an average of 2.8 sessions of resistance exercise per week for an 
average duration of 20.5 weeks. Lean body mass was found to be significantly 
increased as a result of resistance exercise (pooled mean estimate = 1.1 kg, 95% CI: 
0.9, 1.2 kg, p < 0.001) (Peterson et al., 2011). Additionally, increased volumes of 
training were associated with larger gains (β = 0.05, p = 0.01) and increasing age 
associated with lower gains (β = -0.03, p = 0.01) in lean body mass, although sex, 
study design, exercise frequency, intensity and duration were not significantly 
associated with lean body mass (Peterson et al., 2011). The mean age of the 
EXVITD cohort was 70.83 years, which was younger than the mean age of 
participants included within the above meta-analysis, which also included participants 
≥ 50 years of age; this may be one explanation accounting for the lower gains in lean 
mass observable within EXVITD participants in both groups.  
Again, 2 similar RET and vitamin D3 supplementation studies utilising DXA to 
estimate body composition concluded that there were no significant changes in lean 
mass in any group as a result of the intervention (Bunout et al., 2006a, Uusi-Rasi et 
al., 2015). Percentage change in lean mass within the placebo and vitamin D groups 
of the EXVITD study were comparable to a 12 month study comparing RET and 1000 
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IU/d vitamin D3 supplementation and vitamin D3 alone; the combined intervention of 
RET and vitamin D supplementation resulted in a 0.8% (95% CI -2.6, 1.1) gain in 
total lean mass and vitamin D supplementation alone resulted in a 0.4% (95% CI -
0.6, 1.5) gain in total lean mass with no between-group differences (Gianoudis et al., 
2014). A more recent study estimated lean mass of the right leg using bioelectrical 
impedance after 24 weeks of RET and 1000 IU/d vitamin D3 supplementation in 148 
older adults (≥ 60 years) with vitamin D deficiency at baseline (mean 25(OH)D = 
28.33 nmol/L). Lean mass significantly increased in all groups, with increases in the 
RET alone and vitamin D alone groups comparable to the EXVITD placebo and 
vitamin D groups ; RET alone (+1.88%), vitamin D alone (+0.5%) and RET and 
vitamin D (+3.10%), with no between-group differences (p = 0.208) (Aoki et al., 
2018). 
Appendicular skeletal muscle mass (ASM) nor skeletal muscle index (SMI) were not 
significantly altered as a result of the EXVITD intervention in either group. The 
placebo group gained 1.97 (4.99) kg (equivalent to +9.05%, p = 0.244) and the 
vitamin D group gained 0.02 (0.50) kg (equivalent to +0.29%, p = 0.890) ASM at 
month 6. There were no between-group differences (p = 0.136). At baseline, 2 
participants in the placebo group and 5 within the vitamin D group were considered to 
have low ASM according to the EWGSOP2 criteria (Writing Group for the European 
Working Group on Sarcopenia in Older People 2  et al., 2018); at month 6, 1 
participant within the placebo group and 4 within the vitamin D group had low ASM.  
SMI at baseline did not significantly differ between the groups (p = 0.774). The 
change in SMI at month 6 was small and non-significant within and between the 
groups; placebo group +1.87 (4.85), equivalent to a 6.79% increase (p = 0.254) and 
the vitamin D group -0.15 (0.91), equivalent to a 0.55% decrease (p = 0.626).  
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Exercise intervention studies report contrasting results relating to body composition. 
For example a systematic review and meta-analysis of the effects of exercise 
interventions on anthropometric measures in older adults (mean age range 66.8 to 
81.4 years) with sarcopenic obesity found small, non-significant increases in both 
ASM and SMI; change in pooled mean ASM in a total of 119 participants was 0.22 
(95% CI -0.69, 1.13 kg), p = 0.630 and change in pooled mean SMI in 209 
participants was 0.35 (95% CI -0.20, 0.89), p = 0.210 (Hita-Contreras et al., 2018). 
Conversely, a systematic review of exercise intervention and body composition 
outcomes in sarcopenic older adults (mean age 67.1 to 81.1 years) found a 
significant increase in ALM measured by bioelectrical impedance in 116 participants 
from 2 studies after an average range of duration of 3 to 6 months; 2.11 (95% CI 
0.03, 0.87 kg), p = 0.04 (Vlietstra et al., 2018). 
Among similar RET and vitamin D supplementation studies, only 1 reported ASM. 
After an 8-week period of vitamin D3 supplementation, 69 older adults (mean age = 
77 years) completed 12 weeks of power or strength training or were randomized to a 
sedentary control; ASM change in each group was +0.56%, +1.62% and 0%, 
respectively with no significant between-group changes (Drey et al., 2011). Power 
training in the aforementioned study resulted in gains in ASM comparable to those 
measured within the vitamin D group of the EXVITD study; the changes in ASM 
within the placebo group surpassed those observed in the strength training group, 
although the duration of the EXVITD intervention was longer. Participants in the 
study by (Drey et al., 2011) exhibited comparable serum 25(OH)D concentrations to 
the EXVITD cohort at baseline (50.21 nmol/L). No comparable studies reported SMI, 
and participant weight in the study by (Drey et al., 2011) was not included and as 
such, calculation of SMI was not possible.  
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Although the placebo group showed a significantly higher increase in lean mass and 
also higher gains in ASM and SMI than the vitamin D group, hypertrophy did not 
result in increased power or function; LLEP, SPPB total score and TUG time were 
significantly improved within the vitamin D group but not in the placebo group. 
Furthermore, gait speed improved more within the vitamin D group, although this 
change was not significant. One previous study has in fact attributed gains in leg 
power to be significantly associated with clinically meaningful changes in both the 
SPPB test and gait speed in a secondary analysis of a group of 138 older adults 
(mean age = 75.2 years) who completed either strength training with free weights or 
RET with weighted vests for 16 weeks (Bean et al., 2010). 
This finding is in agreement with an earlier study which randomized 45 older adults 
(mean age = 74.8 years) with self-reported difficulty in ADL to 12 weeks progressive 
strength or power training or control. Although power increased significantly (range of 
+19.9 to +41.4%) in the power group in comparison to the strength and control 
groups, there were no between-group differences in lean mass or ASM; lean mass 
gains were +1.22%, 2.77% and 1.47%  and ASM gains +2.88%, +3.54% and 1.00% 
within the power training, strength training and control groups, respectively (Marsh et 
al., 2009). Furthermore, after 12 weeks of RET, 9 elderly women (median age = 80 
years) increased their lean muscle tissue, as estimated by MRI, by 2.5%, however, 
isometric knee flexion muscle strength was increased by 17% (Greig et al., 2011a).  
Recent experimental evidence has suggested that hypertrophy may not be the main 
mechanism for increases in strength, although this work was completed in younger 
adults; 38 untrained younger adults (mean age = 22 years) were recruited to take 
part in an 8-week study of 2 sessions per week of exercise. Participants randomized 
to the HYPER group aimed to increased muscle mass and strength via high volume 
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RET, which included 4 sets of knee extension and chest press exercises (using a 
Hammer strength plate by Life Fitness) to volitional failure or the TEST group which 
aimed to minimise hypertrophy but increase strength via 1-RM testing of the same 
exercises. Although muscle mass was significantly greater at most sites tested in the 
HYPER versus the TEST group, changes in muscle strength in the upper and lower 
body were not statistically different between the groups (Mattocks et al., 2017). In 
older adults, longitudinal losses in muscle strength have been shown to be greater 
than losses in muscle mass (Marcell, 2003), and one review has suggested that 
muscle hypertrophy and increased strength as a result of resistance exercise “may 
not necessarily be mechanistically linked”, suggesting an observable increase in both 
muscle mass and strength is an association and cannot be assumed to be a causal 
relationship (Loenneke et al., 2019).  
6.3. Secondary outcome measures: Physical activity monitoring 
There were no significant effects of the EXVITD intervention on any of the 
parameters of habitual physical activity within or between groups. Average daily step 
count over 7 days was marginally increased within both the placebo and vitamin D 
groups (+37.70 and +877.53 steps, respectively), as were the average time spent 
sitting/lying (+2.99 and +1.71 hours) and the number of up/down transitions (+4.26 
and +5.50 transitions). Time spent standing and energy expenditure remained 
relatively constant across both groups, as was average time spent stepping within 
the control group. Time spent stepping was increased by 0.29 hours within the 
vitamin D group (p = 0.223). 
Average daily step count of the EXVITD cohort at baseline (5820.34 (2295.44 steps 
per day) revealed that the guideline 7000 – 10,000 steps per day recommended for 
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improved quality of life, maintenance of a healthy weight and immune function 
(Tudor-Locke et al., 2011, Department of Health and Social Care, 2019) was on 
average not achieved, although individual variation was high (1811 to 11,867 steps 
per day). Despite this, the average daily step count of the EXVITD cohort at baseline 
was higher than reported previously by a UK population-based study which analysed 
7-day accelerometer data from 2540 older adults (mean age = 78 years, BMI not 
reported); average step count was measured to be 4662 (95% CI 4567, 4757) steps 
per day (Jefferis et al., 2014). The average daily step count of 24 Scottish older 
adults (mean age = 68 years, mean BMI = 26.2 kg.m-2) assessed via 5-day ActivPAL 
accelerometery was higher than that of the EXVITD cohort; average daily step count 
was 8493 (2291) steps per day, although average age of included participants was 
lower than the EXVITD study and 29.00% of the cohort still maintained Monday-
Friday employment despite being above the retirement age (Fitzsimons et al., 2013).  
Comparing other physical activity outcomes, the aforementioned study involving 
Scottish older adults reported higher mean time spent sitting/lying (18.06 (1.54) hours 
per day), time spent stepping (1.75 (0.42) hours per day) and number of up/down 
transitions (54 (15)), although time spent standing (4.19 (1.34) hours per day) was 
higher within the EXVITD cohort (Fitzsimons et al., 2013). A rapid review of the use 
of ActivPAL to measure physical activity in older adults (mean age range = 66.0 to 
84.2 years) reported mean ranges for time spent stepping (0.13 to 5.02 hours per 
day), standing (0.8 to 3.4 hours per day) and sitting/lying (minimum time was 8.2 
hours per day), of which the EXVITD cohort lay within; 24 papers were included 
within the review, but poor quality and a lack of reporting consistency prevented data 
pooling (Chan et al., 2017).  
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Exercise training studies report both increases and decreases in average daily step 
count following completion of the intervention. One study of 12 weeks balance 
training in 91 older adults (mean age = 75.5 years) with osteoporosis found a small 
decrease in average daily step count measured over 7 days using an Actigraph 
accelerometer at 3-month follow-up post-intervention (6209 (2842) steps to 6064 
(2430) steps, non-significant) (Dohrn et al., 2017). In 49 older adults (mean age = 
70.55 years) with mild cognitive impairment (MMSE average score = 24), average 
daily step count was estimated from a Kenz Lifecorder accelerometer worn daily 
throughout the intervention of 110 minutes per week of aerobic and balance 
exercises for 24 weeks; change in post-intervention step count was significantly 
higher in the intervention group than within the sedentary control group (+3017 steps 
Vs -1392 steps, p < 0.01) (Park et al., 2019). 
As with EXVITD, following 9 months of progressive resistance training, one study 
reported no significant changes in self-assessed physical activity (Physical Activity 
Scale for the Elderly) in 91 mild to moderately frail older adults with a mean age of 83 
years (Binder et al., 2005). Additionally, energy expenditure (33.02 (4.00) METs) and 
percentage increase in energy expenditure (+2.03%) within the vitamin D group of 
the EXVITD study was comparable to values reported by the intervention group of a 
12-month strength training study in 38 older adults (mean age = 76.6 years); energy 
expenditure assessed via the 7-day Paqap, a computerised questionnaire, was 
estimated to be 32.8 (5.5) Kcal kg-1 day-1, which increased by 2.74% following the 
intervention period (Capodaglio et al., 2007). 
Of comparable RET and vitamin D supplementation studies, only one reported 
similar physical activity outcomes to EXVITD; average daily step count of 409 older 
women (mean age = 74.1 years) estimated via a pedometer worn daily throughout 
215 
 
the 24-month intervention was recorded as 5930 (2512) steps, but with a large 
individual range of 1200 to 16,500 steps (Uusi-Rasi et al., 2015). Step count was 
comparable to both EXVITD groups, as was the large range of individual values 
reported.  
6.4. Blood biomarker outcomes 
Regarding serum 25(OH)D, as expected, concentrations within the vitamin D group 
were increased significantly from baseline at month 6 (t (8) = 2.56, p = 0.034) and 
between-group differences were also significant (F (1,17) = 7.21, p = 0.016). The 
degree to which vitamin D3 supplementation raised serum 25(OH)D concentrations 
within the vitamin D group (55.63 to 79.83 nmol/L) was comparable to the exercise 
study by (Uusi-Rasi et al., 2015), which also supplemented with 800 IU D3 per day; 
after 6 months, serum 25(OH)D concentrations had risen by approximately 21.00 
nmol/L within the exercise and vitamin D group (baseline 25(OH)D approximately 66 
nmol/L, 87 nmol/L at month 6, estimated from a graph). By month 6, all participants 
within the vitamin D group of EXVITD had achieved serum 25(OH)D concentrations 
considered to be sufficient (> 50 nmol/L), while this was achieved by 70% of 
participants within the placebo group.  
Parathyroid hormone (PTH) concentrations were not significantly altered within either 
group and between-group differences were also non-significant (p = 0.651). The 
largest increase in serum 25(OH)D concentration within the vitamin D group, 
between baseline and month 1, was concurrent with a fall in serum PTH 
concentration and an increase in calcium concentration. This is in agreement with a 
systematic review and meta-analysis of 1077 adults (mean age range = 28.7 to 63.8 
years) which reported that vitamin D supplementation was associated with a small 
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but significant decrease in PTH concentration (standardized mean difference = - 0.04 
(95% CI – 0.06, - 0.02 pmol/L), p < 0.001) (Lotito et al., 2017). Under normal 
conditions, PTH and vitamin D work to maintain calcium homeostasis; PTH 
stimulates the synthesis of 1,25(OH)2D in the kidneys, increasing serum calcium 
concentrations which in turn exerts negative feedback on PTH production. The 
inverse relationship between serum 25(OH)D and serum PTH in the maintenance of 
calcium homeostasis is well known, but this relationship reaches a plateau  around 
serum 25(OH)D concentrations of 45 nmol/L after which further increases in serum 
25(OH)D exert little additional decreases in PTH concentrations (Steingrimsdottir et 
al., 2005). Since both groups had serum 25(OH)D concentrations >50 nmol/L at 
baseline, this may explain why there were no significant changes in PTH or calcium 
concentrations across the study period. 
Regarding inflammatory markers, there were no significant changes from baseline at 
month 6 in serum IL-6, IL-8 or IL-10 concentrations observed within either group. IL-8 
concentration decreased within both the placebo and vitamin D groups, but to a 
greater degree within the vitamin D group (-31.19%). However, this result was 
concluded from only 3 participants, so should be interpreted with care. 
Vitamin D has previously been considered as an anti-inflammatory agent; for example, 
a bolus dose of 250,000 IU D3 was found to decrease TNF-α (p < 0.01) and IL-6 (p = 
0.09) concentrations in 15 patients with cystic fibrosis (mean age = 24.9 years, serum 
25(OH)D concentration at baseline = 76.38 nmol/L), whilst the 15 patients assigned to 
the placebo group exhibited no significant change in either of the inflammatory markers 
after 12 weeks. However, there was no change in IL-8 or IL-10 concentration in either 
group (Grossmann et al., 2012). Similarly, vitamin D deficiency has been associated 
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with higher concentrations of inflammatory cytokines including TNF-α, IL-6 and CRP 
(Laird et al., 2014, Elizondo-Montemayor et al., 2017). 
6.5. Target population 
The original working title of the EXVITD study in protocol version 1.0 was “The 
influence of combined vitamin D supplementation and resistance exercise training on 
musculoskeletal health in frail older men and women”. The rationale for selecting 
older men and women aged ≥70 years living in a supported housing environment 
was that this population were more likely to be frail and susceptible to 
sarcopenia/functional deficits and therefore stood to benefit from interventions aimed 
to improve musculoskeletal health. The cohort of participants eventually recruited via 
the Clinical Research Network did not reside in sheltered housing and were 
seemingly more able and active than originally planned.  
However, as described above, the placebo group of the EXVITD cohort just achieved 
an average relative LLEP measurement and the vitamin D group fell below the 50th 
centile for power compared to the ADNFS reference data (Sports Council and Health 
Education Authority, 1992). Looking at individual relative LLEP measurements at 
baseline for each group (presented in Table 6.1), 58.33% of participants within the 
placebo group and 66.67% of participants within the vitamin D group had a lower 
than average relative power of the lower limbs at baseline. Although LLEP improved 
by month 6 within both groups, 4 individuals (40.00%) in the placebo group and 5 
individuals (55.56%) in the vitamin D group were still considered to have below 




Table 6.1: Cumulative baseline relative LLEP in the placebo and vitamin D groups of the EXVITD 
study in comparison to UK reference data for older adults (65-75 years) from the Allied Dunbar 
National Fitness Survey 
 Placebo group N=12 
Count (%) 
Vitamin D group N=12 
Count (%) 
Average relative LLEP (SD (W.kg-1)) 2.06 (0.97) 1.53 (0.80) 
 ≤ 5th centile (0.90 W.kg-1) 1 (8.33) 3 (25.00) 
 ≤10th centile (1.10 W.kg-1) 3 (25.00) 4 (33.33) 
 < 50th centile (< 1.81 W.kg-1) 7 (58.33) 8 (66.67) 
 ≤ 50th centile (1.81 W.kg-1) 7 (58.33) 8 (66.67) 
 ≤ 90th centile (2.60 W.kg-1) 10 (83.33) 11 (91.67) 
 ≤95th centile (2.84 W.kg-1) 10 (83.11) 11 (91.67) 
 > 95th centile (> 2.84 W.kg-1) 12 (100.00) 12 (100.00) 
 
Additionally further analysis of the cohort’s SPPB total scores at baseline revealed 
that 9 of the 24 participants (37.50%) randomized could be considered to have lower 
extremity function limitations, defined as a total SPPB score of ≤9; participants with 
SPPB total scores between 7 and 9 had a relative risk for mobility-related disability at 
follow-up of 1.2 - 2.0, compared to participants scoring 10-12 points (Guralnik et al., 
2000). 5 participants from the placebo group and 4 participants from the vitamin D 
group were considered to have functional limitations, however, the 6-month 
intervention, only 1 participant within the placebo group still had a total SPPB score 
of ≤9.  
Finally, low ASM, as defined by the EWGSOP2 (Writing Group for the European 
Working Group on Sarcopenia in Older People 2  et al., 2018) was evident from DXA 
scans in 7 participants (29.17% of the cohort) at baseline. 100% of the participants 
with low ASM were female; 40.00% and 83.33% of women in the placebo and 
vitamin D groups, respectively, had low ASM, reflected by the significant difference in 
lean mass between the groups at baseline (p = 0.001). At month 6, no participants 
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within the placebo group could be classed as having low ASM, although 4 
participants within the vitamin D group still had low ASM (44.44% of the group, all 4 
participants were women).  
At baseline, 2 participants (8.33% of the cohort) were found to be sarcopenic; 1 
participant each in the placebo and vitamin D groups, based on the EWGSOP2 2018 
definition of sarcopenia being a combination of low muscle strength (> 15 seconds for 
5 chair rises) and low muscle quality (ASM <15kg for women and <20kg for men). 
Neither case could be categorized as severe based on functional performance (gait 
speed ≤ 0.8 m/s) (Writing Group for the European Working Group on Sarcopenia in 
Older People 2  et al., 2018); The sarcopenic participants were female. At month 6, 
no participants were sarcopenic.  
6.6. EXVITD attrition, exercise and supplement compliance  
Both the completion (79.17%) and attrition (20.83%) rates in the EXVITD study were 
comparable to (Kelley and Kelley, 2013, Picorelli et al., 2014, van der Deijl et al., 
2014) or higher (Jancey et al., 2007) than those reported in meta-analyses of 
exercise interventions in older adults. This is encouraging, as recruiting and enrolling 
older adults onto an exercise intervention and maintaining their interest in 
participation is challenging; numerous factors affect this decision, including the 
participant-instructor relationship (Hawley-Hague et al., 2013) and the sense of 
community and supportiveness created by a group exercise programme promotes 
adherence (Farrance et al., 2016). 
89.08% of prescribed exercise sessions were attended by participants (Appendix J), 
which is higher than previously reported by other groups (Kelley and Kelley, 2013, 
Picorelli et al., 2014, van der Deijl et al., 2014). Additionally, a total of 92.95% of 
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prescribed supplements were taken by participants (Appendix K), which is 
comparable with similar studies involving older adults (Verreijen et al., 2014, Trabal 
et al., 2015). Of the 48 RET sessions prescribed, there were no significant between-
group differences in number of sessions attended; placebo group mean sessions 
attended = 41.90 (4.38) and vitamin D group mean sessions attended = 42.56 (3.21) 
(p = 0.717). Of the 168 placebo or vitamin D supplements prescribed over the course 
of the 6-month intervention, the placebo group took 155.60 (11.66), whilst the vitamin 
D group took 154.44 (13.67) on average (p = 0.845). Additionally, there were no 
differences between male and female participants in the average number of exercise 
sessions attended (42.92 (3.87) vs 41.00 (3.56), respectively. p = 0.299) attended or 
the average number of supplements taken (158.50 (9.99) vs 149.14 (14.38), 




































CHAPTER  7 
 



















7. Summary and general discussion 
 
The aim of the work reported in this thesis was to determine whether vitamin D3 
supplementation was any more effective in improving musculoskeletal function when 
combined with exercise training compared with exercise training alone. This research 
has expanded current knowledge within this area via the publication of the first 
systematic review and meta-analysis of effects of the combined intervention, a 
secondary data analysis of a large cohort study with novel findings regarding skeletal 
muscle health and associations with 25(OH)D and via the EXVITD study itself, which 
adds valuable data to an under-researched area, additionally reporting novel 
outcomes such as markers of bone turn over and muscle power mechanography. 
However, the role of vitamin D in combatting the onset and progression of factors 
influencing sarcopenia, such as muscle mass, strength and function and whether 
vitamin D supplementation can boost responsiveness to resistance exercise training, 
remains unclear. 
7.1. Summary of findings 
Chapter 2: The effect of combined resistance exercise training and vitamin D3 
supplementation on musculoskeletal health and function in older adults: a systematic 
review and meta-analysis. This was the first review to report on the combined effects 
of RET and vitamin D3 supplementation. The main finding was that muscle strength 
of the lower limb showed a small but significant improvement as a result of the 
combined intervention over RET alone (0.98, 95% CI 0.73, 1.24, p<0.001). 
Additionally, muscle function (TUG) and BMD of the hip and spine were more 
improved as a result of the combined intervention than observed with RET alone. 
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The small number of included studies highlighted the lack of available literature in the 
area, further justifying the rationale for completing an additional randomized 
controlled trial of exercise and vitamin D3 supplementation implementing an 
appropriate design and sample size. 
Chapter 3: Is serum 25(OH)D concentration associated with lean mass and strength 
and is sarcopenic status seasonal-dependent in a subgroup of postmenopausal 
women from the D-FINES cohort? This secondary data analysis presented novel 
findings of the transient nature of sarcopenic status, although the strength of 
conclusions drawn were limited by the very small sample of sarcopenic participants 
present within the D-FINES cohort. Muscle strength was positively associated with 
25(OH)D across all seasons and in all 3 groups, with significance detected during the 
summer and autumn months for the whole cohort and postmenopausal women <65 
years following adjustment for seasonal BMI. Sarcopenia prevalence varied 
seasonally in both postmenopausal women <65 years and ≥65 years, with 
prevalence highest in spring and participants with transient sarcopenic status most 
likely to be sarcopenic in spring in both subgroups 
Chapters 4, 5 & 6: The EXVITD study. The main findings of this study were that all 
muscle function outcome measures were significantly improved within the vitamin D 
group, with the exception of gait speed, which improved non-significantly. The 5-time 
chair rise test, peak power and 5-time chair reaction time using Leonardo 
Mechanography® were significantly improved within the placebo group, all other 
functional outcomes were non-significantly improved within this group, with the 
exception of total SPPB score, which declined (-0.91 points, p = 0.637). Despite the 
substantially greater increases in muscle power and functional outcomes observed 
within the vitamin D group compared with placebo, the conclusions drawn from the 
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EXVITD study are limited as potential between-group differences were not detected, 
most likely due to underpowering.  
7.2. Implications of the findings 
The role of vitamin D3 supplementation in relation to boosting responsiveness to 
exercise in older adults remains unclear. Although the results of the EXVITD study 
indicated that aspects of muscle power and function improved to a greater degree 
within the vitamin D supplemented group, the small sample size meant that the study 
was underpowered to detect any potential between group differences. All fall 
incidences throughout the 6-month duration of the intervention (n=3) occurred in 
participants assigned to the placebo group; while this is an interesting observation, it 
is impossible to make any assumptions based on the very small number of 
observations. Although controversy is still evident regarding the role of vitamin D in 
falls prevention, moderate-quality evidence from a recent Cochrane review suggests 
that vitamin D may play a role in reducing the rate but not risk of falls, particularly in 
individuals with low 25(OH)D concentrations (Cameron et al., 2018). 
Evidenced by the very small number of studies (7) identified in the novel systematic 
review presented in chapter 2, very few data exist in this area, and fewer still (1) of 
the studies identified truly implemented a methodological design most suited to test 
this relationship. However, a meta-analyses including studies of a suitable design 
concluded that the combined intervention indeed resulted in a significant additional 
benefit in muscle strength gains above and beyond that of RET alone (Antoniak and 
Greig, 2017). As a result of these preliminary findings, further research examining the 
potential additive effect of vitamin D supplementation on aspects of musculoskeletal 
health in older adults when combined with exercise is warranted. As stated in a 
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recent systematic review “elucidation of the real potential of a cheap drug such as 
vitamin D could be invaluable to public health worldwide” (Autier et al., 2017). The 
next section includes suggestions regarding future research. 
7.3. Future research 
Vitamin D supplementation has come under heavy criticism in recent years, 
principally by one research group from the Bone and Joint Research Group based at 
the University of Auckland, New Zealand, which has been quite vocal about their lack 
of support for vitamin D supplementation, particularly in the prevention of falls or 
fractures (Bolland et al., 2018b). However, their study, entitled “Effects of vitamin D 
supplementation on musculoskeletal health: systematic review, meta-analyses, and 
trial-sequential analyses” had a focus on falls, fractures and BMD, with no mention of 
muscle mass, strength or function outcomes. Other reviews report mixed results for 
vitamin D supplementation and muscle strength and/or function; one review reported 
that although clinical evidence of benefit on muscle strength was suggested, a 
substantial effect on lower extremity muscle strength was unlikely (positive effect but 
no significance observed from 3 RCTs), despite meta-analyses from 3 studies 
reporting a significant reduction in postural sway (SMD = −0.20. 95% CI −0.39 to 
−0.01, p = 0.04) (Theodoratou et al., 2014). Furthermore, 2 large systematic reviews 
by one research group examined the effects of vitamin D supplementation on non-
skeletal health and reported no significant effects; the earlier study reported 
improvements but no significant effect in favour of vitamin D supplementation on leg 
strength, TUG or balance (Autier et al., 2014) and neutral effects on muscle strength 
from a total of 9 RCTs including 1205 participants in a more recent study (Autier et 




The choice to recruit vitamin D insufficient participants as part of the EXVITD cohort 
was justified as it was deemed unethical to withhold treatment from deficient 
participants randomized to the placebo group. That said, the recruitment of 
insufficient or sufficient participants has been pronounced as “research waste” by 
one study, so said because any beneficial effect of vitamin D is most likely to be 
observable in participants with vitamin D deficiency, which in this instance was 
defined as serum 25(OH)D concentration <25 nmol/L, with insufficiency defined as 
<50 nmol/L (Bolland et al., 2018a). As the most beneficial effects of vitamin D 
supplementation alone on muscle strength and functional outcomes have been 
observed in participants with deficiency (Stockton et al., 2011, Beaudart et al., 
2014b), it would be of future interest to investigate whether deficient participants had 
benefits or additional benefits above insufficient or sufficient participants in a study 
design comparable with EXVITD. However, as evidenced in the systematic review 
and meta-analysis in chapter 2 (Antoniak and Greig, 2017), significant improvements 
in muscle strength were observed with vitamin D3 supplementation combined with 
exercise in studies including either vitamin D insufficient participants (Bunout et al., 
2006a, Uusi-Rasi et al., 2015) or vitamin D sufficient (Agergaard et al., 2015b). 
Additionally, a more recent study not included within the systematic review found that 
vitamin D3 supplementation significantly improved postural and anteroposterior 
steadiness in comparison to exercise training or vitamin D3 supplementation alone in 
participants who were vitamin D sufficient (72 nmol/L) at baseline (Aoki et al., 2018).  
The high supplement compliance reported within the EXVITD study (92.95%) 
demonstrated that a daily supplementation regimen was feasible within community-
dwelling older adults., There is evidence demonstrating that a daily or weekly vitamin 
D supplement is more effective than single or multiple bolus doses on certain health 
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outcomes such as respiratory tract infection risk (Martineau et al., 2017). 
Recommendations regarding dose of vitamin D supplement is more difficult, since 
the optimum dose to potentially benefit musculoskeletal outcomes has not yet been 
determined (Beaudart et al., 2014b). That said, the dose of 800IU/d utilised within the 
EXVITD study which was below the recommended safety limit of 1000IU/d by the UK 
Food Standards Agency (Food Standards Agency, 2003) and the 4000IU/d Tolerable 
Upper Intake Level recommended by the Institute of Medicine (Ross et al., 2011a), 
was nevertheless sufficient to significantly increase 25(OH)D concentrations from 
baseline, and was well tolerated with no occurrences of Adverse or Serious Adverse 
Events. 
One important recommendation, and one of the strengths of the EXVITD study, was 
the use of liquid chromatography‐tandem mass spectrometry to measure 25(OH)D 
concentration. The use of one, highly accurate and validated gold-standard 
methodology (Volmer et al., 2015) could alleviate difficulties comparing serum 
25(OH)D concentration data between studies due to high variability between different 
assays (Salti et al., 2012). The measurement of serum 25(OH)D concentration is the 
best determinant of vitamin D status (including intake from the diet and cutaneous 
production) (Holick, 2009) due to the stable half-life (2 – 3 weeks) of the metabolite 
(Thacher and Clarke, 2011). Although 1,25(OH)D3 is the biologically active metabolite 
of vitamin D, its unstable nature, very low circulating concentration and the influence 
of PTH make it unsuitable when quantifying vitamin D status (Holick, 2009). 
However, 1,25(OH)D3, and not 25(OH)D  has previously been associated with 
psoriasis severity and cardiovascular disease risk factors in 122 middle-aged adults 
with psoriasis (mean age = 49.6 years) (Playford et al., 2019), indicating that the 
measurement of 1,25(OH)D3 may have some clinical relevance.  
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Muscle power was selected as the primary outcome measure since muscle power 
has been shown to be a superior predictor of functional status and decline than 
muscle strength (Foldvari et al., 2000, Suzuki et al., 2001, Bean et al., 2010, Byrne et 
al., 2016). Additionally, muscle power is more generally relatable to activities of daily 
living in older adults, such as rising from a chair and climbing stairs (Foldvari et al., 
2000), although relatively few of the studies included within the meta-analysis in 
chapter 2 (Antoniak and Greig, 2017) included measures of muscle power (Drey et 
al., 2011, Gianoudis et al., 2014).  
Regarding the design of the exercise component of future RCT studies of combined 
exercise and vitamin D supplementation, the initial protocol stated that 3 sessions of 
exercise per week were to be completed for 6 months; the frequency of the exercise 
sessions was one of the major reasons for refusal to participate. Not only was 
participant recruitment more successful once 2 exercise sessions per week were 
implemented, this frequency was sufficient to result in clinically meaningful changes 
in 2 important functional outcomes; the SPPB score and gait speed, with 
improvements in muscle power outcomes, gait speed, TUG and 5-time chair rise test 
observed in both groups. 2 exercise sessions per week would also fulfil the physical 
activity guidelines for older adults in the recently produced UK Chief Medical Officer’s 
report (Department of Health and Social Care, 2019), whilst the observed compliance 
to the exercise sessions was high (89.08), suggesting that 2 sessions of exercise per 
week was feasible for the selected population. 
A minimum duration of 6 months would be recommended for future interventions, 
particularly if BMD is to be included as an outcome measure, since this has been 
suggested as the minimum period for remodelling to be evident on DXA scans (Zhao 
et al., 2015). Additionally, it has been suggested that new behaviours taking around 6 
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months to be adopted in the long-term (Hawley-Hague et al., 2013), since older 
adults are most likely to abandon new exercise commitments within the initial 6 
months, largely dependent on whether their expectations are met within this period 
(Stiggelbout et al., 2006, Jancey et al., 2007). 
Significant improvements in muscle strength and function have been observed after 
less frequent exercise sessions; a group of 46 older adults (aged 65 to 79 years) 
completed 24 weeks of RET, with no difference in any strength or function outcome 
measure between participants exercising one, two or three times per week for the 
study duration (Taaffe et al., 1999b). Mode as opposed to frequency appears to be of 
more importance to muscle strength in the design of exercise studies involving older 
adults (Taaffe et al., 1999a, Henwood and Taaffe, 2006, DiFrancisco-Donoghue et 
al., 2007), with resistance training (more explosive concentric phase with increasing 
percentage of 1RM) producing superior improvements in function in older adults  
than strength training (slower and equal concentric and eccentric phases and static 
percentage of 1RM) (Henwood and Taaffe, 2006). A dose-response relationship has 
been shown between exercise intensity and muscle strength, with high intensity 
training confers more benefit than moderate or low intensity training (Beneka et al., 
2005, Steib et al., 2010).  
The justification for not using quantifiable measures of exertion, exercise progression 
or muscle loading was sound since the use of objective measures such as heart rate 
monitors would add additional participant burden, however, implementing rate of 
perceived exertion scales may have been a good compromise. Additionally, the 
rationale that the use of more familiar exercise equipment would be more readily 
adapted and maintained in daily practice appeared to come to fruition at the close of 
the study, since many of the participants continued to attend exercise sessions with 
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the specialist exercise instructor. That said, exertion, exercise progression or muscle 
loading data would have been very informative, particularly as exercise intensity has 
been found to be of importance to outcome measures including strength (Beneka et 
al., 2005, Steib et al., 2010).  
One suggestion which would be informative for the design of future studies would be 
preliminary observations regarding the vitamin D status of the target population, a 
recommendation made previously by (Bolland et al., 2018a). Looking retrospectively 
at the EXVITD study, this approach would have been informative regarding functional 
ability also; the participants recruited were not necessarily those we were intending to 
target initially since sheltered-housing accommodation residents were much frailer, 
with more comorbidities than expected. For example, of the 23 screening failures, 
47.83% were due to low serum 25(OH)D concentration, whilst 56.52% were due to 
comorbidities identified via the health questionnaire. Difficulties in recruiting from this 
population would have been better anticipated had some form of preliminary 
observations been completed.  
7.4. Personal reflections 
From a personal stand point, the dynamics of the study team supported the protocol 
presented in Chapter 4. The support and flexibility of the staff at the Clinical 
Research Facility (research nurses, radiologists and receptionists) was one factor 
which helped ensure that study data were collected accurately and on time. 
Recruitment was immeasurably quicker and more efficient subsequent to the support 
of the local Clinical Research Network; if their support had been gained when 




Logistic issues were one of the main, time consuming challenges encountered once 
the intervention had begun. On one hand, overseeing the coordination of transport 
for participants was a method of monitoring exercise session attendance in addition 
to the attendance register; however, the quality of the taxi service received was 
intermittent, and on a small number of occasions resulted in missed sessions when 
taxis did not arrive.  
The personal interaction with participants and encouraging socialising both after and 
outside of the sessions was helpful from not only a compliance and monitoring 
perspective but getting to know the participants was something I personally enjoyed. 
Several participants remarked to me after study completion that they had considered 
dropping out in the early weeks of the intervention, but continued due to the social 
aspect and rapport built with myself, the specialist exercise instructor and other 
participants. This is in agreement with previous studies which found that drop-outs 
were most likely to occur in the initial stages of an intervention (Stiggelbout et al., 
2005, Hawley-Hague et al., 2013) and group cohesion and social interaction and 
support has been shown to promote adherence (Hawley-Hague et al., 2013, 
Farrance et al., 2016), particularly in older adults (Stiggelbout et al., 2005). 
7.5. Conclusions 
Observational and interventional data propose a relationship between vitamin D and 
musculoskeletal health. The body of research presented here collectively provides 
tentative support for the use of vitamin D supplementation in combination with 
resistance training to improve aspects of sarcopenia. Future research is justified as 
vitamin D could prove to be a cost-effective method of maintaining musculoskeletal 
health and function in older adults, should its potential be confidently deduced.  
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Not only is it uncertain whether vitamin D boosts the responsiveness of muscle tissue 
to exercise, but the knowledge that is evidently still missing is one of basic science; 
what is the potential mechanism by which vitamin D interacts with exercise to boost 
the muscle anabolic response?  
It may be that vitamin D protects muscle and bone from the increase in inflammatory 
cytokines observed during “inflammageing” and these cytokines “block” the effects of 
resistance training. Vitamin D deficiency has been shown to predispose older adults 
to a pro-inflammatory environment (Laird et al., 2014, Elizondo-Montemayor et al., 
2017), which in turn enters the body into a catabolic state of muscle mass loss, 
potentially linked to sarcopenia (Dalle et al., 2017). Moreover, vitamin D replete older 
adults have a better response to resistance training in terms of muscle strength than 
older adults considered to be vitamin D deficient (Fuller et al., 2011); it may be that 
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Appendix B: Narrative analysis summary of findings for Group 2 primary outcome measures 
Category Outcome Assessment point Study 
Intervention group change from 
baseline (%) 
Control group change from 
baseline (%) 
Mean SD N Mean SD N 
Muscle strength 
Isometric knee extensor strength 
(Nm) 
6 months Verschueren et al., 2011 +3.01 2.67 28 +0.11 3.18 28 
Muscle power 
Sit-to-stand transfer power (W) 12 weeks Drey et al., 2011 +8.99* 5.51 23 +2.61 2.49 22 
Functional stair climbing muscle 
power (W) 
12 months Gianoudis et al., 2014 +10.40* 13.00 81 +6.20 12.70 81 
Muscle function 
30 second sit-to-stand (number 
of stands) 
12 months Gianoudis et al., 2014 +18.30* 23.60 81 +2.70 17.2 81 
5-time chair stand time (s) 24 months Uusi-Rasi et al., 2015 -6.95 2.50 102 -3.49 3.30 102 
Normal walking speed (m/s) 24 months Uusi-Rasi et al., 2015 -1.80 0.20 102 -3.30 0.21 102 
Endurance: 12-minute walk (m) 9 months Bunout et al., 2006 +8.80 17.60 22 +20.90 27.70 24 
Balance 
Romberg ratio (%) 9 months Bunout et al., 2006 +2.80 33.80 22 -0.60 35.80 24 
Four square step test (s) 12 months Gianoudis et al., 2014 -12.00* 14.10 81 -5.20 14.90 81 
Body sway (cm) 32 weeks Jessup et al., 2003 -26.39* 0.52 9 +2.90 0.49 9 
Backwards walking (% able to 
complete) 





























Assessment point Study Intervention group change 
from baseline (%) 
Control group change from 
baseline (%) 




mass (Kg) 12 weeks 
Drey et al., 2011 +1.65 0.71 23 +0.00 0.87 22 
Muscle mass of 
upper limb (cm3) 6 months 
Verschueren et al., 2011 -0.16 0.57 28 -0.25 0.38 28 
BMD of femoral 
neck (g/cm2) 6 months 
Verschueren et al., 2011 






Appendix D: Unadjusted associations between serum 25(OH)D concentration and lean mass and muscle strength 
 
 All postmenopausal women Postmenopausal women aged <65 years Postmenopausal women aged ≥65 years 
 N rs 
(95% CI) 
p N rs 
(95% CI) 
p N rs 
(95% CI) 
p 
25(OH)D x relative 
appendicular skeletal 
muscle index Autumn 
145 -.054 
(-0.22, 0.12) 
0.534 111 -.221 
(-0.42, -0.04) 
0.018 31 -.171 
(-0.48, 0.21) 
0.333 
  25(OH)D x relative 
appendicular skeletal 
muscle index Spring 
148 .037 
(-0.13, 0.20) 
0.655 103 -.218 
(-0.39, -0.05) 
0.026        28  -.094 
(-0.43, 0.27) 
0.615 
  25(OH)D x HGS Summer 167 .285 
(0.14, 0.41) 
<0.001 123 .300 
(0.14, 0.42) 
0.001 44 .318 
(0.07, 0.51) 
0.035 
  25(OH)D x HGS Autumn 157 .194 
(0.03, 0.35) 
0.015 118 .233 
(0.03, 0.36) 
0.011 39 .176 
(-0.19, 0.50) 
0.284 
  25(OH)D x HGS Winter 145 .180 
(0.01, 0.34) 
0.030 108 .216 
(0.02, 0.33) 
0.025 44 .190 
(-0.11, 0.46) 
0.260 
  25(OH)D x HGS Spring 144 .201 
(0.04, 0.35) 
0.016 110 .237 
(0.05, 0.35) 
















THE INFLUENCE OF STRENGTH TRAINING AND VITAMIN D3 
SUPPLEMENTATION ON MUSCLE AND BONE FUNCTION IN OLDER ADULTS 
 
 
You are being invited to take part in a research study. Before you decide, it is 
important for you to understand why the research is being done and what it 
will involve. Please take time to read the following information carefully. Talk 
to others about the study if you wish. 
• Part 1 tells you the purpose of this study and what will happen to you if 
you take part. 
• Part 2 gives you more detailed information about the conduct of the 
study. 
Ask us if there is anything that is not clear or if you would like more 
information. Take time to decide whether or not you wish to take part. 
 
College of Life and 
Environmental Sciences 





What is the purpose of the study? 
Muscle and bone loss are inevitable consequences of ageing, even if our health 
is good. We are looking at ways of reducing muscle and bone loss in  
order to help improve the ability to perform tasks and activities important for 
independent living. The purpose of this research study is to find out whether a 
period of strength training combined with a vitamin D3 supplement is any more 
effective at improving muscle and bone function that strength training alone. In 
order to do this, we would like to measure the size of your muscles, along with 
their strength and power, do some tests to see how well you can perform tasks 
and activities important for daily living plus answer some questions about how 
you feel about your life just now. We would also like to take blood samples. We 
would like to see if any of these measurements change after strength training 
and whether taking vitamin D3 can help to boost these changes. 
Why have I been chosen? 
You have been chosen because you are 65 years of age or over and are living 
independently. 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you do, you will be 
given this information sheet to keep and be asked to sign a consent form. You 
will still be free to withdraw at any time in the future and without giving a 
reason. A decision to withdraw at any time, or a decision not to take part, will 






What will happen to me if I take part? 
If you are interested in taking part, we would like you to complete a brief 
screening health questionnaire. We will use your responses to the 
questionnaire to help determine whether you are eligible to take part in the 
study. If you are eligible to participate, we will ask you to sign a consent form 
and then we will take a small sample of blood (just over a tablespoon full). We 
will also ask you to answer a few short questions about thinking and memory. 
The purpose of these procedures is to help us determine whether it is 
appropriate for you to continue with your participation. We will then ask you to 
wear a small monitor which measures physical activity for 7 days. After this we 
will then ask you to visit either your communal room or a facility close by (we 
will provide taxi transport if necessary) to take part in an exercise training 
study. This will involve getting together in a group with a specialist exercise 
instructor to do some strength and balance training exercises. This will take 
place 3 times a week for 6 months. You will also be asked to take either a 
vitamin D tablet or a placebo tablet once a day for 6 months. We will provide 
you with tablets 4 weeks at a time. Neither you nor we will know which type of 
tablet you are taking until the end of the study. Before and after the 6 months 
of exercise training combined with the tablets, we will ask you to come to the 
Wellcome Trust Clinical Research Facility at the Queen Elizabeth Hospital, 
Birmingham, in order to make some physical function measurements. We will 
provide taxi transport. At the end of the study you will be given a DVD to keep 
which includes the exercises you have been doing during the study. If 
something should happen whereby you do not fulfil the eligibility criteria any 
longer, then we would not continue with the collection of data but you may 




 ‘What tests and procedures will be carried out as part of this study’ 
Measurement of bone and body composition (DXA scan): This gives us 
information about your bone strength and body composition (that is, the 
amount of muscle, bone and fat in your body). The scan takes about 30 
minutes and involves X-rays. However, the radiation exposure you will receive 
by taking part in this study is equivalent to 4 days of naturally occurring 
background radiation which is an extra 1% of the annual naturally occurring 
back ground radiation. This additional risk is comparable to travelling 50 miles 
by car. 
Test of muscle power: Your leg muscle power will be measured using 
specialised equipment and will involve simple pushing movements which you 
will be asked to hold for a few seconds. These tests will take about 10 minutes 
so you may feel a little tired afterwards but the tests should not cause any pain 
or discomfort. We will also measure the power you exert when you get out of a 
chair using a special force platform. This will take only a minute. 
Test of functional ability (short physical performance battery): This is a short 
series of tests of balance, walking speed (over a few feet) and chair rise. It will 
take about 10 minutes. 
Test of functional ability (timed up-and-go): This test will measure your ability 
to get up out of a chair and walk a few feet then turn around and go back to 
your chair. It will take 5 minutes. 
Questionnaires: You will be asked to complete two questionnaires; one asks 
about your quality of life and the other about pain/ discomfort in muscles and 




Measurement of physical activity: We will measure this just before you do the 
other tests. We will attach a small physical activity monitor to your thigh with 
sticky pads and ask you to wear it for 7 days.  We would ask you to remove 
some of your clothing for a few minutes so that we can attach the monitor. The 
monitors are very small (1.5x2.5 inches) and lightweight (less than 1oz). You 
may bathe/ take a shower during this time (although if you wish to bathe we 
would ask you to remove the monitor while you  
 are bathing). We will collect the monitor from you or provide you with a 
stamp-addressed envelope to return the monitor to us after 7 days.  
Food diary: We will give you a special diary so that you can record the things 
you eat and drink over the course of 2 days (in other words 2 days at the 
beginning of the study and 2 days at the end). 
A blood test: We will take small samples of blood from a vein (a total of four 
blood samples of 20ml which is just a bit more than a tablespoon). We will take 
a sample at the beginning (which we mentioned earlier), two during the study 
and one at the end. The samples will be used to check your vitamin D and 
calcium levels as well as other important chemicals in your blood.  
Measurement of blood pressure: This test will allow us to measure your blood 
pressure whilst seated and also whilst standing. 
What are the possible disadvantages and risks of taking part? 
We have taken every step in the design of this study to minimise any possible 





What are the possible benefits of taking part? 
Regular exercise has many benefits not only in terms of improving muscle and 
bone function but also improving the ability to perform normal everyday tasks 
as well as helping to improve quality of life. We cannot guarantee that you will 
receive all of these benefits but we would be surprised if you didn’t receive 
any. Taking vitamin D3 supplements may confer a small additional benefit. 
Even if you do not benefit directly from taking part in the study, the 
information we receive may help us to find ways of slowing down muscle and 
bone loss, not just in relatively healthy older people but in people with certain 
diseases characterized by muscle wasting. 
Part 2 
What if relevant new information becomes available? 
If any clinically significant information comes to light as a consequence of 
taking part in this study, we will inform your GP (with your permission). 
What will happen if I don’t want to carry on with the study? 
You can withdraw from the study at any time without having to give a reason. 
However, we may still choose (with your permission) to use any data obtained 
as a result of your participation. Any identifiable data will be anonymised. 
What if there is a problem? 
Complaints: If you have a concern about any aspect of this study, you should 
ask to speak with the researchers who will do their best to answer your 
questions. If you remain unhappy and wish to complain formally, you can do 
this by contacting Dr Sean Jennings, Research Support Group, University of 
Birmingham (0121 415 8011 or s.jennings@bham.ac.uk). 
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Harm: In the event that something does go wrong and you are harmed during 
the research study, the University has in force a Public Liability Policy and/or 
Clinical Trials policy which provides cover for claims for "negligent harm" and 
the activities here are included within that coverage. 
Will my taking part in this study be kept confidential? 
Yes. All information which is collected about you during the course of the 
research will be kept strictly confidential. However, we would like to inform 
your GP of your involvement in this study but we will require your permission 
to do this. All other information about you which leaves the University of 
Birmingham will have your name, address and date of birth removed so that 






What will happen to the results of the current research study?  
The results of this study will be published in medical journals, reports and 
textbooks. You will not be identifiable in any publication or report.  
Who is organising and funding the research? 
The research is being organised and sponsored by the University of 
Birmingham. The study is funded by the National Osteoporosis Society. 
 
Who has reviewed the study? 
This study has been given a favourable ethical opinion for conduct in the NHS 




You may contact me (one of the Principal Researchers) directly by telephoning 
0121 414 8743 or email c.a.greig@bham.ac.uk for further information at any 
time. Alternatively, you may contact Dr Alison Rushton (School of Sport, 
Exercise and Rehabilitation Sciences) who is acting as an independent advisor. 
Her contact telephone number is 0121 415 8597 (email 
a.b.rushton@bham.ac.uk)  
 
Many thanks for taking the time to read this information. 
Dr Carolyn Greig PhD  
School of Sport Exercise and Rehabilitation Sciences 
MRC-ARUK Centre for Musculoskeletal Ageing Research 






























If the answer is YES to any of the following questions, please give some 
details including dates where possible. 
 
 
Have you any history of heart trouble? 





Have you any history of problems with blood vessels? 







Have you any history of chest problems? 




Have you ever smoked? 





Do you suffer from diabetes? 
(if YES please state if insulin dependent) 
 
 
Have you any history of major illness now or in the last 20 years? 














Do you suffer from osteoarthritis? 
(if YES please state joints affected and indicate mild, moderate or severe and 








Do you have any problems with your bones? 




Have you any history of back problems? If so, when did they start and do they 





















Have you had any acute illness in the last six months? 




Please state any medication, prescribed or over the counter, regularly taken for 
any condition 
 









Do you have any physical disabilities? 






Is there any other illness or condition that affects your general health or 




Approximately how tall are you? 
 
Approximately how much do you weigh? 
 
 
Your Doctor’s Name: 
 
Your Doctor’s Address: 
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1. I confirm that I have read and understand the information 
sheet dated 13 July 2016 (version 6.0) for the above study. 
I have had the opportunity to consider the information, 
ask questions and have had these answered 
satisfactorily. 
 
2. I understand that my participation is voluntary and that I 
am free to withdraw at any time, without giving any 
reason, without my medical care or legal rights being 
affected. 
 
3. I understand that relevant sections of any of my medical 
notes and data collected during the study may be looked 
at by responsible individuals from the University 
Hospitals Birmingham NHS Foundation Trust, where it is 
relevant to my taking part in this research. I give 
permission for these individuals to have access to my 
records. 
 
College of Life and 
Environmental Sciences 










4. I understand that personal data collected during the 
study will be kept anonymised and stored securely at the 
University of Birmingham. 
 
5. I agree to my GP being informed of my participation in the 
study. I agree to take part in the above study. 
 
6. I agree to the storage of samples taken during the course 
of this study so that they may be considered for use in 






________________________         ___________                    






________________________         ___________                    















Case Report Form 
 
EXVITD: Influence of combined vitamin D3 
supplementation and resistance exercise training on 






                       Participant ID:                           
 
 
Chief Investigator: Dr Carolyn Greig 
School of Sport, Exercise and Rehabilitation Sciences 









Sponsor reference number: RG_14-185 
 
CRF study number: 1464 
 









All clinical data collected during the study has to be documented in this case report form. 
 
Please use a black ball-point pen for filling in the case report form. 
 
Incorrect entries should be deleted with a single line. The original entry must be kept legible. 
All changes and/or corrections made to the case report form must be initialled and dated by 
the investigator or by another responsible person of the respective study centre. 
 
Please answer all questions and write clearly. 
 
Identification of subject throughout the study is done by subject number only. 
 
Please enter only one digit in one box. Data should be entered at the right hand margin. If 
not enough digits are available to fill all fields, please prefix the number by recording “0”. 
 
Please enter complete dates wherever possible. If day or month of a date should be 
unknown, please enter “NK” in the respective fields. e.g.: NK/05/2004 
 
Times should be entered using the 24-hour clock. Please enter times from 00:00 to 23:59. 
Do not use 24:00. 
If a question is not applicable, please record “NA” for “not applicable”. 
If an examination was not done, please record “ND” for “not done”. 
If a result is zero, please enter “0”. 
If a page has not been used, please enter the subject number and cross out the page.  
Comments should be as short as possible. Please do not enter comments outside the 
predefined areas (Final Comment Page). 
 
The case report form has to be signed by the investigator. If a premature termination of the 
trial occurs in a subject, the case report form should be completed up to this day and the 






Date of Assessment      
 
Informed Consent  Yes No Date of Consent 
 
Date of Birth   Age  yrs 
 




Health Questionnaire completed? Yes  No 
MMSE completed? Yes  No 
Venous blood sample collected? Yes  No 
GP notified? Yes  No 





















Aged 65 years and over 
  
Living independently  








History of myocardial infarction within the previous 2 years 
  
Cardiac illness: moderate/ severe aortic stenosis, acute pericarditis, acute myocarditis, 
aneurysm, severe angina, clinically significant valvular disease, uncontrolled 
dysrrhythmia, claudication, within the previous 10 years   
Thrombophlebitis or pulmonary embolus within the previous 2 years 
  
History of cerebrovascular disease (CVA or TIA) within the previous 2 years 
  
Acute febrile illness within the previous 3 months 
  
Severe airflow obstruction 
  
Uncontrolled metabolic disease (e.g. thyroid disease) 
  
Significant emotional distress, psychotic illness or depression within the previous 2 
years   
Major systemic disease active within the previous 2 years (e.g. cancer, rheumatoid 
arthritis)   
Significant emotional distress, psychotic illness or depression within the previous 2 
years   
Lower limb fracture sustained within the previous 2 years/ upper limb fracture within the 
previous 6 months  
   
Non arthroscopic lower limb joint surgery within the previous 2 years 
  
Any reason for a loss of mobility for greater than 1 week in the previous 2 months or 
greater than 2 weeks in the previous 6 months   
Resting systolic blood pressure > 200mmHg or resting diastolic blood pressure > 
























   NO 
Poorly controlled atrial fibrillation; poor (chronic) pain control 
   
Moderate/severe cognitive impairment (mini mental state examination (MMSE) score 
<23) 
   
Vitamin D deficient (serum 25(OH)D3 <30nmol/l); current antiresorptive or anabolic 
treatment for osteoporosis  
   
Treatment with bisphosphonates for osteoporosis in the past two years 
  
Current use of glucocortocoids; known primary hyperparathyroidism; hypercalcaemia 
(albumin-adjusted serum calcium >2.60 mmol/l) 
   
Renal impairment (Stage 4 or 5) 
  
 
 If any of the shaded boxes are ticked, the participant is not eligible for the study 
Previously taken vitamin D3 supplement? Yes  No 
 
If ‘yes’ please state dose _______________ IU.day-1 
 
ELIGIBILITY 
Is the subject eligible to participate in the study Yes No 











Date of Assessment   
Height  cm  
Weight .  kg BMI  .  kg/m2 
 
Pulse   per minute   Measured after 5 minutes rest, sitting, on the dominant arm 
 
 
Blood Pressure Sitting 
 
Measurement 1: Systolic   mmHg Diastolic   mmHg 
 
Measurement 2: Systolic   mmHg Diastolic   mmHg 
 
Measurement 3: Systolic   mmHg Diastolic   mmHg 
 
Blood Pressure Standing 
 
Measurement 1: Systolic   mmHg Diastolic  mmHg 
 
Measurement 2: Systolic   mmHg Diastolic   mmHg 
 
Measurement 3: Systolic   mmHg Diastolic   mmHg 
 
 Blood pressure to be measured in 5 minutes intervals on the dominant arm 
 
 
Concomitant Medication present? Yes No 
 If yes, please complete Concomitant Medication page 
Has the participant had a loss of mobility in the last 2 months?      Yes No 
 If yes, please tick Exclusion Criterion 13 as “No” and exclude the subject 
Accelerometer returned? Yes  No 
3-day food diary handed out? Yes  No 
 
 
DXA scan performed?               Yes  No 
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 Sitting Standing 











Date of Assessment   
  
 
Has the Concomitant Medication changed since the previous visit? Yes  No 
 If yes, please complete Concomitant Medication page 
 
 
3-day Food Diary returned? Yes  No 
 
Accelerometer returned? Yes  No 
 
Venous Blood sample taken? Yes  No 
 







Start of physical monitoring 
Date   Time  :  
 
End of physical monitoring 










































































SHORT PHYSICAL PERFORMANCE BATTERY TEST 
 




C: Tandem Stand 
 
 
Held for 10 secs 
(2 points) 
Held for 3 – 9.99 
secs (1 point) 
Held for <3 
secs (0 points) 
Not attempted/failed. 
0 points (please select 






   
 
Key 
Dominant limb (L/R)  
Seat length (cm)  
Position of non-dominant foot  
 Power Output (Watts.kg-1) 
Measurement 1  
Measurement 2  
Measurement 3  
Measurement 4  
Measurement 5  
Best measurement  
 
Held for 10 secs (1 
point) 
Held for <10 secs (0 points, 
please state time) 
Not attempted/failed.  
0 points (please select 
reason from key) 
Side-by-Side 
Stand 
   
Semi-Tandem 
Stand 
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1. 1 Tried but unable 
2. 2 Participant could not hold position unassisted 
3. 3 Not attempted – you felt it was unsafe 
4. 4 Not attempted – participant felt unsafe 
5. 5 Participant unable to understand instructions 
6. 6 Participant refused 















Gait Speed Test 
 
Time for 3m walk 
(secs) 
Walking aid? (None, cane, 
other) 
Not attempted/failed  
(Please select reason from 
key) 
Attempt 1    





     
     
1.  Tried but unable 
2. Participant could not hold position 
unassisted 
3. Not attempted – you felt it was unsafe 
4. Not attempted – participant felt unsafe 
5. Participant unable to understand 
instructions 
6. Participant refused 










Time taken to complete 5 
stands (secs) 
With or without using 
arms? 
Not attempted/failed 
(Please select reason from 
key) 






1. Tried but unable 
2. Participant could not hold the position unassisted 
3. Not attempted – you felt it was unsafe 
4. Not attempted – participant felt unsafe 
5. Participant unable to understand instructions 
6. Participant refused 





Scoring for Complete Short Physical Performance Battery  
 
Test Scores  
 
Total Balance Test score  _______ points  
 
Gait Speed Test score   _______ points 
 
 Chair Stand Test score   _______ points  
 




Participant unable to complete 5 chair stands or 
completes stands in >60 sec: ❒0 points 
 
If chair stand time is 16.70 sec or more: ❒1 point 
 
If chair stand time is 13.70 to 16.69 sec or more: 
❒2 points 
 
If chair stand time is 11.20 to 13.69 sec:  ❒3 points 
 







Timed 3-metre up and go  
 
 3m up and go 
[sec] 
Repetition 1  
Repetition 2  
Repetition 3  


















Attempt number CRT5 (seconds) Power(Max) (W.kg-1) 
1   
2   
3   
4   













The SF-36v2™ Health Survey 
SF1: In general, would you say your health is: 
Excellent Very good Good Fair Poor 
     
 
SF2: Compared to one year ago, how would you rate your health in general now? 
Much better 




than one year 
ago 
About the 




than one year 
ago 
Much worse 
now than one 
year ago 
     
 
SF3: The following questions are about activities you might do during a typical day. Does your 
health now limit you in these activities? If so, how much? 
 Yes 





not limited at 
all 
Vigorous activities, such as running, lifting heavy 
objects, participating in strenuous sports    
Moderate activities, such as moving a table, 
pushing a vacuum cleaner, bowling, or playing golf    
Lifting or carrying groceries    
Climbing several flights of stairs    
Climbing one flight of stairs    
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Bending, kneeling, or stooping    
Walking more than a mile    
Walking several hundred yards    
Walking one hundred yards    




The SF-36v2™ Health Survey Continued 
SF4: During the past 4 weeks, have you had any of the following problems with your work or 
other regular daily activities as a result of your physical health? 











Cut down on the amount of time you spent on work  
or other activities       
Accomplished less than you would like      
Were limited in the kind of work or other activities      
Had difficulty performing the work or other activities 
(e.g, it took extra effort)      
 
SF5: During the past 4 weeks, have you had any of the following problems with your work or 
other regular daily activities as a result of any emotional problems (such as feeling 
depressed or anxious)? 











Cut down on the amount of time you spent on 
work or other activities      
Accomplished less than you would like      
Did work or other activities less carefully than 




SF6: During the past 4 weeks, to what extent has your physical health or emotional problems 
interfered with your normal social activities with family, friends, neighbors, or groups? 
Not at all Slightly Moderately Quite a bit Extremely 
     
SF7: How much bodily pain have you had during the past 4 weeks? 
None Very mild Mild Moderate Severe Very severe 
      
SF8: During the past 4 weeks, how much did pain interfere with your normal work (including 
both work outside the home and housework)? 
Not at all A little bit Moderately Quite a bit Extremely 
     
 
 
The SF-36v2™ Health Survey Continued 
SF9: These questions are about how your feel and how things have been with you during the 
past 4 weeks. For each question, please give the one answer that comes closest to the 
way you have been feeling.  How much of the time during the past 4 weeks… 











did you feel full of life?      
have you been very nervous?      
have you felt so down in the dumps nothing could 
cheer you up?      
have you felt calm and peaceful?      
did you have a lot of energy?      
have you felt downhearted and depressed?      
did you feel worn out?      
have you been happy?      




SF10: During the past 4 weeks, how much of the time has your physical health or emotional 
problems interfered with your social activities (like visiting friends, relatives, etc.)? 
All of the time Most of the time Some of the time A little of the 
time 
None of the time 
     
 











I seem to get sick a little easier than other 
people      
I am as healthy as anybody I know      
I expect my health to get worse      
My health is excellent 
 




Date of Assessment   
  
 
Has the Concomitant Medication changed since the previous visit? Yes  No 
 If yes, please complete Concomitant Medication page 
 
 









Date of  
 
Assessment   
  
 
Has the Concomitant Medication changed since the previous visit? Yes  No 
 If yes, please complete Concomitant Medication page 
 
 







Date of Assessment   
 
Pulse   per minute   Measured after 5 minutes rest, sitting, on the dominant arm 
 
Blood Pressure Sitting 
Measurement 1: Systolic   mmHg Diastolic   mmHg 
 
Measurement 2: Systolic   mmHg Diastolic   mmHg 
 
Measurement 3: Systolic   mmHg Diastolic   mmHg 
 
Blood Pressure Standing 
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Measurement 1: Systolic   mmHg Diastolic  mmHg 
 
Measurement 2: Systolic   mmHg Diastolic   mmHg 
 
Measurement 3: Systolic   mmHg Diastolic   mmHg 
 
 Blood pressure to be measured in 5 minutes intervals on the dominant arm 
Concomitant Medication present? Yes No 
 If yes, please complete Concomitant Medication page 
Physical Activity Monitor attached? Yes  No 
3-day food diary handed out? Yes  No 
 
DXA scan performed?               Yes  No 
 
 























 Sitting Standing 






Date of Assessment   
Has the Concomitant Medication changed since the previous visit? Yes  No 
 Sitting Standing 




 If yes, please complete Concomitant Medication page 
3-day Food Diary returned? Yes  No 
 
Accelerometer returned? Yes  No 
 
Venous Blood sample taken? Yes  No 
 
Musculoskeletal Pain/Comfort  Yes  No 
Questionnaires completed? 
 
DXA scan completed Yes  No 
 
 
PHYSICAL ACITIVITY MONITOR RESULTS 
 
Start of physical monitoring 
Date   Time  :  
 
End of physical monitoring 


























       
 
MUSCLE EXAMINATION 
















SHORT PHYSICAL PERFORMANCE BATTERY TEST 
Balance Tests: A and B. Side-by-Side Stand and Semi-Tandem Stand 
 
 
C: Tandem Stand 
 
 
Held for 10 secs 
(2 points) 
Held for 3 – 9.99 
secs (1 point) 
Held for <3 
secs (0 points) 
Not attempted/failed. 
0 points (please select 






   
 
Key 
1. Tried but unable 
Dominant limb (L/R)  
Seat length (cm)  
Position of non-dominant foot  
 Power Output (Watts.kg-1) 
Measurement 1  
Measurement 2  
Measurement 3  
Measurement 4  
Measurement 5  
Best measurement  
 Held for 10 secs (1 point) 
Held for <10 secs (0 points, 
please state time) 
Not attempted/failed.  
0 points (please select 
reason from key) 
Side-by-Side Stand    
Semi-Tandem Stand    
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2. Participant could not hold the position unassisted 
3. Not attempted – you felt it was unsafe 
4. Not attempted – participant felt unsafe 
5. Participant unable to understand instructions 
6. Participant refused 















Gait Speed Test 
 
Time for 3m walk 
(secs) 
Walking aid? (None, cane, 
other) 
Not attempted/failed  
(Please select reason from 
key) 
Attempt 1    





      
    
1    Tried but unable 
2 Participant could not hold position unassisted 
3 Not attempted – you felt it was unsafe 
4 Not attempted – participant felt unsafe 
5 Participant unable to understand instructions 
6  Participant refused 
7     Other (please specify) 
 
 
Repeated Chair Stand 
 
Time taken to complete 5 
stands (secs) 
With or without using 
arms? 
Not attempted/failed 
(Please select reason from 
key) 
Attempt    
 
Key 
1. Tried but unable 
2. Participant could not hold the position 
unassisted 
3. Not attempted – you felt it was unsafe 
4. Not attempted – participant felt unsafe 
5. Participant unable to understand instructions 
6. Participant refused 
7. Other (please specify)  
 
Scoring for Complete Short Physical 
Performance Battery  
 
Test Scores  
 
Total Balance Test score  _______ points  
 
Gait Speed Test score   _______ points 
 





If time is more than 6.52 secs:   ❒1 point 
If time is 4.66 to 6.52 secs:  ❒2 points 
If time is 3.62 to 4.65 secs:   ❒3 points 





Participant unable to complete 5 chair stands or completes 
stands in >60 sec: ❒0 points 
 
If chair stand time is 16.70 sec or more: ❒1 points 
 
If chair stand time is 13.70 to 16.69 sec or more: ❒2 points 
 
If chair stand time is 11.20 to 13.69 sec:  ❒3 points 
 









Timed 3-metre up and go  
 
 3m up and go 
[sec] 
Repetition 1  
Repetition 2  
Repetition 3  


















Attempt number CRT5 (seconds) Power(Max) (W/kg) 
1   
2   
3   
4   



























Did any Serious Adverse Events occur during the study? Yes No 
 If yes, please complete SAE Report 
 
Did the subject terminate the study as planned  Yes 
    No   Please state reason below 
 
Date of last study procedure   
 
 
If the study was not terminated as planned, please state the reason for study termination: 
Subject withdrawal of consent  
Investigator’s discretion   
Intercurrent illness  
Changes in the subject’s condition   
Noncompliance with study procedures  
Termination of the clinical trial  



































  30-second sit to stand Band colour used Ankle weight used Number of squats 
























001 1 9 14 - - Red Blue - - 0 0.75 - - 10 10 - - 
 002 1 9 24 27 30 Red Blue Black Black 0 0.75 1 1 10 10 40 60 
 004 1 15 27 25 29 Green Green Blue Blue 0.5 0.5 0.75 0.75 16 20 180 320 
 005 2 12 22 22 24 Green Green Blue Black 0.5 0.5 0.75 1 16 20 180 300 
 006 1 12 18 21 27 Red Red Blue Blue 0 0.75 0.5 0.5 10 10 40 60 
 007 2 11 17 22 29 Red Blue Blue Blue 0 0.75 0.5 0.5 10 10 40 60 
 008 2 16 22 21 21 Green Green Blue Blue 0.5 0.5 0.75 0.75 32 60 160 300 
 009 1 - - - - - - - - - - - - - - - - 
 010 1 4 12 12 13 Red Green Green Blue 0.5 0.5 0.5 0.5 30 60 160 300 
 011 2 17 18 18 19 Blue Black Black Black 0.75 1 1 1 220 290 300 300 
 012 1 16 30 31 37 Green Black Blue Blue 0.5 1 1 1 100 150 350 500 
 013 2 
 
16 26 27 34 Green Green Blue Blue 0.5 0.75 0.75 1 100 150 350 500 
                   014 2 - 
 
- - - - 
 
- - - - - - - - - - - 


























  30-second sit to stand Band colour used Ankle weight used Number of squats 
























016 1 26 28 31 34 Black Black Black Black 1 1 1 1 100 150 350 500 
 017 1 12 29 32 35 Green Blue Black Black 0.5 1 1 1 100 150 350 500 
 018 2 12 22 31 35 Green Green Blue Blue 0.5 0.5 1 1 100 150 350 500 
 019 2 7 14 15 15 - Green Blue Black - 0.75 1 1 70 120 200 500 
 020 2 25 30 33 38 Blue Black Black Black 0.5 1 1 1 200 350 500 600 
 021 1 24 28 30 33 Blue Black Black Black 1 1 1 1 150 300 500 1000 
 024 1 3 15 12 12 - Green Blue Black - 0.75 1 1 70 120 200 400 
 026 2 - - - - - - - - - - - - - - - - 
029 2 17 22 24 30 Green Blue Blue Black 0.75 1 1 1 150 200 250 500 
 030 2 - - - - - - - - - - - - - - - - 












































001 1 100.00 100.00 N/A N/A N/A N/A 
 002 1 87.50 87.50 100.00 100.00 100.00 100.00 
 004 1 100.00 100.00 75.00 25.00 87.50 75.00 
 005 2 87.50 100.00 75.00 87.50 75.00 75.00 
 006 1 62.50 75.00 37.50 100.00 100.00 100.00 
 007 2 100.00 87.50 100.00 87.50 100.00 100.00 
 008 2 87.50 75.00 75.00 62.50 100.00 100.00 
 010 1 100.00 87.50 87.50 75.00 75.00 62.50 
 011 2 100.00 87.50 100.00 87.50 100.00 100.00 
 012 1 100.00 75.00 100.00 100.00 87.50 100.00 
 013 2 75.00 100.00 100.00 100.00 100.00 100.00 
 015 1 100.00 100.00 87.50 87.50 62.50 62.50 
 016 1 100.00 100.00 100.00 87.50 100.00 100.00 
 017 1 87.50 100.00 87.50 87.50 87.50 100.00 
 018 2 75.00 87.50 87.50 87.50 87.50 100.00 
 019 2 100.00 75.00 100.00 75.00 100.00 100.00 
 020 2 100.00 100.00 62.50 100.00 62.50 100.00 
 021 1 87.50 75.00 50.00 87.50 87.50 37.50 
 024 1 100.00 100.00 100.00 100.00 87.50 75.00 
100.00 029 2 87.50 75.00 100.00 100.00 100.00 - 





APPENDIX K: SUPPLEMENT COMPLIANCE LOG 
 












001 1 89.29 82.12 N/A N/A N/A N/A 
 002 1 100.00 60.71 75.00 92.86 100.00 100.00 
 004 1 96.43 100.00 50.00 100.00 75.00 42.86 
 005 2 96.43 92.86 71.43 92.86 92.86 42.86 
 006 1 100.00 100.00 100.00 100.00 92.86 100.00 
 007 2 100.00 100.00 100.00 89.29 100.00 100.00 
 008 2 78.57 89.29 82.12 78.57 75.00 67.88 
 010 1 71.43 92.86 92.86 100.00 100.00 100.00 
 011 2 92.86 100.00 100.00 100.00 100.00 100.00 
 012 1 100.00 100.00 92.86 92.86 85.71 100.00 
 013 2 100.00 96.43 92.86 92.86 89.29 85.71 
 015 1 92.86 100.00 92.86 89.29 85.71 100.00 
 016 1 96.43 96.43 92.86 92.86 92.86 85.71 
 017 1 82.12 85.71 92.86 75.00 89.29 100.00 
 018 2 85.71 96.43 96.43 92.86 92.86 100.00 
 019 2 100.00 100.00 100.00 100.00 100.00 100.00 
 020 2 89.29 100.00 100.00 100.00 100.00 100.00 
 021 1 100.00 100.00 100.00 100.00 100.00 100.00 
 024 1 100.00 100.00 100.00 100.00 100.00 100.00 
100.00 029 2 100.00 100.00 100.00 100.00 100.00 - 
Groups: 1 = placebo, 2 = vitamin D 
  
 
